Patient ID	Tissue ID	Allen Institute #	Swedish #	Hyperlink to specimen page for division of tumor into blocks, MRI snapshot, and images for ISH and histology profiling	Age At Initial Diagnosis (in years)	Gender	KPS	Weight	Height	Mini Mental Status Score	History Of Seizures	Neurologic Deficit	Presentation Symptoms	Location	Extent	Chemotherapy	Radiationtherapy	Histopathology	1p19q_deletion	EGFR	PTEN	MGMT PCR	MGMT	MGMT MS-MLPA:R1	MGMT MS-MLPA:R2	MGMT MS-MLPA:R3	IDH1	EGFR vIII	Surgery (primary or recurrent)	Gliadel	Awake Mapping	Stealth Scan	MRI Confirmation	Followups	Surgery (days since initial diagnosis)	Age at surgery (in days)	Time To Progression (in days)	Time To Last Follow-up (in days)	Survival (in days)	Cause Of Death	Anti-epileptic regimens	Anti-depressant regimens	Anti-viral regimens	Anti-thrombotic regimens	Steroids regimens	Chloroquine regimens	Avastin regimens	Temozolomide regimens	Avastin regimens	XL-184 regimens	antihypertensive regimens	Cholesterol lowering regimens	cardiotonic regimens	Etoposide regimens	Irinotecan regimens	Lomustine regimens	Carboplatin regimens	Disulfiram regimens	multi-vitamin regimens	NovoCure	Exelixis, Relapsed Astrocytic Tumors with XL184 Regimen, 10041	DCVax	Toca 511	Celldex Act IV	Med_1: Medication	Med_1: Start (days since initial diagnosis)	Med_1: Dosage	Med_1: Drug	Med_1: End (days since initial diagnosis)	Med_2: Medication	Med_2: Start (days since initial diagnosis)	Med_2: Dosage	Med_2: Drug	Med_2: End (days since initial diagnosis)	Med_3: Medication	Med_3: Start (days since initial diagnosis)	Med_3: Dosage	Med_3: Drug	Med_3: End (days since initial diagnosis)	Med_4: Medication	Med_4: Start (days since initial diagnosis)	Med_4: Dosage	Med_4: Drug	Med_4: End (days since initial diagnosis)	Med_5: Medication	Med_5: Start (days since initial diagnosis)	Med_5: Dosage	Med_5: Drug	Med_5: End (days since initial diagnosis)	Med_6: Medication	Med_6: Start (days since initial diagnosis)	Med_6: Dosage	Med_6: Drug	Med_6: End (days since initial diagnosis)	Med_7: Medication	Med_7: Start (days since initial diagnosis)	Med_7: Dosage	Med_7: Drug	Med_7: End (days since initial diagnosis)	Med_8: Medication	Med_8: Start (days since initial diagnosis)	Med_8: Dosage	Med_8: Drug	Med_8: End (days since initial diagnosis)	Med_9: Medication	Med_9: Start (days since initial diagnosis)	Med_9: Dosage	Med_9: Drug	Med_9: End (days since initial diagnosis)	Med_10: Medication	Med_10: Start (days since initial diagnosis)	Med_10: Dosage	Med_10: Drug	Med_10: End (days since initial diagnosis)	Med_11: Medication	Med_11: Start (days since initial diagnosis)	Med_11: Dosage	Med_11: Drug	Med_11: End (days since initial diagnosis)	Med_12: Medication	Med_12: Start (days since initial diagnosis)	Med_12: Dosage	Med_12: Drug	Med_12: End (days since initial diagnosis)	Med_13: Medication	Med_13: Start (days since initial diagnosis)	Med_13: Dosage	Med_13: Drug	Med_13: End (days since initial diagnosis)	Med_14: Medication	Med_14: Start (days since initial diagnosis)	Med_14: Dosage	Med_14: Drug	Med_14: End (days since initial diagnosis)	Med_15: Medication	Med_15: Start (days since initial diagnosis)	Med_15: Dosage	Med_15: Drug	Med_15: End (days since initial diagnosis)	Med_16: Medication	Med_16: Start (days since initial diagnosis)	Med_16: Dosage	Med_16: Drug	Med_16: End (days since initial diagnosis)	Chemo_1: Medication	Chemo_1: Start (days since initial diagnosis)	Chemo_1: Dosage	Chemo_1: Description	Chemo_1: End (days since initial diagnosis)	Chemo_2: Medication	Chemo_2: Start (days since initial diagnosis)	Chemo_2: Dosage	Chemo_2: Description	Chemo_2: End (days since initial diagnosis)	Chemo_3: Medication	Chemo_3: Start (days since initial diagnosis)	Chemo_3: Dosage	Chemo_3: Description	Chemo_3: End (days since initial diagnosis)	Chemo_4: Medication	Chemo_4: Start (days since initial diagnosis)	Chemo_4: Dosage	Chemo_4: Description	Chemo_4: End (days since initial diagnosis)	Chemo_5: Medication	Chemo_5: Start (days since initial diagnosis)	Chemo_5: Dosage	Chemo_5: Description	Chemo_5: End (days since initial diagnosis)	Chemo_6: Medication	Chemo_6: Start (days since initial diagnosis)	Chemo_6: Dosage	Chemo_6: Description	Chemo_6: End (days since initial diagnosis)	Chemo_7: Medication	Chemo_7: Start (days since initial diagnosis)	Chemo_7: Dosage	Chemo_7: Description	Chemo_7: End (days since initial diagnosis)	Chemo_8: Medication	Chemo_8: Start (days since initial diagnosis)	Chemo_8: Dosage	Chemo_8: Description	Chemo_8: End (days since initial diagnosis)	Chemo_9: Medication	Chemo_9: Start (days since initial diagnosis)	Chemo_9: Dosage	Chemo_9: Description	Chemo_9: End (days since initial diagnosis)	Radn_1: Start (days since initial diagnosis)	Radn_1: Type	Radn_1: Dosage	Radn_1: Fraction	Radn_1: End (days since initial diagnosis)	Radn_2: Start (days since initial diagnosis)	Radn_2: Type	Radn_2: Dosage	Radn_2: Fraction	Radn_2: End (days since initial diagnosis)	Radn_3: Start (days since initial diagnosis)	Radn_3: Type	Radn_3: Dosage	Radn_3: Fraction	Radn_3: End (days since initial diagnosis)	Radn_4: Start (days since initial diagnosis)	Radn_4: Type	Radn_4: Dosage	Radn_4: Fraction	Radn_4: End (days since initial diagnosis)	Rady_1: (days since initial diagnosis)	Rady_1: Scan Type	Rady_1: When	Rady_1: Evidence of Progression	Rady_1: Type of Progression	Rady_1: Notes	Rady_1: nCBV-Enhancing Tumor	Rady_1: nCBV-Surrounding T2 Signal Change	Rady_1: nCBV-Comparison Normal Brain Tissue	Rady_1: ADC-Enhancing Tumor	Rady_1: ADC-Surrounding T2 Signal Change	Rady_1: ADC-Comparison Normal Brain Tissue	Rady_1: Spectroscopy-Enhancing Tumor	Rady_1: Spectroscopy-Surrounding T2 Signal Change	Rady_1: Spectroscopy-Comparison Normal Brain Tissue	Rady_1: Change in Enhancing Tumor Volume (%)	Rady_1: Change in T2 Signal Volume (%)	Rady_2: (days since initial diagnosis)	Rady_2: Scan Type	Rady_2: When	Rady_2: Evidence of Progression	Rady_2: Type of Progression	Rady_2: Notes	Rady_2: nCBV-Enhancing Tumor	Rady_2: nCBV-Surrounding T2 Signal Change	Rady_2: nCBV-Comparison Normal Brain Tissue	Rady_2: ADC-Enhancing Tumor	Rady_2: ADC-Surrounding T2 Signal Change	Rady_2: ADC-Comparison Normal Brain Tissue	Rady_2: Spectroscopy-Enhancing Tumor	Rady_2: Spectroscopy-Surrounding T2 Signal Change	Rady_2: Spectroscopy-Comparison Normal Brain Tissue	Rady_2: Change in Enhancing Tumor Volume (%)	Rady_2: Change in T2 Signal Volume (%)	Rady_3: (days since initial diagnosis)	Rady_3: Scan Type	Rady_3: When	Rady_3: Evidence of Progression	Rady_3: Type of Progression	Rady_3: Notes	Rady_3: nCBV-Enhancing Tumor	Rady_3: nCBV-Surrounding T2 Signal Change	Rady_3: nCBV-Comparison Normal Brain Tissue	Rady_3: ADC-Enhancing Tumor	Rady_3: ADC-Surrounding T2 Signal Change	Rady_3: ADC-Comparison Normal Brain Tissue	Rady_3: Spectroscopy-Enhancing Tumor	Rady_3: Spectroscopy-Surrounding T2 Signal Change	Rady_3: Spectroscopy-Comparison Normal Brain Tissue	Rady_3: Change in Enhancing Tumor Volume (%)	Rady_3: Change in T2 Signal Volume (%)	Rady_4: (days since initial diagnosis)	Rady_4: Scan Type	Rady_4: When	Rady_4: Evidence of Progression	Rady_4: Type of Progression	Rady_4: Notes	Rady_4: nCBV-Enhancing Tumor	Rady_4: nCBV-Surrounding T2 Signal Change	Rady_4: nCBV-Comparison Normal Brain Tissue	Rady_4: ADC-Enhancing Tumor	Rady_4: ADC-Surrounding T2 Signal Change	Rady_4: ADC-Comparison Normal Brain Tissue	Rady_4: Spectroscopy-Enhancing Tumor	Rady_4: Spectroscopy-Surrounding T2 Signal Change	Rady_4: Spectroscopy-Comparison Normal Brain Tissue	Rady_4: Change in Enhancing Tumor Volume (%)	Rady_4: Change in T2 Signal Volume (%)	Rady_5: (days since initial diagnosis)	Rady_5: Scan Type	Rady_5: When	Rady_5: Evidence of Progression	Rady_5: Type of Progression	Rady_5: Notes	Rady_5: nCBV-Enhancing Tumor	Rady_5: nCBV-Surrounding T2 Signal Change	Rady_5: nCBV-Comparison Normal Brain Tissue	Rady_5: ADC-Enhancing Tumor	Rady_5: ADC-Surrounding T2 Signal Change	Rady_5: ADC-Comparison Normal Brain Tissue	Rady_5: Spectroscopy-Enhancing Tumor	Rady_5: Spectroscopy-Surrounding T2 Signal Change	Rady_5: Spectroscopy-Comparison Normal Brain Tissue	Rady_5: Change in Enhancing Tumor Volume (%)	Rady_5: Change in T2 Signal Volume (%)	Rady_6: (days since initial diagnosis)	Rady_6: Scan Type	Rady_6: When	Rady_6: Evidence of Progression	Rady_6: Type of Progression	Rady_6: Notes	Rady_6: nCBV-Enhancing Tumor	Rady_6: nCBV-Surrounding T2 Signal Change	Rady_6: nCBV-Comparison Normal Brain Tissue	Rady_6: ADC-Enhancing Tumor	Rady_6: ADC-Surrounding T2 Signal Change	Rady_6: ADC-Comparison Normal Brain Tissue	Rady_6: Spectroscopy-Enhancing Tumor	Rady_6: Spectroscopy-Surrounding T2 Signal Change	Rady_6: Spectroscopy-Comparison Normal Brain Tissue	Rady_6: Change in Enhancing Tumor Volume (%)	Rady_6: Change in T2 Signal Volume (%)	Rady_7: (days since initial diagnosis)	Rady_7: Scan Type	Rady_7: When	Rady_7: Evidence of Progression	Rady_7: Type of Progression	Rady_7: Notes	Rady_7: nCBV-Enhancing Tumor	Rady_7: nCBV-Surrounding T2 Signal Change	Rady_7: nCBV-Comparison Normal Brain Tissue	Rady_7: ADC-Enhancing Tumor	Rady_7: ADC-Surrounding T2 Signal Change	Rady_7: ADC-Comparison Normal Brain Tissue	Rady_7: Spectroscopy-Enhancing Tumor	Rady_7: Spectroscopy-Surrounding T2 Signal Change	Rady_7: Spectroscopy-Comparison Normal Brain Tissue	Rady_7: Change in Enhancing Tumor Volume (%)	Rady_7: Change in T2 Signal Volume (%)	Rady_8: (days since initial diagnosis)	Rady_8: Scan Type	Rady_8: When	Rady_8: Evidence of Progression	Rady_8: Type of Progression	Rady_8: Notes	Rady_8: nCBV-Enhancing Tumor	Rady_8: nCBV-Surrounding T2 Signal Change	Rady_8: nCBV-Comparison Normal Brain Tissue	Rady_8: ADC-Enhancing Tumor	Rady_8: ADC-Surrounding T2 Signal Change	Rady_8: ADC-Comparison Normal Brain Tissue	Rady_8: Spectroscopy-Enhancing Tumor	Rady_8: Spectroscopy-Surrounding T2 Signal Change	Rady_8: Spectroscopy-Comparison Normal Brain Tissue	Rady_8: Change in Enhancing Tumor Volume (%)	Rady_8: Change in T2 Signal Volume (%)	Rady_9: (days since initial diagnosis)	Rady_9: Scan Type	Rady_9: When	Rady_9: Evidence of Progression	Rady_9: Type of Progression	Rady_9: Notes	Rady_9: nCBV-Enhancing Tumor	Rady_9: nCBV-Surrounding T2 Signal Change	Rady_9: nCBV-Comparison Normal Brain Tissue	Rady_9: ADC-Enhancing Tumor	Rady_9: ADC-Surrounding T2 Signal Change	Rady_9: ADC-Comparison Normal Brain Tissue	Rady_9: Spectroscopy-Enhancing Tumor	Rady_9: Spectroscopy-Surrounding T2 Signal Change	Rady_9: Spectroscopy-Comparison Normal Brain Tissue	Rady_9: Change in Enhancing Tumor Volume (%)	Rady_9: Change in T2 Signal Volume (%)	Rady_10: (days since initial diagnosis)	Rady_10: Scan Type	Rady_10: When	Rady_10: Evidence of Progression	Rady_10: Type of Progression	Rady_10: Notes	Rady_10: nCBV-Enhancing Tumor	Rady_10: nCBV-Surrounding T2 Signal Change	Rady_10: nCBV-Comparison Normal Brain Tissue	Rady_10: ADC-Enhancing Tumor	Rady_10: ADC-Surrounding T2 Signal Change	Rady_10: ADC-Comparison Normal Brain Tissue	Rady_10: Spectroscopy-Enhancing Tumor	Rady_10: Spectroscopy-Surrounding T2 Signal Change	Rady_10: Spectroscopy-Comparison Normal Brain Tissue	Rady_10: Change in Enhancing Tumor Volume (%)	Rady_10: Change in T2 Signal Volume (%)	Rady_11: (days since initial diagnosis)	Rady_11: Scan Type	Rady_11: When	Rady_11: Evidence of Progression	Rady_11: Type of Progression	Rady_11: Notes	Rady_11: nCBV-Enhancing Tumor	Rady_11: nCBV-Surrounding T2 Signal Change	Rady_11: nCBV-Comparison Normal Brain Tissue	Rady_11: ADC-Enhancing Tumor	Rady_11: ADC-Surrounding T2 Signal Change	Rady_11: ADC-Comparison Normal Brain Tissue	Rady_11: Spectroscopy-Enhancing Tumor	Rady_11: Spectroscopy-Surrounding T2 Signal Change	Rady_11: Spectroscopy-Comparison Normal Brain Tissue	Rady_11: Change in Enhancing Tumor Volume (%)	Rady_11: Change in T2 Signal Volume (%)	Rady_12: (days since initial diagnosis)	Rady_12: Scan Type	Rady_12: When	Rady_12: Evidence of Progression	Rady_12: Type of Progression	Rady_12: Notes	Rady_12: nCBV-Enhancing Tumor	Rady_12: nCBV-Surrounding T2 Signal Change	Rady_12: nCBV-Comparison Normal Brain Tissue	Rady_12: ADC-Enhancing Tumor	Rady_12: ADC-Surrounding T2 Signal Change	Rady_12: ADC-Comparison Normal Brain Tissue	Rady_12: Spectroscopy-Enhancing Tumor	Rady_12: Spectroscopy-Surrounding T2 Signal Change	Rady_12: Spectroscopy-Comparison Normal Brain Tissue	Rady_12: Change in Enhancing Tumor Volume (%)	Rady_12: Change in T2 Signal Volume (%)	Rady_13: (days since initial diagnosis)	Rady_13: Scan Type	Rady_13: When	Rady_13: Evidence of Progression	Rady_13: Type of Progression	Rady_13: Notes	Rady_13: nCBV-Enhancing Tumor	Rady_13: nCBV-Surrounding T2 Signal Change	Rady_13: nCBV-Comparison Normal Brain Tissue	Rady_13: ADC-Enhancing Tumor	Rady_13: ADC-Surrounding T2 Signal Change	Rady_13: ADC-Comparison Normal Brain Tissue	Rady_13: Spectroscopy-Enhancing Tumor	Rady_13: Spectroscopy-Surrounding T2 Signal Change	Rady_13: Spectroscopy-Comparison Normal Brain Tissue	Rady_13: Change in Enhancing Tumor Volume (%)	Rady_13: Change in T2 Signal Volume (%)	Rady_14: (days since initial diagnosis)	Rady_14: Scan Type	Rady_14: When	Rady_14: Evidence of Progression	Rady_14: Type of Progression	Rady_14: Notes	Rady_14: nCBV-Enhancing Tumor	Rady_14: nCBV-Surrounding T2 Signal Change	Rady_14: nCBV-Comparison Normal Brain Tissue	Rady_14: ADC-Enhancing Tumor	Rady_14: ADC-Surrounding T2 Signal Change	Rady_14: ADC-Comparison Normal Brain Tissue	Rady_14: Spectroscopy-Enhancing Tumor	Rady_14: Spectroscopy-Surrounding T2 Signal Change	Rady_14: Spectroscopy-Comparison Normal Brain Tissue	Rady_14: Change in Enhancing Tumor Volume (%)	Rady_14: Change in T2 Signal Volume (%)	Rady_15: (days since initial diagnosis)	Rady_15: Scan Type	Rady_15: When	Rady_15: Evidence of Progression	Rady_15: Type of Progression	Rady_15: Notes	Rady_15: nCBV-Enhancing Tumor	Rady_15: nCBV-Surrounding T2 Signal Change	Rady_15: nCBV-Comparison Normal Brain Tissue	Rady_15: ADC-Enhancing Tumor	Rady_15: ADC-Surrounding T2 Signal Change	Rady_15: ADC-Comparison Normal Brain Tissue	Rady_15: Spectroscopy-Enhancing Tumor	Rady_15: Spectroscopy-Surrounding T2 Signal Change	Rady_15: Spectroscopy-Comparison Normal Brain Tissue	Rady_15: Change in Enhancing Tumor Volume (%)	Rady_15: Change in T2 Signal Volume (%)	Rady_16: (days since initial diagnosis)	Rady_16: Scan Type	Rady_16: When	Rady_16: Evidence of Progression	Rady_16: Type of Progression	Rady_16: Notes	Rady_16: nCBV-Enhancing Tumor	Rady_16: nCBV-Surrounding T2 Signal Change	Rady_16: nCBV-Comparison Normal Brain Tissue	Rady_16: ADC-Enhancing Tumor	Rady_16: ADC-Surrounding T2 Signal Change	Rady_16: ADC-Comparison Normal Brain Tissue	Rady_16: Spectroscopy-Enhancing Tumor	Rady_16: Spectroscopy-Surrounding T2 Signal Change	Rady_16: Spectroscopy-Comparison Normal Brain Tissue	Rady_16: Change in Enhancing Tumor Volume (%)	Rady_16: Change in T2 Signal Volume (%)	Rady_17: (days since initial diagnosis)	Rady_17: Scan Type	Rady_17: When	Rady_17: Evidence of Progression	Rady_17: Type of Progression	Rady_17: Notes	Rady_17: nCBV-Enhancing Tumor	Rady_17: nCBV-Surrounding T2 Signal Change	Rady_17: nCBV-Comparison Normal Brain Tissue	Rady_17: ADC-Enhancing Tumor	Rady_17: ADC-Surrounding T2 Signal Change	Rady_17: ADC-Comparison Normal Brain Tissue	Rady_17: Spectroscopy-Enhancing Tumor	Rady_17: Spectroscopy-Surrounding T2 Signal Change	Rady_17: Spectroscopy-Comparison Normal Brain Tissue	Rady_17: Change in Enhancing Tumor Volume (%)	Rady_17: Change in T2 Signal Volume (%)	Rady_18: (days since initial diagnosis)	Rady_18: Scan Type	Rady_18: When	Rady_18: Evidence of Progression	Rady_18: Type of Progression	Rady_18: Notes	Rady_18: nCBV-Enhancing Tumor	Rady_18: nCBV-Surrounding T2 Signal Change	Rady_18: nCBV-Comparison Normal Brain Tissue	Rady_18: ADC-Enhancing Tumor	Rady_18: ADC-Surrounding T2 Signal Change	Rady_18: ADC-Comparison Normal Brain Tissue	Rady_18: Spectroscopy-Enhancing Tumor	Rady_18: Spectroscopy-Surrounding T2 Signal Change	Rady_18: Spectroscopy-Comparison Normal Brain Tissue	Rady_18: Change in Enhancing Tumor Volume (%)	Rady_18: Change in T2 Signal Volume (%)	Rady_19: (days since initial diagnosis)	Rady_19: Scan Type	Rady_19: When	Rady_19: Evidence of Progression	Rady_19: Type of Progression	Rady_19: Notes	Rady_19: nCBV-Enhancing Tumor	Rady_19: nCBV-Surrounding T2 Signal Change	Rady_19: nCBV-Comparison Normal Brain Tissue	Rady_19: ADC-Enhancing Tumor	Rady_19: ADC-Surrounding T2 Signal Change	Rady_19: ADC-Comparison Normal Brain Tissue	Rady_19: Spectroscopy-Enhancing Tumor	Rady_19: Spectroscopy-Surrounding T2 Signal Change	Rady_19: Spectroscopy-Comparison Normal Brain Tissue	Rady_19: Change in Enhancing Tumor Volume (%)	Rady_19: Change in T2 Signal Volume (%)	Rady_20: (days since initial diagnosis)	Rady_20: Scan Type	Rady_20: When	Rady_20: Evidence of Progression	Rady_20: Type of Progression	Rady_20: Notes	Rady_20: nCBV-Enhancing Tumor	Rady_20: nCBV-Surrounding T2 Signal Change	Rady_20: nCBV-Comparison Normal Brain Tissue	Rady_20: ADC-Enhancing Tumor	Rady_20: ADC-Surrounding T2 Signal Change	Rady_20: ADC-Comparison Normal Brain Tissue	Rady_20: Spectroscopy-Enhancing Tumor	Rady_20: Spectroscopy-Surrounding T2 Signal Change	Rady_20: Spectroscopy-Comparison Normal Brain Tissue	Rady_20: Change in Enhancing Tumor Volume (%)	Rady_20: Change in T2 Signal Volume (%)	Rady_21: (days since initial diagnosis)	Rady_21: Scan Type	Rady_21: When	Rady_21: Evidence of Progression	Rady_21: Type of Progression	Rady_21: Notes	Rady_21: nCBV-Enhancing Tumor	Rady_21: nCBV-Surrounding T2 Signal Change	Rady_21: nCBV-Comparison Normal Brain Tissue	Rady_21: ADC-Enhancing Tumor	Rady_21: ADC-Surrounding T2 Signal Change	Rady_21: ADC-Comparison Normal Brain Tissue	Rady_21: Spectroscopy-Enhancing Tumor	Rady_21: Spectroscopy-Surrounding T2 Signal Change	Rady_21: Spectroscopy-Comparison Normal Brain Tissue	Rady_21: Change in Enhancing Tumor Volume (%)	Rady_21: Change in T2 Signal Volume (%)	Rady_22: (days since initial diagnosis)	Rady_22: Scan Type	Rady_22: When	Rady_22: Evidence of Progression	Rady_22: Type of Progression	Rady_22: Notes	Rady_22: nCBV-Enhancing Tumor	Rady_22: nCBV-Surrounding T2 Signal Change	Rady_22: nCBV-Comparison Normal Brain Tissue	Rady_22: ADC-Enhancing Tumor	Rady_22: ADC-Surrounding T2 Signal Change	Rady_22: ADC-Comparison Normal Brain Tissue	Rady_22: Spectroscopy-Enhancing Tumor	Rady_22: Spectroscopy-Surrounding T2 Signal Change	Rady_22: Spectroscopy-Comparison Normal Brain Tissue	Rady_22: Change in Enhancing Tumor Volume (%)	Rady_22: Change in T2 Signal Volume (%)	Rady_23: (days since initial diagnosis)	Rady_23: Scan Type	Rady_23: When	Rady_23: Evidence of Progression	Rady_23: Type of Progression	Rady_23: Notes	Rady_23: nCBV-Enhancing Tumor	Rady_23: nCBV-Surrounding T2 Signal Change	Rady_23: nCBV-Comparison Normal Brain Tissue	Rady_23: ADC-Enhancing Tumor	Rady_23: ADC-Surrounding T2 Signal Change	Rady_23: ADC-Comparison Normal Brain Tissue	Rady_23: Spectroscopy-Enhancing Tumor	Rady_23: Spectroscopy-Surrounding T2 Signal Change	Rady_23: Spectroscopy-Comparison Normal Brain Tissue	Rady_23: Change in Enhancing Tumor Volume (%)	Rady_23: Change in T2 Signal Volume (%)	Rady_24: (days since initial diagnosis)	Rady_24: Scan Type	Rady_24: When	Rady_24: Evidence of Progression	Rady_24: Type of Progression	Rady_24: Notes	Rady_24: nCBV-Enhancing Tumor	Rady_24: nCBV-Surrounding T2 Signal Change	Rady_24: nCBV-Comparison Normal Brain Tissue	Rady_24: ADC-Enhancing Tumor	Rady_24: ADC-Surrounding T2 Signal Change	Rady_24: ADC-Comparison Normal Brain Tissue	Rady_24: Spectroscopy-Enhancing Tumor	Rady_24: Spectroscopy-Surrounding T2 Signal Change	Rady_24: Spectroscopy-Comparison Normal Brain Tissue	Rady_24: Change in Enhancing Tumor Volume (%)	Rady_24: Change in T2 Signal Volume (%)	Rady_25: (days since initial diagnosis)	Rady_25: Scan Type	Rady_25: When	Rady_25: Evidence of Progression	Rady_25: Type of Progression	Rady_25: Notes	Rady_25: nCBV-Enhancing Tumor	Rady_25: nCBV-Surrounding T2 Signal Change	Rady_25: nCBV-Comparison Normal Brain Tissue	Rady_25: ADC-Enhancing Tumor	Rady_25: ADC-Surrounding T2 Signal Change	Rady_25: ADC-Comparison Normal Brain Tissue	Rady_25: Spectroscopy-Enhancing Tumor	Rady_25: Spectroscopy-Surrounding T2 Signal Change	Rady_25: Spectroscopy-Comparison Normal Brain Tissue	Rady_25: Change in Enhancing Tumor Volume (%)	Rady_25: Change in T2 Signal Volume (%)	Rady_26: (days since initial diagnosis)	Rady_26: Scan Type	Rady_26: When	Rady_26: Evidence of Progression	Rady_26: Type of Progression	Rady_26: Notes	Rady_26: nCBV-Enhancing Tumor	Rady_26: nCBV-Surrounding T2 Signal Change	Rady_26: nCBV-Comparison Normal Brain Tissue	Rady_26: ADC-Enhancing Tumor	Rady_26: ADC-Surrounding T2 Signal Change	Rady_26: ADC-Comparison Normal Brain Tissue	Rady_26: Spectroscopy-Enhancing Tumor	Rady_26: Spectroscopy-Surrounding T2 Signal Change	Rady_26: Spectroscopy-Comparison Normal Brain Tissue	Rady_26: Change in Enhancing Tumor Volume (%)	Rady_26: Change in T2 Signal Volume (%)	Rady_27: (days since initial diagnosis)	Rady_27: Scan Type	Rady_27: When	Rady_27: Evidence of Progression	Rady_27: Type of Progression	Rady_27: Notes	Rady_27: nCBV-Enhancing Tumor	Rady_27: nCBV-Surrounding T2 Signal Change	Rady_27: nCBV-Comparison Normal Brain Tissue	Rady_27: ADC-Enhancing Tumor	Rady_27: ADC-Surrounding T2 Signal Change	Rady_27: ADC-Comparison Normal Brain Tissue	Rady_27: Spectroscopy-Enhancing Tumor	Rady_27: Spectroscopy-Surrounding T2 Signal Change	Rady_27: Spectroscopy-Comparison Normal Brain Tissue	Rady_27: Change in Enhancing Tumor Volume (%)	Rady_27: Change in T2 Signal Volume (%)	Rady_28: (days since initial diagnosis)	Rady_28: Scan Type	Rady_28: When	Rady_28: Evidence of Progression	Rady_28: Type of Progression	Rady_28: Notes	Rady_28: nCBV-Enhancing Tumor	Rady_28: nCBV-Surrounding T2 Signal Change	Rady_28: nCBV-Comparison Normal Brain Tissue	Rady_28: ADC-Enhancing Tumor	Rady_28: ADC-Surrounding T2 Signal Change	Rady_28: ADC-Comparison Normal Brain Tissue	Rady_28: Spectroscopy-Enhancing Tumor	Rady_28: Spectroscopy-Surrounding T2 Signal Change	Rady_28: Spectroscopy-Comparison Normal Brain Tissue	Rady_28: Change in Enhancing Tumor Volume (%)	Rady_28: Change in T2 Signal Volume (%)	Rady_29: (days since initial diagnosis)	Rady_29: Scan Type	Rady_29: When	Rady_29: Evidence of Progression	Rady_29: Type of Progression	Rady_29: Notes	Rady_29: nCBV-Enhancing Tumor	Rady_29: nCBV-Surrounding T2 Signal Change	Rady_29: nCBV-Comparison Normal Brain Tissue	Rady_29: ADC-Enhancing Tumor	Rady_29: ADC-Surrounding T2 Signal Change	Rady_29: ADC-Comparison Normal Brain Tissue	Rady_29: Spectroscopy-Enhancing Tumor	Rady_29: Spectroscopy-Surrounding T2 Signal Change	Rady_29: Spectroscopy-Comparison Normal Brain Tissue	Rady_29: Change in Enhancing Tumor Volume (%)	Rady_29: Change in T2 Signal Volume (%)	Visit_1: (days since initial diagnosis)	Visit_1: KPS	Visit_1: Mini Mental Status Exam Score	Visit_1: History of seizures since last visit	Visit_1: Neurologic Deficit	Visit_1: Neurologic Deficit Notes	Visit_1: Presentation Notes	Visit_1: Symptoms Notes	Visit_2: (days since initial diagnosis)	Visit_2: KPS	Visit_2: Mini Mental Status Exam Score	Visit_2: History of seizures since last visit	Visit_2: Neurologic Deficit	Visit_2: Neurologic Deficit Notes	Visit_2: Presentation Notes	Visit_2: Symptoms Notes	Visit_3: (days since initial diagnosis)	Visit_3: KPS	Visit_3: Mini Mental Status Exam Score	Visit_3: History of seizures since last visit	Visit_3: Neurologic Deficit	Visit_3: Neurologic Deficit Notes	Visit_3: Presentation Notes	Visit_3: Symptoms Notes	Visit_4: (days since initial diagnosis)	Visit_4: KPS	Visit_4: Mini Mental Status Exam Score	Visit_4: History of seizures since last visit	Visit_4: Neurologic Deficit	Visit_4: Neurologic Deficit Notes	Visit_4: Presentation Notes	Visit_4: Symptoms Notes	Visit_5: (days since initial diagnosis)	Visit_5: KPS	Visit_5: Mini Mental Status Exam Score	Visit_5: History of seizures since last visit	Visit_5: Neurologic Deficit	Visit_5: Neurologic Deficit Notes	Visit_5: Presentation Notes	Visit_5: Symptoms Notes	Visit_6: (days since initial diagnosis)	Visit_6: KPS	Visit_6: Mini Mental Status Exam Score	Visit_6: History of seizures since last visit	Visit_6: Neurologic Deficit	Visit_6: Neurologic Deficit Notes	Visit_6: Presentation Notes	Visit_6: Symptoms Notes	Visit_7: (days since initial diagnosis)	Visit_7: KPS	Visit_7: Mini Mental Status Exam Score	Visit_7: History of seizures since last visit	Visit_7: Neurologic Deficit	Visit_7: Neurologic Deficit Notes	Visit_7: Presentation Notes	Visit_7: Symptoms Notes	Visit_8: (days since initial diagnosis)	Visit_8: KPS	Visit_8: Mini Mental Status Exam Score	Visit_8: History of seizures since last visit	Visit_8: Neurologic Deficit	Visit_8: Neurologic Deficit Notes	Visit_8: Presentation Notes	Visit_8: Symptoms Notes	Visit_9: (days since initial diagnosis)	Visit_9: KPS	Visit_9: Mini Mental Status Exam Score	Visit_9: History of seizures since last visit	Visit_9: Neurologic Deficit	Visit_9: Neurologic Deficit Notes	Visit_9: Presentation Notes	Visit_9: Symptoms Notes	Visit_10: (days since initial diagnosis)	Visit_10: KPS	Visit_10: Mini Mental Status Exam Score	Visit_10: History of seizures since last visit	Visit_10: Neurologic Deficit	Visit_10: Neurologic Deficit Notes	Visit_10: Presentation Notes	Visit_10: Symptoms Notes	Visit_11: (days since initial diagnosis)	Visit_11: KPS	Visit_11: Mini Mental Status Exam Score	Visit_11: History of seizures since last visit	Visit_11: Neurologic Deficit	Visit_11: Neurologic Deficit Notes	Visit_11: Presentation Notes	Visit_11: Symptoms Notes	Visit_12: (days since initial diagnosis)	Visit_12: KPS	Visit_12: Mini Mental Status Exam Score	Visit_12: History of seizures since last visit	Visit_12: Neurologic Deficit	Visit_12: Neurologic Deficit Notes	Visit_12: Presentation Notes	Visit_12: Symptoms Notes	Visit_13: (days since initial diagnosis)	Visit_13: KPS	Visit_13: Mini Mental Status Exam Score	Visit_13: History of seizures since last visit	Visit_13: Neurologic Deficit	Visit_13: Neurologic Deficit Notes	Visit_13: Presentation Notes	Visit_13: Symptoms Notes	Visit_14: (days since initial diagnosis)	Visit_14: KPS	Visit_14: Mini Mental Status Exam Score	Visit_14: History of seizures since last visit	Visit_14: Neurologic Deficit	Visit_14: Neurologic Deficit Notes	Visit_14: Presentation Notes	Visit_14: Symptoms Notes	Visit_15: (days since initial diagnosis)	Visit_15: KPS	Visit_15: Mini Mental Status Exam Score	Visit_15: History of seizures since last visit	Visit_15: Neurologic Deficit	Visit_15: Neurologic Deficit Notes	Visit_15: Presentation Notes	Visit_15: Symptoms Notes	Visit_16: (days since initial diagnosis)	Visit_16: KPS	Visit_16: Mini Mental Status Exam Score	Visit_16: History of seizures since last visit	Visit_16: Neurologic Deficit	Visit_16: Neurologic Deficit Notes	Visit_16: Presentation Notes	Visit_16: Symptoms Notes	Visit_17: (days since initial diagnosis)	Visit_17: KPS	Visit_17: Mini Mental Status Exam Score	Visit_17: History of seizures since last visit	Visit_17: Neurologic Deficit	Visit_17: Neurologic Deficit Notes	Visit_17: Presentation Notes	Visit_17: Symptoms Notes	Visit_18: (days since initial diagnosis)	Visit_18: KPS	Visit_18: Mini Mental Status Exam Score	Visit_18: History of seizures since last visit	Visit_18: Neurologic Deficit	Visit_18: Neurologic Deficit Notes	Visit_18: Presentation Notes	Visit_18: Symptoms Notes	Visit_19: (days since initial diagnosis)	Visit_19: KPS	Visit_19: Mini Mental Status Exam Score	Visit_19: History of seizures since last visit	Visit_19: Neurologic Deficit	Visit_19: Neurologic Deficit Notes	Visit_19: Presentation Notes	Visit_19: Symptoms Notes	Visit_20: (days since initial diagnosis)	Visit_20: KPS	Visit_20: Mini Mental Status Exam Score	Visit_20: History of seizures since last visit	Visit_20: Neurologic Deficit	Visit_20: Neurologic Deficit Notes	Visit_20: Presentation Notes	Visit_20: Symptoms Notes	Visit_21: (days since initial diagnosis)	Visit_21: KPS	Visit_21: Mini Mental Status Exam Score	Visit_21: History of seizures since last visit	Visit_21: Neurologic Deficit	Visit_21: Neurologic Deficit Notes	Visit_21: Presentation Notes	Visit_21: Symptoms Notes	Visit_22: (days since initial diagnosis)	Visit_22: KPS	Visit_22: Mini Mental Status Exam Score	Visit_22: History of seizures since last visit	Visit_22: Neurologic Deficit	Visit_22: Neurologic Deficit Notes	Visit_22: Presentation Notes	Visit_22: Symptoms Notes	Visit_23: (days since initial diagnosis)	Visit_23: KPS	Visit_23: Mini Mental Status Exam Score	Visit_23: History of seizures since last visit	Visit_23: Neurologic Deficit	Visit_23: Neurologic Deficit Notes	Visit_23: Presentation Notes	Visit_23: Symptoms Notes	Visit_24: (days since initial diagnosis)	Visit_24: KPS	Visit_24: Mini Mental Status Exam Score	Visit_24: History of seizures since last visit	Visit_24: Neurologic Deficit	Visit_24: Neurologic Deficit Notes	Visit_24: Presentation Notes	Visit_24: Symptoms Notes	Visit_25: (days since initial diagnosis)	Visit_25: KPS	Visit_25: Mini Mental Status Exam Score	Visit_25: History of seizures since last visit	Visit_25: Neurologic Deficit	Visit_25: Neurologic Deficit Notes	Visit_25: Presentation Notes	Visit_25: Symptoms Notes	Visit_26: (days since initial diagnosis)	Visit_26: KPS	Visit_26: Mini Mental Status Exam Score	Visit_26: History of seizures since last visit	Visit_26: Neurologic Deficit	Visit_26: Neurologic Deficit Notes	Visit_26: Presentation Notes	Visit_26: Symptoms Notes	Visit_27: (days since initial diagnosis)	Visit_27: KPS	Visit_27: Mini Mental Status Exam Score	Visit_27: History of seizures since last visit	Visit_27: Neurologic Deficit	Visit_27: Neurologic Deficit Notes	Visit_27: Presentation Notes	Visit_27: Symptoms Notes	Visit_28: (days since initial diagnosis)	Visit_28: KPS	Visit_28: Mini Mental Status Exam Score	Visit_28: History of seizures since last visit	Visit_28: Neurologic Deficit	Visit_28: Neurologic Deficit Notes	Visit_28: Presentation Notes	Visit_28: Symptoms Notes
1	W1-1-1, SN154-1	W1-1-1	 SN154-1	None	67	Male	100	106.5 kg 	180 cm	None	Yes	No	Six-week history of mental status changes	Right Temporal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Primary	No	Yes	No	Yes	0	1	67	95	NA	106	Deceased due to tumor progression	3	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	-29	300-400 mg	fosphenytoin	5	Anti-epileptic	1	3000 mg	levetiracetam	106	Steroids	1	2-16 mg	dexamethasone	106	Anti-epileptic	1	1500 mg ONE TIME	fosphenytoin	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	25	140mg	concurrent	67	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	25	WBRT	5000cGy	30	57	58	WBRT	800cGy	5	67	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	None	7.77	n/a	1	1.77	3.9	None	n/a	n/a	n/a	None	None	2	MRI	Post-surgery	No	NA	Slight residual enhancement suggested.	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	7.29	None	None	5	CT	Follow up	No	NA	There has been increase in mass effect in the right hemisphere since the prior study; unclear whether the increasing mass effect is due to parenchymal edema or increase in fluid in the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	8	CT	Follow up	No	NA	Postoperative changes as before. Continued prominent right to left shift, stable. No evidence of interval hemorrhage or hydrocephalus.	None	None	1	None	None	None	None	None	None	None	None	95	MRI	Follow up	Yes	Increase in T2 signal	Postsurgical changes, gliotic change secondary to radiation, previously identified residual tumor noted.	n/d	n/d	n/d	.44	1.12	.79	n/a	n/a	n/a	Yes	Yes	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
1	W1-1-2, SN154-5	W1-1-2	 SN154-5	http://glioblastoma.alleninstitute.org/ish/specimen/show/285041108	67	Male	100	106.5 kg 	180 cm	None	Yes	No	Six-week history of mental status changes	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	amplification	deletion	unmethylated	40%	0.15	0.1	0.07	wildtype	not detected	Primary	No	Yes	No	Yes	0	1	67	95	NA	106	Deceased due to tumor progression	3	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	-29	300-400 mg	fosphenytoin	5	Anti-epileptic	1	3000 mg	levetiracetam	106	Steroids	1	2-16 mg	dexamethasone	106	Anti-epileptic	1	1500 mg ONE TIME	fosphenytoin	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	25	140mg	concurrent	67	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	25	WBRT	5000cGy	30	57	58	WBRT	800cGy	5	67	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	None	7.77	n/a	1	1.77	3.9	None	n/a	n/a	n/a	None	None	2	MRI	Post-surgery	No	NA	Slight residual enhancement suggested.	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	7.29	None	None	5	CT	Follow up	No	NA	There has been increase in mass effect in the right hemisphere since the prior study; unclear whether the increasing mass effect is due to parenchymal edema or increase in fluid in the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	8	CT	Follow up	No	NA	Postoperative changes as before. Continued prominent right to left shift, stable. No evidence of interval hemorrhage or hydrocephalus.	None	None	1	None	None	None	None	None	None	None	None	95	MRI	Follow up	Yes	Increase in T2 signal	Postsurgical changes, gliotic change secondary to radiation, previously identified residual tumor noted.	n/d	n/d	n/d	.44	1.12	.79	n/a	n/a	n/a	Yes	Yes	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
2	W2-1-1, SN156	W2-1-1	 SN156	http://glioblastoma.alleninstitute.org/ish/specimen/show/287636995	65	Female	90	62.9 kg	160 cm	None	Yes	No	seizure	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	positive	amplification	loss	methylated	negative	0.312906321	0.710814512	0.723082006	wildtype	not detected	Primary	No	Yes	No	Yes	10	2	65	908	NA	1096	Deceased due to tumor progression	1	0	0	0	1	0	0	3	0	0	0	1	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	-1	1000 mg	levetiracetam	1096	Steroids	-1	1-2 mg	dexamethasone	111	Cholesterol lowering	-1	1200 mg	gemfibrozil	170	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	38	330mg	concurrent	82	Temozolomide	111	250 mg	maintenance 5x/mo.	223	Temozolomide	289	250 mg	maintenance 5x/mo.		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	38	IMRT	4600 cGy	23	69	70	IMRT	1400 cGy	7	82	None	None	None	None	None	None	None	None	None	None	-1	MRI	Pre-surgery	No	NA	None	19	<1	1	.641	1.6	1	n/a	n/a	n/a	None	None	3	MRI	Post-surgery	No	NA	Status post resection right frontal lobe mass. All of the enhancing tumor has been removed.	n/a	n/a	1	n/a	1.3	.68	n/d	n/d	n/d	None	None	5	CT	Follow up	No	NA	Satisfactory postoperative exam with accumulation of fluid at the resection site.	None	None	1	None	None	None	None	None	None	None	None	8	CT	Follow up	No	NA	Unchanged exam.	None	None	1	None	None	None	None	None	None	None	None	20	CT	Follow up	No	NA	Other than the usual evolutionary changes postoperatively, no significant change.	None	None	1	None	None	None	None	None	None	None	None	80	MRI	Follow up	No	NA	Slight increase in the amount of peripheral enhancement at the surgical site, may reflect response to therapy; no new abnormal foci of enhancement.	n/d	n/d	1	n/a	1.41	0.52	n/d	n/d	n/d	None	None	111	MRI	Follow up	No	Increase in T2 signal	Substantial interval decrease in enhancement and mass-like appearance at most areas on the resection margin; there is a question of increased mass effect at the superior left lateral margin of the resection, raising the possibility of progression.	1.67	None	1	0.57	0.66	None	n/d	n/d	None	None	Yes	170	MRI	Follow up	No	NA	Morphologically, there is no evidence of tumor progression.	0.78	0.25	1	1.4	1.2	.723	n/d	n/d	n/d	None	None	223	MRI	Follow up	No	NA	Enhancement appears similar or somewhat decreased in comparison with the prior examination.	n/d	0.52	1	0.3	1.37	0.628	n/d	n/d	n/d	None	None	289	MRI	Follow up	No	Increase in T2 signal	No convincing evidence of tumor progression at this time.	0.7	0.4	1	.258	1.4	.684	n/d	n/d	n/d	None	Yes	352	MRI	Follow up	No	NA	Overall findings are stable in comparison with the prior examination; no convincing interval increase in extent of T2 abnormality, nor is there new enhancement.	None	None	1	None	None	None	None	None	None	None	None	415	MRI	Follow up	No	NA	MRI scan shows no change in the areas of contrast enhancement along the medial aspect of the resection cavity, knowing the extent of surrounding hyperintensity through T2-weighted signal.  This is consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	478	MRI	Follow up	No	NA	No convincing interval change in extent of T2 hyperintensities or new enhancement. nCBV values in the areas of T2 abnormality and nodular area of diffusion restriction remain low. These are compatible with posttherapy changes.	None	None	1	None	None	None	None	None	None	None	None	569	MRI	Follow up	No	NA	No anatomic or perfusion imaging data to suggest tumor progression at this time.	None	None	1	None	None	None	None	None	None	None	None	660	MRI	Follow up	No	NA	No anatomic or perfusion data to suggest tumor progression at this time.	None	None	1	None	None	None	None	None	None	None	None	908	MRI	Follow up	Yes	NA	Tiny focus of enhancement measuring 3 mm in the periventricular region of the left frontal lobe, not previously demonstrated. Suspicious for early progressive disease.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	111	70	None	0	None	None	None	poor concentration, slowed cognition, hallucinations, falls x3	170	None	16	0	None	None	None	cognitive slowing, likely due to bifrontal lobe dysfunction and side effects from temozolomide	223	None	21	0	None	None	None	decreased motivation	289	None	19	0	None	None	None	occasional abnormal thoughts including hallucinations	352	None	21	0	None	None	None	She has had some mild decrease in her endurance.	415	None	20	0	Left	None	patient unable to complete MMSE	gradual deterioration in gait function and some very mild weakness in her left lower extremity	478	None	19	0	None	None	None	Gait has continued to be somewhat of a problem, but is fluctuating substantially where she has some very good days and some rather poor days.	569	None	22	0	None	None	None	Slight further deterioration in her walking.	660	None	17	0	None	None	None	comes in today with a new MRI. Neurologically she continues to have a slow gradual decline. She continues to be pleasantly confused. She is having increase lower extremity weakness and some days is unable to walk. She denies any headaches or seizures. She denies any pain. She does have some fatigue and this is when her walking deteriorates. All other systems are negative except as noted above.	908	None	15	0	None	None	None	Gradual deterioration in neurologic function, most notably in terms of motivation and gait; gradual progression of bilateral frontal lobe dysfunction.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
3	W3-1-1, SN159	W3-1-1	 SN159	http://glioblastoma.alleninstitute.org/ish/specimen/show/264959729	66	Female	100	50.5 kg	158.8 cm	None	No	Left	slurred speech, slight left facial droop, decreased grip strength to left hand	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	amplification	loss	unmethylated	30%	0.253645289	0.047337683	0.039502756	wildtype	detected	Primary	No	Yes	Yes	Yes	27	2	66	328	NA	982	Deceased due to tumor progression	1	1	0	0	1	0	0	4	1	1	6	0	1	0	0	0	0	0	0	Yes	Yes	No	No	No	Steroids	-4	1-12 mg	dexamethasone	982	Anti-epileptic	-4	500-2000 mg	levetiracetam 	982	antihypertensive	0	125 mg	digoxin	433	antihypertensive	0	60 mg	diltiazem	98	cardiotonic	1	10 mg	enalapril	815	Anti-depressant	77	25 mg	quetiapine	134	antihypertensive	419	10 mg	amlodipine	730	antihypertensive	556	10 mg	amlodipine	561	antihypertensive	688	180-240 mg	verapamil	982	antihypertensive	813	80 mg ONE TIME	verapamil	813	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	29	105mg	concurrent	77	Temozolomide	136	215 mg	maintenance 5 days/month x 8 cycles	272	Temozolomide	272	105 mg	21 day cycles	351	XL-184	353	None	None	377	Temozolomide	671	100mg QD	21 day cycles	762	Avastin	766	475mg 	None	973	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	28	IMRT	4500 cGy	25	77	332	Stereotactic	2647 cGy	1	332	625	Stereotactic	2000 cGy	5	631	None	None	None	None	None	2	MRI	Pre-surgery	No	NA	None	4.9	None	1	0.7	1.6	0.743	n/d	n/d	n/d	None	None	3	MRI	Post-surgery	No	NA	No evidence of residual enhancing tumor.	n/a	None	1	n/a	None	None	n/a	None	None	None	None	90	MRI	Follow up	No	NA	Enhancement is seen around the cavity, suggests treatment change.	0.5	None	1	0.58	0.90	0.58	None	None	None	None	None	134	MRI	Follow up	No	NA	Postoperative changes with interval decrease in enhancement.	n/a	0.84	1	n/a	0.826	0.91	n/d	n/d	n/d	None	None	213	MRI	Follow up	No	Increase in T2 signal	The stable nodular enhancement along the posterolateral margin of the resection cavity is unchanged.  There may be slight interval increase in the extent of abnormal FLAIR signal surrounding the resection cavity.	1.41	0.7	1	0.675	0.957	.853	None	None	None	Yes	Yes	272	MRI	Follow up	No	NA	Predominantly post-operative changes.	1.46	0.44	1	0.614	1.223	.881	None	None	None	None	None	328	MRI	Follow up	Yes	NA	Interval increase in size of enhancing focus with adjacent T2 signal change and mass effect, concerning for disease progression in the right superior parietal/posterior frontal cortex.	None	None	1	None	None	None	None	None	None	None	None	336	MRI	Follow up	Yes	NA	No significant interval change when compared to previous one. Redemonstrated is a focal nodular area of enhancement related to the posterosuperior resection margin.	None	None	1	None	None	None	None	None	None	None	None	384	MRI	Follow up	No	NA	The region of enhancement related to the posterior resection margin has increased slightly in size and now has a more cystic/necrotic appearance. However, the lesion is now centrally nonenhancing with a thin rim of peripheral enhancement whereas previously it was homogenously enhancing.  This likely represents a response to treatment.	None	None	1	None	None	None	None	None	None	None	None	405	MRI	Follow up	No	NA	Stable to slightly decreased size of ring-like nodular contrast enhancement in the superior posterior margin of the right frontal resection cavity when compared to prior MRI.	None	None	1	None	None	None	None	None	None	None	None	465	MRI	Follow up	No	NA	There has been no change in the extent of abnormal T2 signal and the small focus of ring enhancement along posterior superior aspect of the tumor is seen on the noncontrast study and outlined and appears unchanged compared to prior exams.  Overall, this is consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	521	MRI	Follow up	Yes	NA	MRI scan shows us new enhancement and worsening edema in the right temporal region.  The differential diagnosis includes progressive tumor and radiation necrosis.	None	None	1	None	None	None	None	None	None	None	None	546	MRI	Pre-surgery	Yes	NA	Interval worsening of enhancement related to the resection margin. Anatomic and perfusion data are most consistent with progression.	None	None	1	None	None	None	None	None	None	None	None	556	MRI	Post-surgery	No	NA	No evidence for residual enhancing tumor demonstrated.	None	None	1	None	None	None	None	None	None	None	None	642	MRI	Follow up	No	NA	Possibility of recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	671	MRI	Follow up	No	NA	Consistent with stable disease after CyberKnife treatment.	None	None	1	None	None	None	None	None	None	None	None	705	MRI	Follow up	No	NA	There is a question of slight increase in thickness of enhancement along the anterior aspect of the resection cavity; however, overall there is no significant change in the study.	None	None	1	None	None	None	None	None	None	None	None	730	MRI	Follow up	No	NA	There has been slight interval increase in the thickness of contrast enhancement around the margin of the resection cavity, but this is a minor change and should not be used to diagnose progressive disease.	None	None	1	None	None	None	None	None	None	None	None	762	MRI	Follow up	Yes	NA	The new MRI scan of the brain is from today and shows mild further increase in the thickness of abnormal contrast enhancement along the anterior margin of the resection cavity. The tumor is clearly showing progressive disease.	None	None	1	None	None	None	None	None	None	None	None	794	MRI	Follow up	No	NA	Findings consistent with response to therapy.	None	None	1	None	None	None	None	None	None	None	None	822	MRI	Follow up	No	NA	Findings consistent with persistent response to therapy.	None	None	1	None	None	None	None	None	None	None	None	856	MRI	Follow up	No	NA	No evidence of disease reccurence.	None	None	1	None	None	None	None	None	None	None	None	884	MRI	Follow up	No	NA	Stable pattern of enhancement and T2 signal prolongation. No clear evidence of progression at this time.	None	None	1	None	None	None	None	None	None	None	None	926	MRI	Follow up	No	NA	Stable areas of confluent irregular T2 hyperintensity in the right cerebral hemisphere, and left frontal parietal periventricular white matter.	None	None	1	None	None	None	None	None	None	None	None	973	MRI	Follow up	Possible	NA	Acute left-sided periventricular infarct, as detailed, without associated diffusion abnormality.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	14	None	27	0	None	None	None	No new problems.	90	90	None	0	None	None	None	Some persistent numbness in her left hand starting about two weeks after surgery, but this has been stable.	134	90	30	0	None	None	None	The first cycle of adjuvant temozolomide chemotherapy was tolerated poorly with abdominal pain, fairly significant nausea, and general ill feeling. 	146	90	None	1	None	None	None	Prominent nausea during cycle 1 of postradiation Temodar.  Other than that, she is clinically stable.	188	100	29	0	None	None	None	There have been no significant new problems.	213	100	30	0	None	None	None	No significant new problems since last visit.	242	100	30	0	None	None	None	No new problems to report,	272	100	30	0	None	None	None	No new problems to report.	328	None	30	0	None	None	None	She has no new problems to report.	350	90	None	0	None	None	None	Her energy is improving since decline following radiation4 month ago. Continues to be quite active.	363	90	None	0	None	None	None	She is having some nausea and anorexia as the side effect of the XL184. 	384	90	30	0	None	None	None	Over the past week off medication she has had significant improvement in nausea, vomiting, and diarrhea.  Her headache has improved.	468	90	None	0	None	None	None	She had come off the investigational XL 184 agent because of side effects.  She is now been on observation and is feeling well.	521	None	30	1	None	None	None	She is now in the observation phase and is doing well with no headaches or seizures.	538	None	30	0	None	None	None	She has no new problems to report.	549	90	None	0	None	None	None	She has been doing well since I last saw her with no significant headaches or seizures.	553	90	None	0	None	None	None	She has had no new problems.	626	90	None	0	None	None	None	She has been doing well with no significant headaches or seizures.	671	90	None	0	None	None	None	Stable disease after CyberKnife treatment.	706	90	None	0	None	None	None	Slight increase in thickness of enhancement along the anterior aspect of the resection cavity; however, overall there is no significant change in the study.	730	90	None	0	None	None	None	Slight interval increase in the thickness of contrast enhancement around the margin of the resection cavity; minor, not conclusive of progressive disease. 	762	80	None	0	None	None	None	Tumor is clearly showing progressive disease, halting TMZ and starting Avastin.	800	70	None	0	Left	left sided weakness	None	Sensory problems in the left side making it difficult for her to use her left arm or to walk without assistance. 	825	70	None	0	None	None	None	Recently admitted to the hospital because of hypertension and her blood pressures, now under control. No further episodes of sudden onset left-sided weakness, although still unable to detect sensation on the left side to light touch.	832	70	None	0	None	None	ER visit	Early followup; potential toxicity after starting Trileptal. Dizziness, confusion, aphasic. CT scan revealed no acute findings, Trileptal discontinued. 	884	70	None	0	None	None	None	She has no new problems to report.  She continues to tolerate the every 2-week Avastin treatments well.	926	70	None	0	None	None	None	Some fluctuations in neurologic status, but overall has been doing well. 	None	None	None	None	None	None	None	None
3	SN236, W3-2-1	 W3-2-1	SN236	None	66	Female	100	50.5 kg	158.8 cm	None	No	Left	slurred speech, slight left facial droop, decreased grip strength to left hand	Right Temporal	Complete resection	Yes	Yes	recurrent/residual glioblastoma, WHO grade IV	NA	NA	NA	unmethylated	20%	0.39	0.06	0.03	NA	detected	Recurrent	Yes	Yes	Yes	Yes	27	556	68	328	NA	982	Deceased due to tumor progression	1	1	0	0	1	0	0	4	1	1	6	0	1	0	0	0	0	0	0	Yes	Yes	No	No	No	Steroids	-4	1-12 mg	dexamethasone	982	Anti-epileptic	-4	500-2000 mg	levetiracetam 	982	antihypertensive	0	125 mg	digoxin	433	antihypertensive	0	60 mg	diltiazem	98	cardiotonic	1	10 mg	enalapril	815	Anti-depressant	77	25 mg	quetiapine	134	antihypertensive	419	10 mg	amlodipine	730	antihypertensive	556	10 mg	amlodipine	561	antihypertensive	688	180-240 mg	verapamil	982	antihypertensive	813	80 mg ONE TIME	verapamil	813	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	29	105mg	concurrent	77	Temozolomide	136	215 mg	maintenance 5 days/month x 8 cycles	272	Temozolomide	272	105 mg	21 day cycles	351	XL-184	353	None	None	377	Temozolomide	671	100mg QD	21 day cycles	762	Avastin	766	475mg 	None	973	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	28	IMRT	4500 cGy	25	77	332	Stereotactic	2647 cGy	1	332	625	Stereotactic	2000 cGy	5	631	None	None	None	None	None	2	MRI	Pre-surgery	No	NA	None	4.9	None	1	0.7	1.6	0.743	n/d	n/d	n/d	None	None	3	MRI	Post-surgery	No	NA	No evidence of residual enhancing tumor.	n/a	None	1	n/a	None	None	n/a	None	None	None	None	90	MRI	Follow up	No	NA	Enhancement is seen around the cavity, suggests treatment change.	0.5	None	1	0.58	0.90	0.58	None	None	None	None	None	134	MRI	Follow up	No	NA	Postoperative changes with interval decrease in enhancement.	n/a	0.84	1	n/a	0.826	0.91	n/d	n/d	n/d	None	None	213	MRI	Follow up	No	Increase in T2 signal	The stable nodular enhancement along the posterolateral margin of the resection cavity is unchanged.  There may be slight interval increase in the extent of abnormal FLAIR signal surrounding the resection cavity.	1.41	0.7	1	0.675	0.957	.853	None	None	None	Yes	Yes	272	MRI	Follow up	No	NA	Predominantly post-operative changes.	1.46	0.44	1	0.614	1.223	.881	None	None	None	None	None	328	MRI	Follow up	Yes	NA	Interval increase in size of enhancing focus with adjacent T2 signal change and mass effect, concerning for disease progression in the right superior parietal/posterior frontal cortex.	None	None	1	None	None	None	None	None	None	None	None	336	MRI	Follow up	Yes	NA	No significant interval change when compared to previous one. Redemonstrated is a focal nodular area of enhancement related to the posterosuperior resection margin.	None	None	1	None	None	None	None	None	None	None	None	384	MRI	Follow up	No	NA	The region of enhancement related to the posterior resection margin has increased slightly in size and now has a more cystic/necrotic appearance. However, the lesion is now centrally nonenhancing with a thin rim of peripheral enhancement whereas previously it was homogenously enhancing.  This likely represents a response to treatment.	None	None	1	None	None	None	None	None	None	None	None	405	MRI	Follow up	No	NA	Stable to slightly decreased size of ring-like nodular contrast enhancement in the superior posterior margin of the right frontal resection cavity when compared to prior MRI.	None	None	1	None	None	None	None	None	None	None	None	465	MRI	Follow up	No	NA	There has been no change in the extent of abnormal T2 signal and the small focus of ring enhancement along posterior superior aspect of the tumor is seen on the noncontrast study and outlined and appears unchanged compared to prior exams.  Overall, this is consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	521	MRI	Follow up	Yes	NA	MRI scan shows us new enhancement and worsening edema in the right temporal region.  The differential diagnosis includes progressive tumor and radiation necrosis.	None	None	1	None	None	None	None	None	None	None	None	546	MRI	Pre-surgery	Yes	NA	Interval worsening of enhancement related to the resection margin. Anatomic and perfusion data are most consistent with progression.	None	None	1	None	None	None	None	None	None	None	None	556	MRI	Post-surgery	No	NA	No evidence for residual enhancing tumor demonstrated.	None	None	1	None	None	None	None	None	None	None	None	642	MRI	Follow up	No	NA	Possibility of recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	671	MRI	Follow up	No	NA	Consistent with stable disease after CyberKnife treatment.	None	None	1	None	None	None	None	None	None	None	None	705	MRI	Follow up	No	NA	There is a question of slight increase in thickness of enhancement along the anterior aspect of the resection cavity; however, overall there is no significant change in the study.	None	None	1	None	None	None	None	None	None	None	None	730	MRI	Follow up	No	NA	There has been slight interval increase in the thickness of contrast enhancement around the margin of the resection cavity, but this is a minor change and should not be used to diagnose progressive disease.	None	None	1	None	None	None	None	None	None	None	None	762	MRI	Follow up	Yes	NA	The new MRI scan of the brain is from today and shows mild further increase in the thickness of abnormal contrast enhancement along the anterior margin of the resection cavity. The tumor is clearly showing progressive disease.	None	None	1	None	None	None	None	None	None	None	None	794	MRI	Follow up	No	NA	Findings consistent with response to therapy.	None	None	1	None	None	None	None	None	None	None	None	822	MRI	Follow up	No	NA	Findings consistent with persistent response to therapy.	None	None	1	None	None	None	None	None	None	None	None	856	MRI	Follow up	No	NA	No evidence of disease reccurence.	None	None	1	None	None	None	None	None	None	None	None	884	MRI	Follow up	No	NA	Stable pattern of enhancement and T2 signal prolongation. No clear evidence of progression at this time.	None	None	1	None	None	None	None	None	None	None	None	926	MRI	Follow up	No	NA	Stable areas of confluent irregular T2 hyperintensity in the right cerebral hemisphere, and left frontal parietal periventricular white matter.	None	None	1	None	None	None	None	None	None	None	None	973	MRI	Follow up	Possible	NA	Acute left-sided periventricular infarct, as detailed, without associated diffusion abnormality.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	14	None	27	0	None	None	None	No new problems.	90	90	None	0	None	None	None	Some persistent numbness in her left hand starting about two weeks after surgery, but this has been stable.	134	90	30	0	None	None	None	The first cycle of adjuvant temozolomide chemotherapy was tolerated poorly with abdominal pain, fairly significant nausea, and general ill feeling. 	146	90	None	1	None	None	None	Prominent nausea during cycle 1 of postradiation Temodar.  Other than that, she is clinically stable.	188	100	29	0	None	None	None	There have been no significant new problems.	213	100	30	0	None	None	None	No significant new problems since last visit.	242	100	30	0	None	None	None	No new problems to report,	272	100	30	0	None	None	None	No new problems to report.	328	None	30	0	None	None	None	She has no new problems to report.	350	90	None	0	None	None	None	Her energy is improving since decline following radiation4 month ago. Continues to be quite active.	363	90	None	0	None	None	None	She is having some nausea and anorexia as the side effect of the XL184. 	384	90	30	0	None	None	None	Over the past week off medication she has had significant improvement in nausea, vomiting, and diarrhea.  Her headache has improved.	468	90	None	0	None	None	None	She had come off the investigational XL 184 agent because of side effects.  She is now been on observation and is feeling well.	521	None	30	1	None	None	None	She is now in the observation phase and is doing well with no headaches or seizures.	538	None	30	0	None	None	None	She has no new problems to report.	549	90	None	0	None	None	None	She has been doing well since I last saw her with no significant headaches or seizures.	553	90	None	0	None	None	None	She has had no new problems.	626	90	None	0	None	None	None	She has been doing well with no significant headaches or seizures.	671	90	None	0	None	None	None	Stable disease after CyberKnife treatment.	706	90	None	0	None	None	None	Slight increase in thickness of enhancement along the anterior aspect of the resection cavity; however, overall there is no significant change in the study.	730	90	None	0	None	None	None	Slight interval increase in the thickness of contrast enhancement around the margin of the resection cavity; minor, not conclusive of progressive disease. 	762	80	None	0	None	None	None	Tumor is clearly showing progressive disease, halting TMZ and starting Avastin.	800	70	None	0	Left	left sided weakness	None	Sensory problems in the left side making it difficult for her to use her left arm or to walk without assistance. 	825	70	None	0	None	None	None	Recently admitted to the hospital because of hypertension and her blood pressures, now under control. No further episodes of sudden onset left-sided weakness, although still unable to detect sensation on the left side to light touch.	832	70	None	0	None	None	ER visit	Early followup; potential toxicity after starting Trileptal. Dizziness, confusion, aphasic. CT scan revealed no acute findings, Trileptal discontinued. 	884	70	None	0	None	None	None	She has no new problems to report.  She continues to tolerate the every 2-week Avastin treatments well.	926	70	None	0	None	None	None	Some fluctuations in neurologic status, but overall has been doing well. 	None	None	None	None	None	None	None	None
4	W4-1-1, SN160	W4-1-1	 SN160	http://glioblastoma.alleninstitute.org/ish/specimen/show/268415230	51	Female	90	86.183 kg	163.56 cm	30	No	Left	Left-sided weakness 4/5, headache.	Right Frontal	Complete resection	Yes	Yes	Glioblastoma WHO grade IV 	Normal	gain	deletion	unmethylated	80%	0.252065773	0.037667297	0.010635661	wildtype	not detected	Primary	No	Yes	Yes	Yes	18	0	51	102	NA	540	Deceased due to tumor progression	2	1	0	0	4	0	0	3	1	0	1	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-4	2-16 mg	dexamethasone	488	Anti-epileptic	-4	100-300 mg	fosphenytoin	5	Anti-epileptic	-3	100 mg	phenytoin	87	Steroids	-3	1000-2000 mg	levetiracetam	488	Anti-depressant	-3	10-20 mg	citalopram	540	Steroids	259	5 mg	prednisone	340	antihypertensive	273	25 mg	losartan	540	Steroids	355	12.5-20 mg	prednisone	540	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	22	140mg/day	concurrent	69	Temozolomide	78	140mg/day	maintenance	94	Temozolomide	133	100mg/day	long-term		Avastin	214	875mg	None	425	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	26	IMRT	4500 cGy	25	70	26	IMRT	1080 cGy	6	70	None	None	None	None	None	None	None	None	None	None	-4	MRI	Pre-surgery	No	NA	Large rim-enhancing parenchymal brain mass in the right frontal lobe with central necrosis and moderate amount of surrounding edema. These findings are most consistent with aggressive brain neoplasm, most likely glioblastoma multiforme.	None	None	1	None	None	None	None	None	None	None	None	0	MRI	Post-surgery	No	NA	Some minimal residual enhancement may be present in the caudal most aspect of the resection margin.	None	None	1	None	None	None	None	None	None	None	None	102	MRI	Pre-surgery	Yes	NA	Findings consistent with nodular recurrence. There is extensive abnormal T2 signal.	None	None	1	None	None	None	None	None	None	None	None	106	MRI	Post-surgery	No	NA	The predominantly solid-appearing region of enhancement seen related to the right lateral margin of the prior resection cavity has been resected. The more posteriorly positioned nodular area of enhancement has been partially resected and continues to demonstrate enhancement along its left lateral aspect.	None	None	1	None	None	None	None	None	None	None	None	170	MRI	Follow up	Yes	NA	Shows a new left frontal lesion consistent with GBM metastasis.	None	None	1	None	None	None	None	None	None	None	None	205	MRI	Follow up	No	NA	No evidence for new or progressive disease.	None	None	1	None	None	None	None	None	None	None	None	256	MRI	Follow up	No	NA	Residual enhancement, decreased enhancement; significant reduction in the size of the tumor following Cyberknife treatment.	None	None	1	None	None	None	None	None	None	None	None	316	MRI	Follow up	Yes	NA	In the superior-medial aspect, there is an area of suspected enhancement, worrisome for disease progression.	None	None	1	None	None	None	None	None	None	None	None	371	MRI	Follow up	No	NA	No definite enhancement is appreciated. Previously reported enhancement is not noted on the current study.	None	None	1	None	None	None	None	None	None	None	None	425	MRI	Follow up	Yes	NA	Mild hazy enhancement lateral to the probable infarct, considering the presence of enhancement prior to the current study, tumor progression cannot be fully excluded.	None	None	1	None	None	None	None	None	None	None	None	446	MRI	Follow up	Yes	NA	In comparison with the prior examination, there has been interval worsening in extent of T2 signal change within the brain parenchyma, consistent with disease progression. Also, there are new areas of enhancement, again suggestive of disease progression.	None	None	1	None	None	None	None	None	None	None	None	474	MRI	Follow up	Yes	NA	Enlarging masslike enhancement posterior to the right frontal resection cavity, highly suspicious for progressive tumor.	None	None	1	None	None	None	None	None	None	None	None	483	MRI	Follow up	Yes	NA	Enhancing enlarging soft tissue mass posterior to the right frontal resection cavity is  suspicious for recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	21	90	None	0	Left	Left pronator drift. 	None	Fatigued, high fever; patient is depressed.	36	90	None	0	None	None	None	Right sided facial swelling, presthesias, headache. 	78	90	None	0	None	None	None	Temodar radiation tolerated well. Decreased appetite, fatigue, night sweats.	113	90	None	0	None	left weakness	None	Temodar tolerated well. Energy is better, appetite is better. Sleeping better. Still weak on left side, right is better.	126	90	None	0	None	None	None	The patient had a repeat biopsy.	158	80	None	0	Left	left sided weakness	None	Weak left arm, grip poor, swollen. Very dry skin probably related to the Temodar. Decreased appetite, fatigue. 	183	70	None	0	Right	Right Hemiparesis	None	Her functional status has remained the same. She has weakness of the left arm but this is possibly attibutable, in part, to a frozen shoulder. Decreased appetite, fatigue. Otherwise, she feels the same.	209	80	None	0	Left	Left hemiparesis	None	Weakness on upper extremeties. 	259	80	None	0	Left	Left hemiparesis	None	Left sided weakness; not fully functional; incontinence.	322	70	None	0	Left	left hemiparesis. 	None	Decreased appetite, fatigue.	342	80	None	0	Left	left hemiparesis. 	None	n/a	355	70	None	0	Left	left hemiparesis	None	Balance is weak; beginning to fall more frequently.	369	60	None	0	Left	left hemiparesis. 	None	Occasional headaches in the supraorbital region. Falling more. 	376	60	None	0	Left	left hemiparesis	None	Remains weak. 	425	50	None	1	Left	left hemiparesis	None	decrease in balance ability to control the left leg. can no longer stand for longer than 15 minutes. drags left foot when walking. MRI reflected a probable previous stroke. 	446	50	None	0	Left	left hemiparesis. 	None	Worsening ataxia; physical state remains the same. 	460	50	None	1	Left	left hemiplegia	None	Had stroke on Avastin. Patient was also noted to have some hydrocephalus. Decreased appetite, fatigue.	474	50	None	1	Left	left hemiparesis	None	Right legt somewhat compromised. Overall, patient feels about the same.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
4	W4-2-1, SN174	W4-2-1	 SN174	None	51	Female	90	86.183 kg	163.56 cm	30	No	Left	Left-sided weakness 4/5, headache.	Right Frontal	Complete resection (may not be truly recurrent tumor)	Yes	Yes	Glioblastoma WHO grade IV 	NA	NA	NA	unmethylated	60%	0.42	0.05	0.03	NA	NA	Recurrent	Yes	Yes	No	Yes	18	105	51	102	NA	540	Deceased due to tumor progression	2	1	0	0	4	0	0	3	1	0	1	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-4	2-16 mg	dexamethasone	488	Anti-epileptic	-4	100-300 mg	fosphenytoin	5	Anti-epileptic	-3	100 mg	phenytoin	87	Steroids	-3	1000-2000 mg	levetiracetam	488	Anti-depressant	-3	10-20 mg	citalopram	540	Steroids	259	5 mg	prednisone	340	antihypertensive	273	25 mg	losartan	540	Steroids	355	12.5-20 mg	prednisone	540	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	22	140mg/day	concurrent	69	Temozolomide	78	140mg/day	maintenance	94	Temozolomide	133	100mg/day	long-term		Avastin	214	875mg	None	425	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	26	IMRT	4500 cGy	25	70	26	IMRT	1080 cGy	6	70	None	None	None	None	None	None	None	None	None	None	-4	MRI	Pre-surgery	No	NA	Large rim-enhancing parenchymal brain mass in the right frontal lobe with central necrosis and moderate amount of surrounding edema. These findings are most consistent with aggressive brain neoplasm, most likely glioblastoma multiforme.	None	None	1	None	None	None	None	None	None	None	None	0	MRI	Post-surgery	No	NA	Some minimal residual enhancement may be present in the caudal most aspect of the resection margin.	None	None	1	None	None	None	None	None	None	None	None	102	MRI	Pre-surgery	Yes	NA	Findings consistent with nodular recurrence. There is extensive abnormal T2 signal.	None	None	1	None	None	None	None	None	None	None	None	106	MRI	Post-surgery	No	NA	The predominantly solid-appearing region of enhancement seen related to the right lateral margin of the prior resection cavity has been resected. The more posteriorly positioned nodular area of enhancement has been partially resected and continues to demonstrate enhancement along its left lateral aspect.	None	None	1	None	None	None	None	None	None	None	None	170	MRI	Follow up	Yes	NA	Shows a new left frontal lesion consistent with GBM metastasis.	None	None	1	None	None	None	None	None	None	None	None	205	MRI	Follow up	No	NA	No evidence for new or progressive disease.	None	None	1	None	None	None	None	None	None	None	None	256	MRI	Follow up	No	NA	Residual enhancement, decreased enhancement; significant reduction in the size of the tumor following Cyberknife treatment.	None	None	1	None	None	None	None	None	None	None	None	316	MRI	Follow up	Yes	NA	In the superior-medial aspect, there is an area of suspected enhancement, worrisome for disease progression.	None	None	1	None	None	None	None	None	None	None	None	371	MRI	Follow up	No	NA	No definite enhancement is appreciated. Previously reported enhancement is not noted on the current study.	None	None	1	None	None	None	None	None	None	None	None	425	MRI	Follow up	Yes	NA	Mild hazy enhancement lateral to the probable infarct, considering the presence of enhancement prior to the current study, tumor progression cannot be fully excluded.	None	None	1	None	None	None	None	None	None	None	None	446	MRI	Follow up	Yes	NA	In comparison with the prior examination, there has been interval worsening in extent of T2 signal change within the brain parenchyma, consistent with disease progression. Also, there are new areas of enhancement, again suggestive of disease progression.	None	None	1	None	None	None	None	None	None	None	None	474	MRI	Follow up	Yes	NA	Enlarging masslike enhancement posterior to the right frontal resection cavity, highly suspicious for progressive tumor.	None	None	1	None	None	None	None	None	None	None	None	483	MRI	Follow up	Yes	NA	Enhancing enlarging soft tissue mass posterior to the right frontal resection cavity is  suspicious for recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	21	90	None	0	Left	Left pronator drift. 	None	Fatigued, high fever; patient is depressed.	36	90	None	0	None	None	None	Right sided facial swelling, presthesias, headache. 	78	90	None	0	None	None	None	Temodar radiation tolerated well. Decreased appetite, fatigue, night sweats.	113	90	None	0	None	left weakness	None	Temodar tolerated well. Energy is better, appetite is better. Sleeping better. Still weak on left side, right is better.	126	90	None	0	None	None	None	The patient had a repeat biopsy.	158	80	None	0	Left	left sided weakness	None	Weak left arm, grip poor, swollen. Very dry skin probably related to the Temodar. Decreased appetite, fatigue. 	183	70	None	0	Right	Right Hemiparesis	None	Her functional status has remained the same. She has weakness of the left arm but this is possibly attibutable, in part, to a frozen shoulder. Decreased appetite, fatigue. Otherwise, she feels the same.	209	80	None	0	Left	Left hemiparesis	None	Weakness on upper extremeties. 	259	80	None	0	Left	Left hemiparesis	None	Left sided weakness; not fully functional; incontinence.	322	70	None	0	Left	left hemiparesis. 	None	Decreased appetite, fatigue.	342	80	None	0	Left	left hemiparesis. 	None	n/a	355	70	None	0	Left	left hemiparesis	None	Balance is weak; beginning to fall more frequently.	369	60	None	0	Left	left hemiparesis. 	None	Occasional headaches in the supraorbital region. Falling more. 	376	60	None	0	Left	left hemiparesis	None	Remains weak. 	425	50	None	1	Left	left hemiparesis	None	decrease in balance ability to control the left leg. can no longer stand for longer than 15 minutes. drags left foot when walking. MRI reflected a probable previous stroke. 	446	50	None	0	Left	left hemiparesis. 	None	Worsening ataxia; physical state remains the same. 	460	50	None	1	Left	left hemiplegia	None	Had stroke on Avastin. Patient was also noted to have some hydrocephalus. Decreased appetite, fatigue.	474	50	None	1	Left	left hemiparesis	None	Right legt somewhat compromised. Overall, patient feels about the same.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
5	W5-1-1, SN161	W5-1-1	 SN161	http://glioblastoma.alleninstitute.org/ish/specimen/show/286570366	65	Female	90	85.3 kg 	160 cm	None	No	Left	Weakness of left upper extremity, left facial droop.	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Normal	amplification	loss	unmethylated	20%	0.751090128	0	0.782615912	wildtype	not detected	Primary	No	Yes	Yes	Yes	19	0	65	115	1029	NA	NA	2	1	0	0	1	0	0	3	1	3	0	0	0	0	0	0	0	0	0	Yes	Yes	No	No	No	Anti-epileptic	0	1500 mg	levetiracetam	126	Steroids	0	2-16 mg	dexamethosone	37	Anti-depressant	8	10 mg	citalopram	14	Anti-epileptic	126	500 mg	divalproex	231	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	35	140mg	concurrent	81	Temozolomide	115	180mg	maintenance 5 days/month 	141	Temozolomide	141	380mg	maintenance 5 days/month	216	XL-184	238	125mg	clinical trial	269	XL-184	269	75mg	clinical trial	463	XL-184	463	50mg	clinical trial	1029	Avastin	845	None	1x/2wks		None	None	None	None	None	None	None	None	None	None	36	IMRT	4500 cGy	25	69	70	IMRT	1440 cGy	8	81	None	None	None	None	None	None	None	None	None	None	1	MRI	Pre-surgery	No	NA	None	9.76	0.28	1	0.748	1.474	0.821	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Interval resection of an anterior/inferior right parietal mass with a minimal amount of hemorrhage about the resection cavity perimeter and in the right subdural space.	n/a	n/a	1	n/a	n/a	None	None	None	None	None	None	115	MRI	Follow up	Yes	NA	Postoperative changes; region of enhancement worrisome for residual tumor.	4.21	0.7	1	0.996	1.462	0.790	None	None	None	None	None	129	MRI	Follow up	Yes	Increase in size	Interval increase in extent of the "solid" portion of the tumor at the right thalamusl; findings consistent with at least partial response to therapy.	0.45	1.8	1	0.752	1.498	0.643	None	None	None	None	None	174	MRI	Follow up	Yes	Increase in T2 signal	Slight interval increase in size of region of enhancement, probably represents post-treatment effect. Interval increase in size of FLAIR-hyperintensity, probably represents treatment effect, rather than recurrent tumor. However, further close imaging followup is warranted.	1.46	0.35	1	0.944	0.976	0.705	None	None	None	Yes	Yes	216	MRI	Follow up	Yes	NA	Region of abnormal enhancement and mass effect with surrounding FLAIR hyperintensity centered superior and laterial to the right thalmus is suspicious for tumor recurrence.	None	None	1	None	None	None	None	None	None	None	None	269	MRI	Follow up	No	NA	MRI shows a diminution in the overall size of the tumor on T1 post contrast axial images sufficient for a minor response, but not sufficient for a partial response.  Overall, however, there has been marked decrease in the conspicuity of contrast enhancement.	None	None	1	None	None	None	None	None	None	None	None	464	MRI	Follow up	No	NA	MRI shows no evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	497	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	545	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	644	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	689	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	752	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	70	90	None	0	Left	left hemiparesis	None	Unscheduled visit because of vesicular rash.	115	60	28	1	Left	left hemiparesis	None	Gradual, steady improvement in left lower extremity strength. Left arm is still very weak and functionally useless. 	126	70	None	0	Left	left hemiparesis	None	Keppra discontinued due to rash, risk of seizure possibly increased.	174	70	29	1	Left	left hemiparesis	None	Functions improving gradually. Elevated LFTs, discontinue dapsone. 	216	None	28	0	Left	left hemiparesis	None	Slightly better control of left leg.	227	70	None	0	Left	left hemiparesis	None	n/a	231	70	None	0	Left	left hemiparesis	None	None	269	70	None	0	Left	left hemiparesis	None	Tolerating therapy without difficulties.	393	70	None	0	Left	left hemiparesis	None	Diminution in taste, decreased appetite, and has had corresponding weight loss.  	464	70	None	0	Left	left hemiparesis	None	n/a	482	70	None	0	Left	left hemiparesis	None	Recurrent episodes of diarrhea. Continues to have decreased appetite. Weight has dropped to a greater than 20% reduction of baseline weight at the initiation of the study.	497	70	None	0	Left	left hemiparesis	None	Weight stabilized.	525	70	None	0	Left	left hemiparesis	None	Denies any problems with rash, diarrhea is easily managed, her energy level is adequate and her appetite is improved. She does admit to challenges, however, maintaining weight.	545	70	None	0	Left	left hemiparesis	None	She had two days of diarrhea last week. She admits to having a decreased appetite with weight loss, but in general, she has a good appetite. Her energy level is adequate and she has been able to maintain weight until this recent episode of diarrhea. 	644	70	None	0	Left	left hemiparesis	None	n/a	752	70	None	1	Left	left hemiparesis	None	Had partial seizure with postictal confusion a couple days ago, uneventful recovery. 	840	60	None	1	Left	left hemiparesis	None	Had another partial seizure about a month ago with postictal confusion, but reluctant to take anti convulsant medication. 	926	60	None	0	Left	left hemiparesis	None	Weight loss, discontinue XL 184 for a week.	1029	50	None	0	Left	left hemiparesis	None	Failed first investigational therapy and now treated on second relapse with single agent Avastin.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
6	W6-1-1, SN162	W6-1-1	 SN162	http://glioblastoma.alleninstitute.org/ish/specimen/show/268000781	73	Female	90	55.067 kg	162.6 cm	None	No	Right	Difficulty with reading comprehension and writing.	Left Occipital	Complete resection	Yes	Yes	Glioblastoma WHO grade IV 	Normal	gain	Normal	unmethylated	90%	0.193418734	0.047114023	0.019431304	wildtype	not detected	Primary	No	Yes	No	Yes	16	14	73	107	NA	647	Deceased due to tumor progression	3	1	0	0	1	0	0	2	1	0	1	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	12	200 mg	phenytoin	107	Steroids	12	12-16 mg	dexamethasone	107	Anti-epileptic	14	300 mg	fosphenytoin	16	Anti-epileptic	284	1000 mg	levetiracetam	547	antihypertensive	380	5 mg	amlodipine	512	Anti-depressant	436		xanax	547	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	50	120 mg/day	concurrent	87	Temozolomide	110	200 mg/day	maintenance 5x/mo.	165	Avastin	165	None	1x/2 wks		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	42	IMRT	5940 cGy	33	90	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery		NA	Multiple small focal areas of increased signal intensity are seen in the periventricular  and subcortical  white matter on T2 weighted and FLAIR sequances. These measured up to 8 mm, probably represent old infarcts secondary to small vessel disease. Nonspecific appearence of the bilobed enhancing abnormality, left occipital lobe with surrounding edema. In the differential diagnosis, one has to consider parasitic abscess including cysticercosis and toxoplasmosis, bacterial abscess and glioblastoma multiforme.	None	None	1	None	None	None	None	None	None	None	None	12	MRI	Pre-surgery		NA	Centrally necrotic mass in the left temporo-occipital region measures 5.2 cm x 2.8 cm lesion extends to the occipital horn of the left lateral ventrical.	None	None	1	None	None	None	None	None	None	None	None	14	CT	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	15	MRI	Post-surgery	No	NA	No convincing evidence of residual tumor.	None	None	1	None	None	None	None	None	None	None	None	107	MRI	Follow up	Yes	NA	A few anterior nodular regions of enhancement about the resection cavity, possibly representing tumor recurrence.	None	None	1	None	None	None	None	None	None	None	None	165	MRI	Follow up	Yes	NA	Significant interval progression involving the left sided resection cavity, concerning for disease progression.  Short interval follow up should be considered.	None	None	1	None	None	None	None	None	None	None	None	221	MRI	Follow up	No	NA	Compared to previous one, there has been significant interval decrease in the amount of enhancement seen related to the resection margin and adjacent temporal and parietal lobes. There has been progression of white matter change within the cerebral hemispheres bilaterally in a roughly symmetric pattern, most consistent with radiation change.	None	None	1	None	None	None	None	None	None	None	None	284	MRI	Follow up	No	NA	Overall, there is no evidence of tumor progression at this time. Decreasing enhancement about the resection margin.	None	None	1	None	None	None	None	None	None	None	None	342	MRI	Follow up	No	NA	There may be slight decrease in enhancement in the left temporal lobe periventricular region as compared to the prior study. No new lesion seen.	None	None	1	None	None	None	None	None	None	None	None	474	MRI	Follow up	Yes	NA	Streaky areas of enhancement around the post-op encephalomalacia and extending into the temporal and parietal lobes consistent with progression of the neoplasm.	None	None	1	None	None	None	None	None	None	None	None	536	MRI	Follow up	Yes	NA	Findings are consistent with tumor progression. Increasing enhancing soft tissue infiltrating anteriorly into the temporal lobe and superiorly into the parietal lobe with a small component extending across the corpus callosum into the right occipital region.	None	None	1	None	None	None	None	None	None	None	None	544	MRI	Follow up	Yes	NA	There is clear tumor progression in the left side supratentorial brain with tumor extension through the splenium of the corpus callosum. The overall degree of contrast enhancement has also increased.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	26	90	None	0	Right	right homonymous hemianopia.	None	Difficulty with right-sided vision.	107	None	27	0	Right	right homonymous hemianopia.	None	Fatigue.	165	70	17	0	Right	right homonymous hemianopia.	None	n/a	221	None	25	0	Right	right homonymous hemianopia.	None	Deteriorating language, speech is returning to baseline. 	260	80	None	0	Right	right homonymous hemianopia	None	Reading is still arduous, but spelling and writing are becoming better. Denies any other new neurological deficits. 	284	80	None	1	Right	right homonymous hemianopia.	None	One month ago ER visit; patient reported to have numbness of the left arm and leg. Probable seizure. 	309	70	None	0	Right	right homonymous hemianopia.	None	Keppra is giving patient some difficulty with fatigue and loss of appetite.	337	70	None	1	Right	right homonymous hemianopia.	None	Difficulty with concentration. Probable previous seizure, which was demonstrated by some difficulty the right eye as well as also memory and speech. Resolved.	351	70	None	0	Right	right homonymous hemianopia.	None	Some difficulty with thinking; relatively stable.	380	70	None	1	Right	right homonymous hemianopia.	None	Moderate seizure yesterday.  	414	60	None	1	Right	right homonymous hemianopia.	None	Recent seizure problem 3 days ago. Patient is still having difficutly with vision and comprehension. Hand-eye coordination is somewhat worse than before.	436	60	None	1	Right	right homonymous hemianopia.	None	Another small seizure of the right extremity; they are generally accompanied by difficulty with speech.	485	50	None	1	Right	right homonymous hemianopia.	None	Recurrent albeit minor seizures. One month ago patient had either a seizure or a fall with pain. Then 3 days later patient was admitted with mental status changes, probable dehydration. Patient may have had petit mal seizure yesterday. Weight loss, mild.	512	60	None	0	Right	right homonymous hemianopia.	None	Difficulty with concentration. No more seizures or hospitalizations for UTI. 	540	60	None	0	Right	right homonymous hemianopia.	None	No changes.	547	50	None	0	Right	right homonymous hemianopia.	None	No new neurological complaints.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
7	W7-1-1, SN163	W7-1-1	 SN163	http://glioblastoma.alleninstitute.org/ish/specimen/show/293485791	61	Male	100	79.833 kg	182.61 cm	26	No	No	Progressive right-sided/pancranial headaches, nausea, emesis, sense of imbalance, dizziness.	Right Temporal	Subtotal resection 90%	Yes	Yes	Glioblastoma WHO grade IV 	Normal	gain	loss	methylated	negative	0.473459822	0.38712508	0.395032755	wildtype	not detected	Primary	No	Yes	No	Yes	5	0	61	366	NA	437	Deceased due to tumor progression	1	0	0	0	1	0	0	1	1	0	2	1	0	0	1	0	0	0	0	No	No	No	No	No	Anti-epileptic	-2	1000-2000 mg	levetiracetam	392	Steroids	-2	8-24 mg	dexamethasone	392	Cholesterol lowering	-2	20 mg	simvastatin	9	antihypertensive	12	12.5 mg	olmesartan	392	antihypertensive	392	20 mg	lisinopril	392	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	20	155mg QD	21 day cycles	68	Avastin	371	10mg/kg	Q14D		Irinotecan	385	125mg/m2	4 out of 6 week cycles	413	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	20	IMRT	5940 cGy	33	68	366	Stereotactic	38 Gy		366	None	None	None	None	None	None	None	None	None	None	-1	MRI	Pre-surgery	No	NA	Ring-enhancing lesion within the right temporal lobe with surrounding edema and mass effect.	None	None	1	None	None	None	None	None	None	None	None	0	MRI	Post-surgery	No	NA	The majority of the right temporal region tumor has been removed. There are findings worrisome for a small amount of residual enhancing tumor at the anterior resection cavity margin.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Follow up	No	NA	Enhancing tissue concerning for residual tumor has largely been removed from the anteromedial aspect of the right temporal resection cavity.	None	None	1	None	None	None	None	None	None	None	None	62	MRI	Follow up	No	NA	None	None	None	None	None	None	None	None	None	None	None	None	109	MRI	Follow up	No	NA	Small volume of rim enhancement.	None	None	1	None	None	None	None	None	None	None	None	366	MRI	Follow up	Yes	NA	Increase in size and extent of enhancement of lesion involving the left mid brain and cerebellum.  Increase in size of the left inferior frontal lobe enhancing lesion, now measuring 7 x 5 mm in size.  Several additional patchy areas of enhancement in the left frontal lobe.	None	None	1	None	None	None	None	None	None	None	None	380	MRI	Follow up	Yes	NA	Evidence for previous right temporoparietal tumor resection with large area of encephalomalacia and surrounding gliosis identified without significant enhancement.  Two enhancing foci identified within the left frontal lobe, measuring up to 1cm.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	9	100	None	0	None	None	None	In the intervening time, he has done exceedingly well and notes no symptoms at the present time. 	99	100	None	0	None	None	None	Occasional headaches. Speech has been good. No memory changes. Overall, doing great. 	343	90	None	0	None	None	None	The only new complaints of the vision changes, with diplopia and dizziness. 	392	None	26	0	None	None	None	Approximately one month ago, he began to complain of dizziness and some diplopia and mild mental confusion. A few days after that he underwent gamma knife treatment for six lesions.	400	70	None	1	None	None	The patient is neurologically deteriorating	He has been unsteady of foot. There has been no worsening confusion. Appetite improved today. There is no nausea, vomiting, or worsening headache. He is globally weak, but has no focal neurological deficit. Patient is fatigued.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
9	W9-1-1, SN179-1	W9-1-1	 SN179-1	http://glioblastoma.alleninstitute.org/ish/specimen/show/298128056	51	Male	90	100.245 kg	173.72 cm	23	No	No	Headaches, memory and balance problems	Right Frontal	Complete resection (Left hemisphere tumor not resected)	Yes	Yes	Glioblastoma	Normal	gain	loss	unmethylated	30%	0.210228374	0.063881572	0	wildtype	not detected	Primary	No	Yes	No	Yes	6	0	51	109	NA	145	Deceased due to tumor progression	3	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-1	4-16 mg	dexamethasone	145	Anti-epileptic	0	300 mg	fosphenytoin	1	Anti-epileptic	1	300 mg	phenytoin	2	Anti-epileptic	3	1000 mg	levetiracetam	145	Steroids	104	50 mg	prednisone	104	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	32	140 mg TD	concurrent	76	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	32	WBRT	4500 cGy	25	64	68	WBRT	1400 cGy	8	76	None	None	None	None	None	None	None	None	None	None	-1	MRI	Pre-surgery	No	NA	Bihemispheric lesions; findings could be secondary to metastatic disease or due to multicentric glioma.	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Post-surgery	No	NA	Ring-enhancing lesion appears resected without evidence suggesting residual tumor at the site of surgery. Left hemisphere lesion is unchanged.	None	None	1	None	None	None	None	None	None	None	None	109	MRI	Follow up	Yes	NA	Interval decrease in extent of T2 signal abnormality involving the right frontal resection site, with interval increase in enhancement and mass related to the left temporo-occipital/parietal area of tumor, consistent with disease progression in this area.	None	None	1	None	None	None	None	None	None	None	None	136	MRI	Follow up	Yes	NA	There are changes of surgical resection to a right frontal lobe mass. Interval increase in enhancing nodularity along the inferior margins of the right frontal lobe resection cavity which is worrisome for tumor recurrence.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	8	90	23	0	None	None	None	He has been doing well. No longer evidence of left hemiparesis. 	18	90	None	0	None	None	None	Appetite is good, he has gained weight. Denies any neurological symptoms, able to walk without balance issues.	70	80	None	0	None	None	None	Occasional headache when waking up in morning. Appetite has been excellent. Denies any neurological changes. 	84	80	None	0	None	None	None	Woke up with headache in the morning that persisted throughout day. No fever or chills, reports no new neurological symptoms. Did report feeling sleepy.	109	70	None	0	None	None	None	Significant problems with memory. Failed an attempted dexamethasone taper. Trouble with fatigue, but otherwise tolerated the treatment well.	110	70	None	0	None	None	None	Began having headaches one week ago at which point he was taking 1 mg of Decadron daily. 	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
9	SN179-2	NA	SN179-2	None	51	Male	90	100.245 kg	173.72 cm	23	No	No	Headaches, memory and balance problems	Right Frontal	Complete resection	Yes	Yes	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Primary	No	Yes	No	Yes	6	0	51	109	NA	145	Deceased due to tumor progression	3	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-1	4-16 mg	dexamethasone	145	Anti-epileptic	0	300 mg	fosphenytoin	1	Anti-epileptic	1	300 mg	phenytoin	2	Anti-epileptic	3	1000 mg	levetiracetam	145	Steroids	104	50 mg	prednisone	104	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	32	140 mg TD	concurrent	76	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	32	WBRT	4500 cGy	25	64	68	WBRT	1400 cGy	8	76	None	None	None	None	None	None	None	None	None	None	-1	MRI	Pre-surgery	No	NA	Bihemispheric lesions; findings could be secondary to metastatic disease or due to multicentric glioma.	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Post-surgery	No	NA	Ring-enhancing lesion appears resected without evidence suggesting residual tumor at the site of surgery. Left hemisphere lesion is unchanged.	None	None	1	None	None	None	None	None	None	None	None	109	MRI	Follow up	Yes	NA	Interval decrease in extent of T2 signal abnormality involving the right frontal resection site, with interval increase in enhancement and mass related to the left temporo-occipital/parietal area of tumor, consistent with disease progression in this area.	None	None	1	None	None	None	None	None	None	None	None	136	MRI	Follow up	Yes	NA	There are changes of surgical resection to a right frontal lobe mass. Interval increase in enhancing nodularity along the inferior margins of the right frontal lobe resection cavity which is worrisome for tumor recurrence.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	8	90	23	0	None	None	None	He has been doing well. No longer evidence of left hemiparesis. 	18	90	None	0	None	None	None	Appetite is good, he has gained weight. Denies any neurological symptoms, able to walk without balance issues.	70	80	None	0	None	None	None	Occasional headache when waking up in morning. Appetite has been excellent. Denies any neurological changes. 	84	80	None	0	None	None	None	Woke up with headache in the morning that persisted throughout day. No fever or chills, reports no new neurological symptoms. Did report feeling sleepy.	109	70	None	0	None	None	None	Significant problems with memory. Failed an attempted dexamethasone taper. Trouble with fatigue, but otherwise tolerated the treatment well.	110	70	None	0	None	None	None	Began having headaches one week ago at which point he was taking 1 mg of Decadron daily. 	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
17	W8-1-1, SN175	W8-1-1	 SN175	http://glioblastoma.alleninstitute.org/ish/specimen/show/286840051	50	Female	70	53.1 kg 	165.0 cm	9	No	Right	Progressive speech disturbance, clumsiness with right hand.	Left Parietal	Complete resection (Temporal not resected)	Yes	Yes	Glioblastoma, WHO grade IV	Normal	gain	loss	unmethylated	30%	1.024080679	0.047513901	0.048225987	wildtype	not detected	Primary	No	Yes	Yes	Yes	13	0	50	29	NA	442	Deceased due to tumor progression	1	0	0	0	1	0	0	3	1	0	0	0	0	1	0	2	1	0	0	No	No	No	No	No	Anti-epileptic	-4	100-400 mg	phenytoin	442	Steroids	-4	4-40mg	dexamethasone 	442	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	18	120mg	concurrent	62	Avastin	29	520mg	twice monthly	404	Temozolomide	76	225 mg	daily oral	81	Temozolomide	99	300 mg	every 2-3 weeks oral	225	Etoposide	214	50mg BID	21 day cycles	337	Lomustine	323	180mg	One time administration	323	Lomustine	337	None	daily oral	366	Carboplatin	371	465mg	One time administration	371	None	None	None	None	None	18	IMRT	4500 cGy	25	47	48	IMRT	1440 cGy	8	62	None	None	None	None	None	None	None	None	None	None	-3	MRI	Pre-surgery	No	NA	Multifocal areas of enhancement, involving the left temporal and parietal cortex.	13.4	0.8	1	0.71	1.33	0.63	None	None	None	None	None	1	MRI	Post-surgery	No	NA	Resection cavities are identified, laterally in the left parieto-occipital region. The two largest, enhancing masses, in the lateral aspect of the left parieto-occipital lobe appear to have been completely resected.	n/d	None	1	0.941	1.28	0.848	None	None	None	None	None	29	MRI	Follow up	Yes	NA	Tumor is showing marked progression early on during radiation and chemotherapy.	3.3	1.0	1	0.963	1.34	.610	None	None	None	None	None	78	MRI	Follow up	No	NA	Overall findings consistent with a predominant response to therapy with overall decreased enhancement, decreased mass effect, and decreased tumor size within the left hemisphere.	2.5	1.0	1	0.951	1.12	0.957	None	None	None	None	None	123	MRI	Follow up	Yes	Increase in T2 signal	Interval decrease in nCBV value, with similar or slightly decreased enhancement, but increased "masslike" area posteriorly, overall findings are consistent with features seen with Avastin therapy. Likely this represents a mixed response.	1.67	1.0	1	1.02	1.12	0.895	None	None	None	None	Yes	155	MRI	Follow up	Yes	NA	Findings consistent with progression, with increased T2 signal abnormality, mass effect and masslike area, relatively low perfusion and T1 dynamic imaging metrics is suggestive of Avastin affect.	None	None	1	None	None	None	None	None	None	None	None	214	MRI	Follow up	Yes	NA	Stable extent of T2 signal abnormality. There is qualitative interval increase in extent of enhancement at the medial margin of the resection, between the resection cavity and the left ventricular atria, this suggests interval progression.	None	None	1	None	None	None	None	None	None	None	None	268	MRI	Follow up	Yes	NA	Interval worsening of enhancement about the resection margin when compared to prior examinations. Anatomic and perfusion data is consistent with tumor progression.	None	None	1	None	None	None	None	None	None	None	None	323	MRI	Follow up	Yes	NA	Slight interval worsening of enhancement about the resection margin. Anatomic and perfusion data suggest progression.	None	None	1	None	None	None	None	None	None	None	None	350	MRI	Follow up	Yes	NA	There has been some interval worsening of enhancement, findings suggest tumor progression.	None	None	1	None	None	None	None	None	None	None	None	400	MRI	Follow up	Yes	NA	Significant interval worsening of T2 signal prolongation and abnormal enhancement. Anatomic and perfusion data are consistent with tumor progression.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	-3	70	9	0	Right	progressive speech disturbance, clumsiness with right hand. 	None	None	8	None	9	0	None	None	None	Hesitant spontaneous speech, mild difficulty following one-step motor commands, and moderate difficulty with more complex commands, mild anomia.	25	None	10	0	None	aphasia	None	Some increase in headache, language difficulty, and right-sided weakness. Some clinical deterioration.	29	None	9	0	Right	rightsided weakness,  aphasia	None	Right-sided weakness affecting predominantly the face and right arm over the last two weeks. Deteriorating motor function.	78	None	14	0	Right	rightsided weakness,  aphasia	None	Improvement in clinical symptoms. 	123	None	12	0	Right	rightsided weakness,  aphasia	None	Some increase in sensory abnormality in the ulnar aspect of the right hand.	155	None	13	0	Right	right sided weakness , aphasia	None	Continuing to have deteriorating sensory function of the right hand and also now has begun to note some difficulties in the right leg. 	183	None	16	1	Right	right sided weakness , aphasia	None	Increased right hand numbness; sensation loss in her right ankle/foot.	214	None	16	0	Right	right sided weakness , aphasia	None	Sensory disturbance on the right side.	268	None	21	0	None	right sided weakness , aphasia	None	n/a	366	60	None	0	Right	right sided weakness , aphasia	None	Further decrease in motor function on the right side. Walking into the hospital today, pt slipped and fell on right shoulder and has acute right shoulder pain. 	371	60	None	0	None	right sided weakness , aphasia	None	n/a	400	50	None	0	Right	right sided weakness , aphasia	None	Gradual decline in neurologic function. This has become more marked over the last two to three days; no longer able to comprehend conversations to any degree, and right arm has become functionless.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
21	W10-1-1, SN183	W10-1-1	 SN183	http://glioblastoma.alleninstitute.org/ish/specimen/show/287469103	45	Female	100	100.4 kg 	177.8 cm 	None	No	No	Progressive headache, nausea, blurry vision.	Left Parietal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	positive	gain	gain	methylated	negative	0.868646503	0	0.869387354	R132H	not detected	Primary	No	Yes	Yes	Yes	24	0	45	NA	1801	NA	NA	2	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	1	No	No	No	No	No	Anti-epileptic	-90	1000-2000 mg	KEPPRA	-62	multi-vitamin	-90	1 cap daily oral		-73	Anti-epileptic	-62	25-50 mg	lamotrigine 	496	Steroids	-2	4-16 mg	dexamethasone 	496	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	30	140mg	concurrent	105	Temozolomide	105	300mg	maintenance 5x/mo.	556	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	30	IMRT	6300 cGy	35	78	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	-2	MRI	Pre-surgery	No	NA	Left sided parietal occipital mass lesion, as described, with markedly elevated nCBV values, and hemorrhage, overall findings are consistent with a high grade glioma.	6.28	None	1	0.884	1.00	0.789	None	None	None	None	None	0	MRI	Post-surgery	No	NA	No unexpected findings after tumor removal. No residual tumor suspected.	n/a	n/a	1	n/a	n/a	None	None	None	None	None	None	90	MRI	Follow up	No	NA	No evidence for residual or recurrent tumor.	n/a	nd	1	n/a	0.698	0.878	None	None	None	None	None	153	MRI	Follow up	No	NA	There is no evidence for abnormal enhancement at the surgical cavity site or elsewhere to indicate recurrent disease.	None	None	1	None	None	None	None	None	None	None	None	216	MRI	Follow up	No	NA	Stable postoperative appearance.	None	None	1	None	None	None	None	None	None	None	None	279	MRI	Follow up	No	NA	MRI scan does not show any evidence of tumor recurrence. Linear enhancement around the resection cavity has diminished, which is consistent with postoperative change.	None	None	1	None	None	None	None	None	None	None	None	370	MRI	Follow up	No	NA	There are small foci of enhancement along the walls of the surgical cavity, without definite nodularity and are consistent with postsurgical granulation tissue as opposed to residual or recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	433	MRI	Follow up	No	NA	No evidence for local tumor reccurence.	None	None	1	None	None	None	None	None	None	None	None	496	MRI	Follow up	No	NA	No new mass effect; stable findings at resection site.	None	None	1	None	None	None	None	None	None	None	None	587	MRI	Follow up	No	NA	Stable, no evidence of tumor progression.	None	None	1	None	None	None	None	None	None	None	None	685	MRI	Follow up	No	NA	No evidence of progression.	None	None	1	None	None	None	None	None	None	None	None	783	MRI	Follow up	No	NA	No pathologic enhancement is seen at the resection site. Stable appearance of the brain when compared to most recent previous study.	None	None	1	None	None	None	None	None	None	None	None	881	MRI	Follow up	No	NA	No convincing evidence for interval progression of disease.	None	None	1	None	None	None	None	None	None	None	None	1007	MRI	Follow up	No	NA	No findings concerning for disease progression.	None	None	1	None	None	None	None	None	None	None	None	1126	MRI	Follow up	No	NA	No apparent evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	1259	MRI	Follow up	No	NA	1. No convincing evidence for interval progression. 2. Stable right sphenoid sinus disease.	None	None	1	None	None	None	None	None	None	None	None	1623	MRI	Follow up	No	NA	No changes are seen in the left parietal occipital region resection cavity or in the surrounding T2 hyperintensity in the brain parenchyma. No abnormal contrast enhancement is detected. Diffusion images show no evidence of acute ischemia. Gradient echo images show no areas of susceptibility effect in the brain parenchyma. Perfusion images show no evidence of a territorial perfusion defect. Globes and orbits are unremarkable. Flow voids are present in the major intracranial arteries. Fluid is present within a right sphenoid air cell.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	5	100	None	0	Right	right homonymous hemianopia	None	n/a	22	90	None	1	Right	right homonymous hemianopia	None	Mild edema. Mild problems with fatigue. 	36	90	None	0	Right	right homonymous hemianopia	None	n/a	55	90	None	0	Right	Right homonymous hemianopsia.	None	None	77	90	None	0	Right	right homonymous hemianopia	None	Persistent headaches throughout treatments.	90	90	None	0	Right	right homonymous hemianopia	None	n/a	258	80	None	0	Right	right homonymous hemianopia	None	Lightheadedness, some nausea. The headaches are sometimes worse in the morning. Depression, muscle aches.	279	80	None	0	Right	right homonymous hemianopia	None	n/a	342	80	None	0	Right	right homonymous hemianopia	None	Some numbness/tingling, which she periodically has in the mornings and less in the afternoons. Depression.	370	80	None	0	Right	right homonymous hemianopia	None	Experienced a couple of severe headaches over the past week. These headaches were diffuse and time-limited to a couple of hours. 	379	80	None	0	Right	right homonymous hemianopia	None	Gets headaches from Temodar. No depression. Lightheadedness, numbness, tingling. 	400	80	None	0	Right	right homonymous hemianopia	None	n/a	412	80	None	0	Right	right homonymous hemianopia	None	Nausea is controlled well with p.r.n. antiemetics. 	433	80	None	0	Right	right homonymous hemianopia	None	n/a	496	70	None	0	Right	right homonymous hemianopia	None	Intermittent headaches, some worsening of coordination.	587	70	None	0	Right	right homonymous hemianopia	None	Some bruising, daily headaches.	685	70	None	0	Right	right homonymous hemianopia	None	Headaches, balance problems.	783	70	None	0	Right	right homonymous hemianopia 	None	Mild dysmetria on the left, daily headaches.	881	70	None	0	Right	right homonymous hemianopsia	None	Headache, neck pain.	1007	60	None	0	Right	right homonymous hemianopsia	None	Difficulty with balance, mild dysmetria with right hand.	1259	80	None	0	None	None	None	No residual enhancement and there is no change or any sign of tumor recurrence.	1373	70	None	0	None	None	None	Patient has no significant new symptoms or problems. She has chronic headache related to her glioblastoma.	1623	70	None	0	None	None	None	She reports that she is doing well and without new complaints.	1801	None	None	0	None	None	Follow-up visit.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
23	W11-1-1, SN187	W11-1-1	 SN187	http://glioblastoma.alleninstitute.org/ish/specimen/show/298129069	58	Male	100	82.3 kg	177.8 cm	None	Yes	No	Dizziness, imbalance, and nausea.	Right Parietal	Complete resection (motor mapping)	Yes	Yes	Glioblastoma, WHO grade IV	Negative	gain	loss	methylated	50%	0.345438822	0	0.528812725	wildtype	not detected	Primary	No	Yes	No	Yes	27	0	58	159	NA	1076	Deceased due to tumor progression	1	1	0	0	1	0	0	2	2	0	0	1	0	0	0	1	0	0	0	No	No	No	No	No	Steroids	-48	2-16 mg	dexamethasone	1076	Cholesterol lowering	-4	20 mg	simvastatin	747	Anti-epileptic	-4	100-2000 mg	levetiracetam	1076	Anti-depressant	112	25 mg	sertraline	530	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	38	150 mg TD	concurrent	80	Temozolomide	98	150 mg TD	maintenance 5x/ mo	159	Avastin	222	800 mg	1x/2 wks	860	Lomustine	530	200mg QD	1 dose/month	747	Avastin	860	800 mg	1x/3 wks		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	34	IMRT	4600 cGy	23	64	65	IMRT	1400 cGy	7	76	1016	Stereotactic	2750	5	1022	None	None	None	None	None	-3	MRI	Pre-surgery	No	NA	A heterogeneous, partially solid, partially cystic intra-axial mass is identified, centered in the mesial right parietal lobe. The tumor measures 5.4 x 3.6 x 4.4 cm in maximal AP, transverse, and craniocaudad dimensions respectively. The tumor demonstrates irregular, predominantly peripheral type enhancement.	6.02	None	1	0.69	1.21	0.753	None	None	None	None	None	0	MRI	Post-surgery	No	NA	There appears to have been complete resection of previously demonstrated, enhancing mass lesion in the mesial right parietal lobe. No residual enhancement is demonstrated.	n/a	None	1	n/a	None	None	None	None	None	None	None	96	MRI	Follow up	No	NA	Resolving postoperative change. No convincing evidence of tumor recurrence at this time.	1.12	1.01	1	0.944	1.05	0.738	None	None	None	None	None	159	MRI	Follow up	Yes	NA	Interval increase in T2 signal change, and  with new nodular areas of enhancement anteriorly with elevated nCBV scores and permeability, concerning for tumor recurrence anteriorly.	None	None	1	None	None	None	None	None	None	None	None	222	MRI	Follow up	Yes	NA	Interval increase in T2 hyperintensity and increased thickness of nodular areas of contrast enhancement in the anterior margin of the right parietal resection cavity correlated with elevated nCBV scores and permeability. This is consistent with progressive disease.	None	None	1	None	None	None	None	None	None	None	None	285	MRI	Follow up	No	NA	There has been significant interval decrease in enhancement within the previously-seen tumor mass.  There may also be slight interval decrease in the size of the mass.  The extent of abnormal T2 signal is unchanged. The new MRI scan shows response to Avastin.	None	None	1	None	None	None	None	None	None	None	None	341	MRI	Follow up	No	NA	MRI shows stable disease without significant change in T2 signal or enhancement.	None	None	1	None	None	None	None	None	None	None	None	436	MRI	Follow up	Possible	NA	Overall findings are worrisome for disease progression.	None	None	1	None	None	None	None	None	None	None	None	530	MRI	Follow up	Yes	NA	Shows continued evidence of progression.	None	None	1	None	None	None	None	None	None	None	None	572	MRI	Follow up	Possible	NA	In comparison with the previous one, overall quite similar.	None	None	1	None	None	None	None	None	None	None	None	656	MRI	Follow up	No	NA	The new MRI scan of the brain is stable compared to the prior study.	None	None	1	None	None	None	None	None	None	None	None	705	MRI	Follow up	No	NA	Relatively stable examination. There may be some slight increase T2 signal in the left cortex.	None	None	1	None	None	None	None	None	None	None	None	747	MRI	Follow up	No	NA	Relatively stable examination. No convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	810	MRI	Follow up	No	NA	No change, stable disease.	None	None	1	None	None	None	None	None	None	None	None	860	MRI	Follow up	No	NA	No change, stable disease.	None	None	1	None	None	None	None	None	None	None	None	925	MRI	Follow up	No	NA	No change, stable disease.	None	None	1	None	None	None	None	None	None	None	None	960	MRI	Follow up	Possible	NA	Slight increase in nonenhancing tumor along the margin of the trigone of the right lateral ventricle.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	3	100	None	0	None	None	None	None	5	100	None	1	Left	left homonymous hemianopia	None	Stable disease.	7	100	None	0	None	left homonymous hemianopsia	None	No new problems to report.	9	90	30	0	Left	left visual field extinction 	None	n/a	43	90	None	1	Left	left visual field extinction 	None	Head pressure, minor nausea.	54	80	None	0	Left	left visual field extinction 	None	Blurry vision, decreased balance and issues with ability to mentate. Reports feeling woozy. Fatigued from treatment. Not sleeping well at night. 	75	90	None	0	Left	left visual field extinction 	None	Vague sense of malaise, no specific complaints referable to treatment. 	96	None	30	0	Left	left visual field extinction 	None	Cognitive difficulties. Failed an attempted dexamethasone taper and is now back on 1 mg twice a day.	126	80	None	0	Left	left vision deficit	None	Fatigue, malaise, and low-grade constant nausea have steadily worsened. Wants to get off of Temodar to see if quality of life will improve by any degree.	159	80	29	0	Left	left vision field deficit	None	Had new transient increase in headache, difficulties with TMZ, which has been discontinued. 	161	90	None	0	Left	left vision field deficit	None	Quality of life has substantially improved over the last month, especially after discontinuing TMZ.	222	None	29	0	Left	left homonymous hemianopia	None	Clinically stable, although there is disease progression. 	253	90	None	0	None	left homonymous hemianopia	None	Denies any difficulty with the Avastin with nausea, vomiting, or diarrhea. No new complaints. 	281	90	None	0	Left	left homonymous hemianopia	None	No new neurological complaints.	285	90	None	0	Left	left homonymous hemianopia	None	n/a	309	90	None	0	Left	left homonymous hemianopia	None	n/a	337	80	None	0	None	None	None	Continues to battle some mild nausea with the infusions, and occasional headaches, but these are unchanged over months, and readily tolerable.	341	80	None	0	None	left homonymous hemianopia	None	None	365	80	None	1	Left	left homonymous hemianopia	None	Fatigue.	530	70	None	0	Left	left homonymous hemianopia.	None	Disease is progressing, starting CCNU.	646	80	None	0	Left	left homonymous hemianopia.	None	Stabilized from clinical standpoint and the new MRI scan shows no evidence of further progression.	705	70	None	0	Left	left homonymous hemianopia.	None	Mild clinical deterioration.	747	80	None	0	None	None	None	n/a	810	80	None	0	Left	left homonymous hemianopia	None	No new problems.	935	80	None	0	Left	left homonymous hemianopsia, mild left hemiparesis	None	New MRI data is consistent with stable disease.	960	70	None	0	Left	left homonymous hemianopsia	None	Deteriorating left leg function; dragging his leg more and has had some falls.	992	60	None	0	Left	left homonymous hemianopsia, left hemiparesis	None	Worsening left hemiparesis; disease may be progressing on Avastin. 	None	None	None	None	None	None	None	None
26	W12-1-1, SN191	W12-1-1	 SN191	http://glioblastoma.alleninstitute.org/ish/specimen/show/267057238	61	Female	70	64.0 kg	160.0 cm	None	No	Left	Worsening headaches, clumsiness of left leg.	Right Temporal	Complete resection (frontal not resected)	No	No	Glioblastoma, with small cell features, WHO grade IV	Negative	amplification	loss	unmethylated	20%	0.449555554	0.148271849	0.076863661	wildtype	not detected	Primary	No	Yes	No	Yes	0	0	61	NA	NA	80	Deceased due to tumor progression	2	1	0	0	2	0	0	0	0	0	1	2	0	0	0	0	0	0	0	No	No	No	No	No	Cholesterol lowering	-2	20 mg	pravastatin	3	Anti-depressant	-2	40-60 mg	citalopram 	15	antihypertensive	-2	50 mg	metoprolol	15	Steroids	0	4mg/1mL injection 4mg 4 times a day	dexamethasone	8	Anti-epileptic	0	1000 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	2	Anti-epileptic	2	1250 mg	valproic acid	14	Cholesterol lowering	3	10 mg	simvastatin	15	Steroids	8	2 mg twice a day oral	dexamethasone	44	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Aggressive appearing deep right hemisphere lesion with vasogenic edema and significant mass effect.	2.91	0.80	1	0.682	1.5	0.75	None	None	None	None	None	1	MRI	Post-surgery	No	NA	Interval debulking of large right deep hemisphere mass lesion. Areas of enhancement persist as outlined above consistent with residual tumor.	n/a	n/a	1	n/a	n/a	None	None	None	None	None	None	7	CT	Follow up	No	NA	Expected evolution of postoperative changes, right temporal lobe. Amount of mass effect has decreased when compared to pre-surgery CT. However, significant mass effect persists.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
26	SN191-2	NA	SN191-2	None	61	Female	70	64.0 kg	160.0 cm	None	No	Left	Worsening headaches, clumsiness of left leg.	Right Temporal	Complete resection	No	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Primary	No	Yes	No	None	0	0	61	NA	NA	80	Deceased due to tumor progression	2	1	0	0	2	0	0	0	0	0	1	2	0	0	0	0	0	0	0	No	No	No	No	No	Cholesterol lowering	-2	20 mg	pravastatin	3	Anti-depressant	-2	40-60 mg	citalopram 	15	antihypertensive	-2	50 mg	metoprolol	15	Steroids	0	4mg/1mL injection 4mg 4 times a day	dexamethasone	8	Anti-epileptic	0	1000 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	2	Anti-epileptic	2	1250 mg	valproic acid	14	Cholesterol lowering	3	10 mg	simvastatin	15	Steroids	8	2 mg twice a day oral	dexamethasone	44	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Aggressive appearing deep right hemisphere lesion with vasogenic edema and significant mass effect.	2.91	0.80	1	0.682	1.5	0.75	None	None	None	None	None	1	MRI	Post-surgery	No	NA	Interval debulking of large right deep hemisphere mass lesion. Areas of enhancement persist as outlined above consistent with residual tumor.	n/a	n/a	1	n/a	n/a	None	None	None	None	None	None	7	CT	Follow up	No	NA	Expected evolution of postoperative changes, right temporal lobe. Amount of mass effect has decreased when compared to pre-surgery CT. However, significant mass effect persists.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
57	W13-1-1, SN195	W13-1-1	 SN195	http://glioblastoma.alleninstitute.org/ish/specimen/show/268416497	60	Female	90	95 kg	160 cm	None	No	No	Personality changes.	Right Parietal	Complete resection	Yes	Yes	Glioblastoma	Negative	amplification	loss	unmethylated	50%	0.16	0.03	0	wildtype	detected	Primary	No	Yes	No	Yes	9	6	60	235	NA	250	Deceased due to tumor progression	4	2	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	0	1000 mg	levetiracetam	5	Steroids	0	4-16 mg	dexamethasone	250	Anti-depressant	1	12.5-25 mg	quetiapine	32	Anti-epileptic	5	125-1000 mg	divalproex	39	Anti-depressant	7	0.5-1.5 mg	risperidone	240	Anti-epileptic	233	300-2000 mg	fosphenytoin	247	Anti-epileptic	247	100-200 mg	lacosamide	251	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	39	140 mg	concurrent	90	Temozolomide	90	140 mg	maintenance 21x/mo.	250	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	81	IMRT	5940 cGy	33	91	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large right temporal occipital mass, measuring approximately 5 x 4.2 x 4.4 cm, overall findings are most consistent with high grade glioma.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	Status post resection of enhancing intra-axial mass lesion, mesial right parieto-occipital lobe. It appears that entire area of abnormal enhancement demonstrated on preoperative study has been resected. No evidence of residual enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	235	MRI	Follow up	Yes	NA	Marked interval increase in extent of T2 signal abnormality, expanded appearance particularly over the splenium of the corpus callosum, the left hippocampus and the bilateral pulvinar of the thalami. Multiple new enhancing areas are also demonstrated, findings are consistent with marked interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	39	90	None	0	Right	mild right visual field cut	None	n/a	68	90	None	0	Left	significant left field cut versus left neglect	None	Profound left neglect, although otherwise stable.	90	90	None	0	Left	significant left field cut versus left neglect	None	Clinically stable.	124	90	None	0	Left	significant left field cut versus left neglect	None	Clinically stable.	138	80	None	0	Left	significant left field cut versus left neglect	None	Notes more fatigue, otherwise stable.	153	80	None	0	Left	significant left field cut versus left neglect	None	More fatigue, otherwise unchanged.	189	80	None	0	Left	significant left field cut versus left neglect	None	Notes more fatigue. She continues to have profound left neglect.	217	70	None	0	Left	significant left field cut versus left neglect	None	Has had more difficulty with incontinence, often requiring more assistance for tranfers.	233	60	None	0	None	None	None	Emergency room: patient had clonic activity of the left arm and to a lesser degree of the left leg. Patient status deteriorating.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
57	SN195-2	NA	SN195-2	None	60	Female	90	95 kg	160 cm	None	No	No	Personality changes.	Right Parietal	Complete resection	Yes	Yes	NA	NA	NA	NA	NA	NA	0.34	0.06	0.02	NA	NA	Primary	No	Yes	No	Yes	9	6	60	235	NA	250	Deceased due to tumor progression	4	2	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	0	1000 mg	levetiracetam	5	Steroids	0	4-16 mg	dexamethasone	250	Anti-depressant	1	12.5-25 mg	quetiapine	32	Anti-epileptic	5	125-1000 mg	divalproex	39	Anti-depressant	7	0.5-1.5 mg	risperidone	240	Anti-epileptic	233	300-2000 mg	fosphenytoin	247	Anti-epileptic	247	100-200 mg	lacosamide	251	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	39	140 mg	concurrent	90	Temozolomide	90	140 mg	maintenance 21x/mo.	250	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	81	IMRT	5940 cGy	33	91	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large right temporal occipital mass, measuring approximately 5 x 4.2 x 4.4 cm, overall findings are most consistent with high grade glioma.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	Status post resection of enhancing intra-axial mass lesion, mesial right parieto-occipital lobe. It appears that entire area of abnormal enhancement demonstrated on preoperative study has been resected. No evidence of residual enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	235	MRI	Follow up	Yes	NA	Marked interval increase in extent of T2 signal abnormality, expanded appearance particularly over the splenium of the corpus callosum, the left hippocampus and the bilateral pulvinar of the thalami. Multiple new enhancing areas are also demonstrated, findings are consistent with marked interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	39	90	None	0	Right	mild right visual field cut	None	n/a	68	90	None	0	Left	significant left field cut versus left neglect	None	Profound left neglect, although otherwise stable.	90	90	None	0	Left	significant left field cut versus left neglect	None	Clinically stable.	124	90	None	0	Left	significant left field cut versus left neglect	None	Clinically stable.	138	80	None	0	Left	significant left field cut versus left neglect	None	Notes more fatigue, otherwise stable.	153	80	None	0	Left	significant left field cut versus left neglect	None	More fatigue, otherwise unchanged.	189	80	None	0	Left	significant left field cut versus left neglect	None	Notes more fatigue. She continues to have profound left neglect.	217	70	None	0	Left	significant left field cut versus left neglect	None	Has had more difficulty with incontinence, often requiring more assistance for tranfers.	233	60	None	0	None	None	None	Emergency room: patient had clonic activity of the left arm and to a lesser degree of the left leg. Patient status deteriorating.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
66	W16-1-1, SN206	W16-1-1	 SN206	http://glioblastoma.alleninstitute.org/ish/specimen/show/308929245	77	Male	100	83 kg	183.88 	None	No	No	Left hand weakness, cognitive changes.	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, with small cell features, WHO grade IV	Negative	amplification	loss	unmethylated	25%	0.15	0.03	0.03	wildtype	detected	Primary	No	Yes	Yes	Yes	5	4	77	97	NA	353	Deceased due to tumor progression	2	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	1	No	No	No	No	No	Steroids	-13	1 mg daily oral	dexamethasone	49	Anti-epileptic	4	300 mg	phenytoin	11	multi-vitamin	7	1 cap daily oral	ONE-A-DAY	19	Anti-depressant	10	15 mg	mirtazapine	100	Anti-epileptic	11	1000 mg	KEPPRA	100	Cholesterol lowering	11	2.8-7.5 mg	warfarin	295	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	17	150 mg	daily oral during radiation	97	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	29	IMRT	4500 cGy	25	58	59	IMRT	1440 cGy	8	77	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large multilobulated enhancing lesion or two adjacent lesions in the posterior right frontal lobe and superior temporal lobe.  Area of involvement measures 3.5 x 3.0 x 4.2 cm.	None	None	1	None	None	None	None	None	None	None	None	4	MRI	Post-surgery	No	NA	Postoperative changes as noted on the right consistent with recent tumor resection. Minimal post contrast resection cavity margin enhancement anteriorly.	None	None	1	None	None	None	None	None	None	None	None	97	MRI	Follow up	Yes	NA	Worsening enhancement as well as a progression of surrounding T2 signal prolongation related to the region of resection when compared to the immediate postoperative study. While tumor progression is not entirely excluded, generally low nCBV values suggest pseudo progression.	None	None	1	None	None	None	None	None	None	None	None	156	MRI	Follow up	Yes	NA	Increased thick, peripheral nodular enhancement in the region of the patients right parietal resection cavity with increased surrounding abnormal T2 signal and mass effect.  Findings are concerning for tumor progression versus post treatment change.	None	None	1	None	None	None	None	None	None	None	None	182	MRI	Follow up	Yes	NA	The nodular enhancement surrounding the right parietal temporal resection cavity has not significantly changed from recent MRI, but has progressed since MRI from one before that.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	97	90	None	0	None	None	None	He has done reasonably well with only moderate fatigue associated with his radiation and Temodar treatment.	112	80	None	0	None	None	None	He has had some mild left-sided weakness but otherwise had not had any other serious symptoms.	156	80	None	0	None	None	None	Clinically doing fairly well, post-RT MRI shows enhancement; increase TMZ dosage.	219	70	None	0	None	None	None	Hospitalized for 3 days about a month ago, because of left hand/arm weakness and numbness. 	295	60	None	0	None	None	None	Numbness, tingling sensation, and unsteadiness.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
71	W18-1-1, SN211	W18-1-1	 SN211	http://glioblastoma.alleninstitute.org/ish/specimen/show/267059417	37	Female	90	78.654 kg	173.72 cm	None	No	Left	Headache, nausea, vomiting, double vision.	Right Parietal	Subtotal resection 90% (intraventricular crossing corpus collosum; butterfly glioma)	Yes	Yes	Glioblastoma, giant cell type, WHO grade IV	Negative	gain	gain	methylated	25%	0.34	0.09	0.14	wildtype	not detected	Primary	No	Yes	No	Yes	18	4	37	489	NA	903	Deceased due to tumor progression	1	1	0	0	9	0	0	2	0	0	0	0	1	0	0	1	0	0	1	No	No	No	No	No	Steroids	0	4mg/1mL injection 4mg 4 times a day	dexamethasone	2	Anti-epileptic	0	1000-2000 mg	KEPPRA	830	Anti-depressant	1	20-40 mg daily oral	citalopram (CELEXA)	157	Steroids	2	4 mg 4 times a day oral	dexamethasone	3	Steroids	3	4mg/1mL injection 4mg 4 times a day	dexamethasone	8	Steroids	8	4 mg 4 times a day oral	dexamethasone	9	Steroids	9	4mg/1mL injection 4-3mg 4 times a day	dexamethasone	12	Steroids	12	2-1 mg 3-2 times a day oral	dexamethasone	18	Steroids	18	4mg/1mL injection 1-4 mg twice a day	dexamethasone	23	cardiotonic	153	5-7.5 mg	warfarin	517	multi-vitamin	408	1 cap daily oral		439	Steroids	489	from 4 mg twice daily till 1 mg 3 times a day oral	dexamethasone	555	Steroids	625	from 4 mg 3 times a day till 2 mg twice a day oral	dexamethasone	695	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	47	150 mg TD	concurrent	102	Temozolomide	110	400 mg TD	maintenance 5 days/month	142	Lomustine	747	100 mg x 2 caps 	oral every 6 weeks	788	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	47	IMRT	4600 cGy	23	70	71	IMRT	6000 cGy	30	102	489	Stereotactic	14 Gy	1		None	None	None	None	None	2	MRI	Pre-surgery	No	NA	Irregularly enhancing mass, centered in the body of right lateral ventricle with invasion through the corpus callosum, into high right frontal lobe. Appearance is most suggestive of high grade tumor, probably a glioblastoma multiforme.	None	None	1	None	None	None	None	None	None	None	None	4	MRI	Post-surgery	No	NA	Status post right parietal craniotomy and resection of intraventricular/intraparenchymal mass, right hemisphere. Small portions of the residual enhancing tumor are demonstrated along the anterosuperior, inferior and posteromedial margins of the resection.	None	None	1	None	None	None	None	None	None	None	None	139	MRI	Follow up	No	NA	MRI shows marked interval improvement in postoperative changes with decrease intrinsic T1-weighted hyperintensity reflecting resolution of blood product signal abnormality.  Only minimal residual contrast enhancement is detected compared to the immediate postoperative scan indicating response to treatment.	None	None	1	None	None	None	None	None	None	None	None	153	MRI	Follow up	No	NA	In comparison with prior MRI, there is decreased density of enhancement.	None	None	1	None	None	None	None	None	None	None	None	216	MRI	Follow up	No	NA	There has not been convincing interval progression in terms of enhancement, or T2 lesion burden.	None	None	1	None	None	None	None	None	None	None	None	275	MRI	Follow up	No	NA	The enhancement is unchanged and the T2 signal is stable.	None	None	1	None	None	None	None	None	None	None	None	345	MRI	Follow up	No	NA	No convincing interval progression in terms of T2 signal abnormalities or enhancement.	None	None	1	None	None	None	None	None	None	None	None	408	MRI	Follow up	No	NA	There is no residual abnormal enhancement seen and the extent of abnormal T2-weighted signal is stable.	None	None	1	None	None	None	None	None	None	None	None	471	MRI	Follow up	No	NA	No change at the original site of the tumor. However, there has been enlargement of the area of a previously noted to show enhancement.	None	None	1	None	None	None	None	None	None	None	None	489	MRI	Follow up	Yes	NA	The right CP angle lesion has increased in size when compared to the previous one.	None	None	1	None	None	None	None	None	None	None	None	517	MRI	Follow up	Yes	NA	Increasing size of right cerebellopontine angle cistern mass.	None	None	1	None	None	None	None	None	None	None	None	555	MRI	Follow up	No	NA	Interval slight increase in ventricular size, with decreased dural enhancement.	None	None	1	None	None	None	None	None	None	None	None	625	MRI	Follow up	No	NA	Relatively stable areas of infiltrative T2 hyperintensity surrounding the resection cavity likely reflective of infiltrating glioma versus postradiation changes.	None	None	1	None	None	None	None	None	None	None	None	695	MRI	Follow up	No	NA	Slightly decreased size of enhancing right mass. Stable appearance of the right parietal tumor resection without convincing evidence for interval progression of disease.	None	None	1	None	None	None	None	None	None	None	None	747	MRI	Follow up	Possible	NA	The focus of metastatic disease in the right cerebellar pontine angle increased in size. 	None	None	1	None	None	None	None	None	None	None	None	786	MRI	Follow up	Possible	NA	Modest interval progression, with increase in leptomeningeal metastasis.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	90	90	None	0	None	None	None	Postoperatively, patient developed hydrocephalus; VP shunt placed. Also developed large pulmonary thrombus. Currently, patient is doing well. 	122	80	None	0	None	None	None	n/a	132	80	None	0	None	None	None	Intermittent right upper quadrant abdominal pain.	139	80	None	1	None	no drift of either outstretched upper extremity	None	She appears well.  Conversation is fluent and coherent.  Repetition is normal.  Visual fields are full to four-quadrant finger confrontation.  Extraocular movements are normal.  Grimace is symmetrical.  She has occasional jerking motions of her left leg, which are involuntary and are associated with end-of-dose effect with her Keppra 500 mg twice a day. She is likely having brief focal motor seizures at the end of each Keppra dose.	152	70	None	0	None	None	None	Her history is somewhat limited, but she is alert and oriented x3, slightly drowsy but able to answer questions pretty clearly. Subacute presentation of mental status change. Starting on approximately a week ago, she started to be more fatigued and having some memory problems. She had mild occasional headaches. She has has a progressive gradual decline of her energy level and mental function. She has been confused, and last night she had nausea and emesis x1. She has also had difficulty with words and twitches with the side of her left arm. This is what she normally gets when she gets a focal seizure. She is also having difficulty with gait, having a shuffled gait. 	188	70	None	0	None	None	None	Patient is alert, awake, cooperative, and pleasant, and in no evident distress. She has some nausea, which is easy to control. She has only had one really bad day of fatigue. No new neurological deficits.	216	80	None	0	None	None	None	Her conversation is fluent and coherent.  Visual fields are full.  There is no evidence of hemiparesis.  She is steady on her feet. She has had some mild headaches. She is doing reasonably well from a clinical standpoint.	223	80	None	0	None	None	None	She is doing pretty well. She was very fatigued at the conclusion of her Temodar, but this resolved fairly quickly. 	244	70	None	0	None	None	None	Patient is alert, cooperative, and pleasant, and in no evident distress. She could not remember when she got her chemotherapy. 	345	80	None	0	None	None	None	None	408	80	None	0	None	None	Doing well.	None	471	80	None	0	Right	minimal symptoms in the right side of face	None	None	523	70	None	0	Right	mild lower motor weakness of the right face	None	None	555	80	None	0	Right	mild right lower motor neuron weakness in the face	Excellent responce to treatment.	None	625	80	None	0	Right	probably related to the radiation treatment	Exelent responce to treatment.	None	695	80	None	0	Right	complete right facial palsy	Stable disease.	None	747	70	None	0	Right	None	None	Nausea and vomiting.	817	60	None	0	Right	deterioration vision in the right eye	None	Clinical deterioration.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
73	W19-1-1, SN214	W19-1-1	 SN214	http://glioblastoma.alleninstitute.org/ish/specimen/show/264627950	68	Female	80	65.722 kg	168.64 cm	None	No	No	Speech disturbances.	Left Temporal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	gain	negative	unmethylated	30%	0.82	0.14	0.07	wildtype	not detected	Primary	No	Yes	Yes	Yes	2	5	68	NA	NA	615	Deceased due to tumor progression	2	1	0	0	1	0	0	1	0	0	2	2	0	0	0	0	0	0	0	No	No	No	No	No	Anti-depressant	4	20mg QD	fluoxetine	10	Steroids	5	2-16 mg	dexamethasone	62	Anti-epileptic	5	300 mg	phenytoin	10	Cholesterol lowering	5	80 mg	simvastatin	10	antihypertensive	6	120 mg	diltiazem	10	antihypertensive	10	12.5 mg	hydrochlorothiazide	14	Anti-epileptic	10	1000 mg	KEPPRA	81	Cholesterol lowering	34	80 mg	lovastatin	60	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	38	130 mg	concurrent	88	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	38	IMRT	4600 cGy	23	77	81	IMRT	1200 cGy	6/7 franctions completed	88	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	3 cm centrally necrotic, peripherally enhancing mass in the left temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	5	MRI	Post-surgery	No	NA	Expected postoperative changes of left anterior temporal craniotomy for resection of tumor. No evidence for abnormal enhancement suspicious for residual tumor.	None	None	1	None	None	None	None	None	None	None	None	102	MRI	Follow up	No	NA	Probable evolving postoperative changes in the left temporal resection cavity.  No compelling evidence for tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	20	80	None	0	Left	left sided hemiparesis	None	Occasional problems with word finding.  Slight imbalance.	102	70	None	0	Left	left sided hemiparesis	None	n/a	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
74	W20-2-1, SN215	W20-2-1	 SN215	http://glioblastoma.alleninstitute.org/ish/specimen/show/287110944	44	Male	90	67.8 kg	186.42 cm	None	No	No	Headaches, some mental confusion, and dizziness.	Right Parietal, Right Temporal	Complete resection	Yes	Yes	recurrent glioblastoma	negative	gain	gain	unmethylated	80%	0.5	0.05	0.02	wildtype	not detected	Recurrent	No	Yes	No	Yes	12	197	45	103	NA	363	Deceased due to tumor progression	1	0	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	103	1000-750 mg twice a day oral	KEPPRA	261	Steroids	194	2-16 mg	dexamethasone	255	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	34	75mg/m2	maintenance 	76	Temozolomide	135	140 mg/day	concurrent	197	Avastin	274	None	None	363	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	34	IMRT	4600 cGy	23	64	66	IMRT	1400 cGy	7	76	None	None	None	None	None	None	None	None	None	None	1	MRI	Pre-surgery		NA	The brain morphology is normal. There is minimal right cerebellar tonsillar ectopia. There is a large ring enhancing mass in the temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	There is thin postsurgical enhancement along the margins of the resection cavity. There is no clear evidence of residual tumor.	None	None	1	None	None	None	None	None	None	None	None	103	MRI	Follow up	Yes	NA	Pre and post contrast T1 weighted imaging demonstrates extensive abnormal enhancement and T1 signal involving predominantly the right temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	121	MRI	Follow up	Yes	NA	Overall, findings suggest pseudo progression.	None	None	1	None	None	None	None	None	None	None	None	156	MRI	Follow up	Yes	NA	Overall findings are concerning for interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	196	MRI	Pre-surgery	Yes	NA	Compared to previous MRI there is evidence of tumor progression and increased mass effect.	None	None	1	None	None	None	None	None	None	None	None	197	MRI	Post-surgery	No	NA	No unanticipated post operative findings status post craniotomy for right temporal glioblastoma.	None	None	1	None	None	None	None	None	None	None	None	275	MRI	Follow up	No	NA	Diminished mass effect and midline shift.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	48	100	None	0	None	None	None	n/a	72	100	None	0	None	None	None	None	103	None	29	0	None	None	None	None	121	None	30	0	None	None	None	Slight imbalance when walking.	146	90	None	1	None	None	None	The Novacure device has caused some slight burns on scalp.	156	None	30	0	None	None	None	n/a	161	90	None	0	None	None	None	None	194	None	30	1	None	None	None	Increased headaches.	226	80	None	0	None	None	None	Pleasant, awake, alert, cooperative, but markedly worse than when seen last. He presented 3 weeks ago with headaches and increasing psudeomeningocele over his craniotomy flap. Reports memory changes postop. He has a significant left vision field cut but otherwise feels well. 	274	70	None	0	Left	left sided weakness	None	Increased confusion, increased left sided weakness.	293	60	None	1	None	None	None	Entered ER for altered mental status and seizure. Continuation of avastin depends on next MRI.	324	70	None	0	None	None	None	n/a	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
75	W21-1-1, SN217	W21-1-1	 SN217	http://glioblastoma.alleninstitute.org/ish/specimen/show/264632322	55	Female	80	62.143 kg	166.1 cm	None	No	Left	Constant headache, some weakness and clumsiness on the left side.	Right Frontal, Right Parietal, Right Temporal	Complete resection	Yes	Yes	Glioblastoma	Negative	amplification in small population	loss	unmethylated	50%	0.23	0.03	0.02	wildtype	not detected	Primary	No	Yes	No	Yes	17	1	55	93	NA	446	Deceased due to tumor progression	4	1	0	0	3	0	0	2	1	0	2	1	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-5	2-16 mg	dexamethazone	11	Anti-epileptic	-5	1000 mg in NS(0.9% NaCl) IV solution 100 mg once	fosphenytoin (CEREBYX)		Anti-epileptic	-5	750-1000-2000 mg oral twice a day	KEPPRA	3	antihypertensive	-4	12.5 mg	hydrochlorothiazide	0	Anti-depressant	-4	50-150 mg	quetiapine	11	antihypertensive	0	10 mg daily oral	olmesartan	5	Anti-epileptic	3	400-500 mg	phenytoin	130	Steroids	94	2 mg daily oral	dexamethasone	130	Anti-epileptic	130	500 mg twice a day oral	KEPPRA	162	Cholesterol lowering	130	10 mg	rosuvastatin	157	Steroids	352	4 mg twice a day oral	dexamethasone	388	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	22	150 mg TD	concurrent	66	Temozolomide	95	120 mg TD	maintenance 12x/mo.	291	Avastin	98	525-620 mg	in NS(0.9% NaCl) IV solution every 2 weeks	334	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	22	IMRT	4500 cGy	25	53	54	IMRT	1260 cGy	7	66	95	Stereotactic	1000 cGy	1		281	Stereotactic	1000 cGy	1		0	MRI	Pre-surgery	No	NA	6.6 x 6.2 x 4.1 cm predominantly cystic right temporal lobe mass with significant mass effect and surrounding edema, with a right-to-left shift of 1.5 cm. There is entrapment of the left lateral ventricle. Primary diagnostic consideration is given to a high-grade glial neoplasm.	None	None	1	None	None	None	None	None	None	None	None	1	MRI	Post-surgery	No	NA	Expected postoperative findings after complex right-sided tumor resection. No evidence of residual enhancing tumor is seen.	None	None	1	None	None	None	None	None	None	None	None	93	MRI	Follow up	Yes	NA	Interval resolution of postoperative mass effect. Areas of enhancement are seen anterior and posterior to the resection margin concerning for tumor progression.	None	None	1	None	None	None	None	None	None	None	None	134	MRI	Follow up	No	NA	Overall findings consistent with response to therapy, without convincing interval progression.	None	None	1	None	None	None	None	None	None	None	None	185	MRI	Follow up	No	NA	No evidence of tumor progression.	None	None	1	None	None	None	None	None	None	None	None	275	MRI	Follow up	No	NA	A small new focus of abnormal enhancement is seen adjacent to the prior lesion noted in the basal ganglia.	None	None	1	None	None	None	None	None	None	None	None	310	MRI	Follow up	Possible	NA	Findings may represent tumor progression/recurrence versus changes related to tumor treatment or both.	None	None	1	None	None	None	None	None	None	None	None	350	MRI	Follow up	Yes	NA	Findings consistent with marked interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	19	90	None	0	None	None	None	Blurred vision after diagnosis.	33	90	None	0	None	None	None	n/a	47	90	None	0	None	None	None	n/a	54	90	None	0	None	None	None	n/a	79	90	None	0	None	None	None	n/a	91	80	None	0	None	None	None	n/a	98	80	None	0	None	None	None	n/a	130	80	None	0	None	None	None	n/a	135	80	None	0	None	None	None	n/a	144	80	None	0	None	None	None	n/a	157	80	None	0	None	None	None	n/a	171	80	None	0	None	None	None	n/a	190	80	None	0	None	None	None	None	200	80	None	1	Left	left upper lip numbness and droop	None	One episode of left upper lip numbness and droop several days prior, resolved.	270	70	None	0	Left	facial droop	None	MRI shows disease progression; hold avastin and TMZ.	291	70	None	0	Left	facial droop	None	Restart Avastin and TMZ.	348	50	None	0	Left	lef facial droop	None	Difficulty dressing self, difficulty in vision increased, increased facial droop.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
76	W22-1-1, SN218	W22-1-1	 SN218	http://glioblastoma.alleninstitute.org/ish/specimen/show/288268994	53	Female	90	73.03 kg	155.94 cm	None	No	Left,Right	word finding difficulties, slurred speech and altered mental status	Left Temporal	Complete resection	Yes	Yes	Edematous glioma	Negative	amplification	loss	methylated	20%	0.22	0.00	0.67	wildtype	detected	Primary	No	Yes	Yes	Yes	25	6	53	753	1634	NA	NA	5	1	0	0	3	0	0	6	1	0	0	0	0	2	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	-1	500mg BID	KEPPRA	9	Steroids	0	4mg QID taper to 3mg QD	Dexamethasone	46	Anti-epileptic	9	1000 mg twice a day oral	KEPPRA	91	Anti-epileptic	115	500 mg twice a day oral	KEPPRA	771	Anti-depressant	368	25mg QD	Amitriptyline	424	Steroids	769	4mg 4 times a day, 4mh 3 times a day	dexamethasone	810	Anti-epileptic	771	1000 mg twice a day oral	KEPPRA	1166	Steroids	916	1 mg twice a day oral	dexamethasone	1032	Anti-epileptic	1166	500 mg twice a day oral	KEPPRA	1690	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	18	140 mg 	daily oral	91	Temozolomide	116	340 mg	daily oral	424	Temozolomide	777	125 mg 	daily oral	1064	Temozolomide	1064	125 mg	everyday for 21 days	1092	Temozolomide	1096	125 mg	everyday for 21 days	1124	Temozolomide	1131	125 mg	everyday for 21 days	1159	Etoposide	1235	100 mg daily oral	at bedtime	1357	Etoposide	1357	50 mg daily oral	at bedtime	1378	Avastin	1414	665-700 mg intravenous 	every 2 weeks	1643	26	IMRT	4600 cGy	23	54	55	IMRT	1400	7	68	822		1500 cGy	5	826	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	There is a heterogeneous lesion with partial peripheral enhancement measuring approximately 3.1 x 2.7 x 3.5 cm within the left temporoparietal region. There is surrounding edema and associated mass effect.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	MRI shows a tiny focus of residual enhancement along the superficial margin of the resection cavity.  There is no significant ischemic change. This most likely represents postoperative enhancement.	None	None	1	None	None	None	None	None	None	None	None	91	MRI	Follow up	No	NA	The new MRI scan of the brain shows significant resolution of immediate postoperative changes in the left temporal lobe.  There is slight enhancement along the margin of the resection cavity, which is postoperative in nature.  Some enhancement along the deep margin of the resection cavity corresponds to an area of ischemic change on the postoperative MRI.  Overall, this is consistent with stable disease after completing involved-field radiation and Temodar.	None	None	1	None	None	None	None	None	None	None	None	143	MRI	Follow up	No	NA	No evidence of tumor progression at this time.	None	None	1	None	None	None	None	None	None	None	None	196	MRI	Follow up	No	NA	No anatomic or perfusion findings to suggest tumor progression.	None	None	1	None	None	None	None	None	None	None	None	255	MRI	Follow up	No	NA	Appears stable with out change in the T2 signal or enhancement.	None	None	1	None	None	None	None	None	None	None	None	314	MRI	Follow up	No	NA	There is no anatomic or perfusion findings to suggest tumor progression.	None	None	1	None	None	None	None	None	None	None	None	368	MRI	Follow up	No	NA	Anatomic imaging shows no evidence for progression and demonstrates stable postoperative changes status post left temporal tumor resection.	None	None	1	None	None	None	None	None	None	None	None	424	MRI	Follow up	No	NA	Stable examination without didnt see evidence for interval progression when compared to sequentially a couple of previous ones.	None	None	1	None	None	None	None	None	None	None	None	507	MRI	Follow up	No	NA	Stable examination with 4 mm nodular focus of enhancement in the medial margin of the left temporal resection cavity without significant change.	None	None	1	None	None	None	None	None	None	None	None	570	MRI	Follow up	No	NA	No convincing evidence for interval progression of disease 	None	None	1	None	None	None	None	None	None	None	None	647	MRI	Follow up	No	NA	no new mass, no new enhancement, Findings suggestive of stable disease	None	None	1	None	None	None	None	None	None	None	None	753	MRI	Follow up	Yes	NA	Findings worrisome for interval disease progression /recurrent tumor	None	None	1	None	None	None	None	None	None	None	None	764	MRI	Pre-surgery	Yes	NA	findings strongly suggestive of disease progression	None	None	1	None	None	None	None	None	None	None	None	769	MRI	Post-surgery	No	NA	The adjacent areas of thin linear enhancement are likely postsurgical.	None	None	1	None	None	None	None	None	None	None	None	813	MRI	Follow up	Possible	NA	Finding is concerning for disease recurrence.	None	None	1	None	None	None	None	None	None	None	None	885	MRI	Follow up	Possible	NA	Findings not mitigating clearly in favor of either radiation or recurrence.	None	None	1	None	None	None	None	None	None	None	None	916	MRI	Follow up	Possible	NA	Overall findings are worrisome for progression of disease.	None	None	1	None	None	None	None	None	None	None	None	993	MRI	Follow up	Possible	NA	CBV values not mitigating clearly in favor of either radiation or recurrence, but decreasing CBV suggestive of response to therapy.	None	None	1	None	None	None	None	None	None	None	None	1064	MRI	Follow up	Possible	NA	Status post resection of left temporal lobe tumor, as before. There is nodular enhancement along the deep aspect of the resection cavity, similar in appearance since 4.5 months ago exam and demonstrating increased cerebral blood volume. Findings are concerning for residual disease, but treatment effect cannot be excluded. Nodular focus of enhancement anterior to the left temporal lobe resection cavity. This focus is not significantly changed in size since the 4.5 months ago exam, but there is increased cerebral blood volume and restricted diffusion, most consistent with residual disease.	None	None	1	None	None	None	None	None	None	None	None	1131	MRI	Follow up	Possible	NA	Left temporal resection cavity demonstrates adjacent regions of nodular enhancement that are overall stable compared to 3 and 4 month ago exams and decreased compared to the 7 month ago exam. However, enhancement along the ependymal surface of the proximal left temporal horn demonstrates gradual increase in size over the course of these exams. Cerebral blood volume is mildly elevated, indeterminate. Findings are concerning for disease progression, although posttreatment change remains in the differential.	None	None	1	None	None	None	None	None	None	None	None	1165	MRI	Follow up	No	NA	No significant interval change is appreciated when compared to the most recent prior examination. Areas of enhancement and T2 signal prolongation about the resection margin appear stable.	None	None	1	None	None	None	None	None	None	None	None	1234	MRI	Follow up	No	NA	Again seen are findings of prior tumor resection. Multiple nonspecific foci of residual enhancement, one of which is larger. MR perfusion values are nonspecific. Additional imaging followup is suggested.	None	None	1	None	None	None	None	None	None	None	None	1314	MRI	Follow up	No	NA	Irregular enhancement at and around the left temporal resection cavity appears similar to slightly larger compared to the prior exam although growth appears less accelerated compared to between two prior exams. No new areas of enhancement or mass effect demonstrated. Similar area of white matter T2 hyperintensity around the enhancing regions. 1 < nCBV < 3; nCBV value is between 1 and 3, based on our internal quality control data, this is an intermediate value, not mitigating clearly in favor of either radiation or recurrence.	None	None	1	None	None	None	None	None	None	None	None	1405	MRI	Follow up	No	NA	Irregular enhancement at and around the left temporal resection cavity appears progressively larger compared to a half a year ago exam. No new areas of enhancement or mass effect demonstrated. Similar area of white matter T2 hyperintensity around the enhancing regions. Relative CBV is again indeterminate, although lower compared to prior exam.	None	None	1	None	None	None	None	None	None	None	None	1463	MRI	Follow up	No	NA	No convincing evidence for progression. Decreasing enhancement anterior and inferior to the left temporal parietal resection cavity, compatible with response to therapy. Stable mild linear enhancement along the ventricles medial to the resection cavity. 	None	None	1	None	None	None	None	None	None	None	None	1519	MRI	Follow up	No	NA	Status post resection of left temporal glioblastoma, as before. There is minimal scattered enhancement adjacent to the resection cavity, unchanged from prior exam but significantly reduced compared to the prior prior exam, likely reflecting Avastin therapy. Adjacent FLAIR signal abnormality is also reduced. Overall, no evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	1574	MRI	Pre-surgery	No	NA	Status post resection of left temporal glioblastoma, as before. Faint enhancement anterior to the resection cavity and surrounding FLAIR hyperintensity are stable compared to the 2 months ago exam but slightly decreased in extent compared to the 5 months ago exam, consistent with response to therapy.	None	None	1	None	None	None	None	None	None	None	None	1634	MRI	Follow up	Possible	NA	Increased, new enhancement along the anterolateral margin of the left temporal resection cavity, since a year ago. 1 < nCBV < 3; nCBV value is between 1 and 3, based on our internal quality control data, this is an intermediate value, not clearly in favor of either radiation or recurrence. Differential consideration would include progressive disease versus radiation necrosis.	None	None	1	None	None	None	None	None	None	None	None	18	100	None	0	None	None	chemo planning	n/a	91	100	None	0	None	None	None	n/a	196	100	None	0	None	n/a	None	n/a	368	90	None	1	None	None	mri followup	n/a	424	90	None	0	None	None	post maint. chemo. followup	n/a	507	90	None	0	None	None	post chemo mri followup	n/a	570	90	None	0	None	None	post chemo mri followup	n/a	647	80	None	0	None	None	post chemo mri followup	some occasions where memory does not seem perfect	749	80	None	0	None	None	mri followup	deterioration in spontaneous language, word finding problems; mri shows signs of progressive disease. planned: repeat craniotomy, Avastin, CCNU	810	70	None	0	None	None	mri followup	difficulty in occasional word finding problems. vision deterioation. start TMZ 21 day cycle. 	993	80	None	0	None	None	None	 is doing well from both clinical and radiographic standpoints	1064	80	None	0	None	None	None	is now able to report the vision problem she has with reading. She describes a line of blurred vision across both eyes when she tries to focus on words. She denies diplopia. Her last vision exam was about 6 months ago. She feels her vision has no changed since her initial surgery.	1096	80	None	0	None	None	None	Doing well, no new problems, no seizures	1118	70	None	0	None	None	None	Replace with a new follow-up visit .......	1166	80	None	0	None	None	None	She has done very well and other than continued problems with speech which is unchanged, she has had no new or progressive symptoms	1235	80	None	0	None	None	None	she denies changes in weight or appetite. she denies fever, chills or signs of infection.HEENT:she denies changes in vision or hearing. NEURO: she denies headaches, seizures or confusion. Strength and balance are unchanged. RESP/CV: she denies cough, shortness of breath, chest pain or swelling of the arms/ legs. GI: she denies nausea, vomiting, diarrhea or constipation.  HEM: she denies unusual bleed of bruising. INTEG: she denies rash or lesions.	1264	80	None	0	None	None	None	She reports significant fatigue and bone pain with the VP 16 which has improved since she stopped taking the medication. We had also started her on Ritalin which has helped her day time fatigue. She feels good now and has no concerns or complaints. She denies headaches and has had no seizures. She denies any new or progressive symptoms. 	1315	80	None	0	None	None	None	On examination, alert and oriented with clear and fluent speech. 	1357	80	None	0	None	None	None	She is doing well and has no new concerns or complaints. She is taking Ritalin once daily with improvement in speech and energy. She has occasional headaches. She reports intermittent bilateral wrist pain with certain activities. She has had no seizures and denies any new neurologic symptoms.	1402	80	None	0	None	None	None	is here for a routine visit. She is currently receiving Avastin monotherapy for a progressing left temporal GBM. She is doing very well and tolerating Aatin without any problems. She denies headaches, seizures, CP, SOB, calf or leg pain and she has had no new neurologic symptoms.	1406	80	None	0	None	None	None	She is doing well and has no new concerns or complaints. She is taking Ritalin once daily with improvement in speech and energy. She denies headaches. She has had no seizures and denies any new neurologic symptoms.	1461	80	None	0	None	None	None	Doing well, no new problems, no sz. Meds: reviewed, no changes. Exam: Alert, fluent in Espaniol (accd to daughter), no drift, gait ok. No new imaging today.	1519	80	None	0	None	None	None	Doing well on single agent Avastin. Continue q 2 wk infusions. RTC 4 weeks and MRI/visit in 8 weeks.	1574	80	None	0	None	None	new doctor	Status post resection of left temporal glioblastoma, as before. Faint enhancement anterior to the resection cavity and surrounding FLAIR hyperintensity are stable compared to the 2 months ago exam but slightly decreased in extent compared to the 5 months ago exam, consistent with response to therapy. 	1634	70	None	0	None	None	None	She is with a left temporal glioblastoma, currently on Avastin monotherapy since a half a year ago, who presents for interval follow-up MRI. She continues to have stable difficulty with word-finding. Denies new or progressive symptoms.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
76	W22-2-1, SN319	W22-2-1	 SN319	http://glioblastoma.alleninstitute.org/ish/specimen/show/278103506	53	Female	90	73.03 kg	155.94 cm	None	No	Left,Right	word finding difficulties, slurred speech and altered mental status	Left Temporal	Complete resection	Yes	Yes	Anaplastic astrocytoma, WHO grade III / IV	Negative	amplification	loss	NA	NA	NA	NA	NA	NA	NA	Recurrent	No	Yes	Yes	None	25	769	55	753	1634	NA	NA	5	1	0	0	3	0	0	6	1	0	0	0	0	2	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	-1	500mg BID	KEPPRA	9	Steroids	0	4mg QID taper to 3mg QD	Dexamethasone	46	Anti-epileptic	9	1000 mg twice a day oral	KEPPRA	91	Anti-epileptic	115	500 mg twice a day oral	KEPPRA	771	Anti-depressant	368	25mg QD	Amitriptyline	424	Steroids	769	4mg 4 times a day, 4mh 3 times a day	dexamethasone	810	Anti-epileptic	771	1000 mg twice a day oral	KEPPRA	1166	Steroids	916	1 mg twice a day oral	dexamethasone	1032	Anti-epileptic	1166	500 mg twice a day oral	KEPPRA	1690	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	18	140 mg 	daily oral	91	Temozolomide	116	340 mg	daily oral	424	Temozolomide	777	125 mg 	daily oral	1064	Temozolomide	1064	125 mg	everyday for 21 days	1092	Temozolomide	1096	125 mg	everyday for 21 days	1124	Temozolomide	1131	125 mg	everyday for 21 days	1159	Etoposide	1235	100 mg daily oral	at bedtime	1357	Etoposide	1357	50 mg daily oral	at bedtime	1378	Avastin	1414	665-700 mg intravenous 	every 2 weeks	1643	26	IMRT	4600 cGy	23	54	55	IMRT	1400	7	68	822		1500 cGy	5	826	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	There is a heterogeneous lesion with partial peripheral enhancement measuring approximately 3.1 x 2.7 x 3.5 cm within the left temporoparietal region. There is surrounding edema and associated mass effect.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	MRI shows a tiny focus of residual enhancement along the superficial margin of the resection cavity.  There is no significant ischemic change. This most likely represents postoperative enhancement.	None	None	1	None	None	None	None	None	None	None	None	91	MRI	Follow up	No	NA	The new MRI scan of the brain shows significant resolution of immediate postoperative changes in the left temporal lobe.  There is slight enhancement along the margin of the resection cavity, which is postoperative in nature.  Some enhancement along the deep margin of the resection cavity corresponds to an area of ischemic change on the postoperative MRI.  Overall, this is consistent with stable disease after completing involved-field radiation and Temodar.	None	None	1	None	None	None	None	None	None	None	None	143	MRI	Follow up	No	NA	No evidence of tumor progression at this time.	None	None	1	None	None	None	None	None	None	None	None	196	MRI	Follow up	No	NA	No anatomic or perfusion findings to suggest tumor progression.	None	None	1	None	None	None	None	None	None	None	None	255	MRI	Follow up	No	NA	Appears stable with out change in the T2 signal or enhancement.	None	None	1	None	None	None	None	None	None	None	None	314	MRI	Follow up	No	NA	There is no anatomic or perfusion findings to suggest tumor progression.	None	None	1	None	None	None	None	None	None	None	None	368	MRI	Follow up	No	NA	Anatomic imaging shows no evidence for progression and demonstrates stable postoperative changes status post left temporal tumor resection.	None	None	1	None	None	None	None	None	None	None	None	424	MRI	Follow up	No	NA	Stable examination without didnt see evidence for interval progression when compared to sequentially a couple of previous ones.	None	None	1	None	None	None	None	None	None	None	None	507	MRI	Follow up	No	NA	Stable examination with 4 mm nodular focus of enhancement in the medial margin of the left temporal resection cavity without significant change.	None	None	1	None	None	None	None	None	None	None	None	570	MRI	Follow up	No	NA	No convincing evidence for interval progression of disease 	None	None	1	None	None	None	None	None	None	None	None	647	MRI	Follow up	No	NA	no new mass, no new enhancement, Findings suggestive of stable disease	None	None	1	None	None	None	None	None	None	None	None	753	MRI	Follow up	Yes	NA	Findings worrisome for interval disease progression /recurrent tumor	None	None	1	None	None	None	None	None	None	None	None	764	MRI	Pre-surgery	Yes	NA	findings strongly suggestive of disease progression	None	None	1	None	None	None	None	None	None	None	None	769	MRI	Post-surgery	No	NA	The adjacent areas of thin linear enhancement are likely postsurgical.	None	None	1	None	None	None	None	None	None	None	None	813	MRI	Follow up	Possible	NA	Finding is concerning for disease recurrence.	None	None	1	None	None	None	None	None	None	None	None	885	MRI	Follow up	Possible	NA	Findings not mitigating clearly in favor of either radiation or recurrence.	None	None	1	None	None	None	None	None	None	None	None	916	MRI	Follow up	Possible	NA	Overall findings are worrisome for progression of disease.	None	None	1	None	None	None	None	None	None	None	None	993	MRI	Follow up	Possible	NA	CBV values not mitigating clearly in favor of either radiation or recurrence, but decreasing CBV suggestive of response to therapy.	None	None	1	None	None	None	None	None	None	None	None	1064	MRI	Follow up	Possible	NA	Status post resection of left temporal lobe tumor, as before. There is nodular enhancement along the deep aspect of the resection cavity, similar in appearance since 4.5 months ago exam and demonstrating increased cerebral blood volume. Findings are concerning for residual disease, but treatment effect cannot be excluded. Nodular focus of enhancement anterior to the left temporal lobe resection cavity. This focus is not significantly changed in size since the 4.5 months ago exam, but there is increased cerebral blood volume and restricted diffusion, most consistent with residual disease.	None	None	1	None	None	None	None	None	None	None	None	1131	MRI	Follow up	Possible	NA	Left temporal resection cavity demonstrates adjacent regions of nodular enhancement that are overall stable compared to 3 and 4 month ago exams and decreased compared to the 7 month ago exam. However, enhancement along the ependymal surface of the proximal left temporal horn demonstrates gradual increase in size over the course of these exams. Cerebral blood volume is mildly elevated, indeterminate. Findings are concerning for disease progression, although posttreatment change remains in the differential.	None	None	1	None	None	None	None	None	None	None	None	1165	MRI	Follow up	No	NA	No significant interval change is appreciated when compared to the most recent prior examination. Areas of enhancement and T2 signal prolongation about the resection margin appear stable.	None	None	1	None	None	None	None	None	None	None	None	1234	MRI	Follow up	No	NA	Again seen are findings of prior tumor resection. Multiple nonspecific foci of residual enhancement, one of which is larger. MR perfusion values are nonspecific. Additional imaging followup is suggested.	None	None	1	None	None	None	None	None	None	None	None	1314	MRI	Follow up	No	NA	Irregular enhancement at and around the left temporal resection cavity appears similar to slightly larger compared to the prior exam although growth appears less accelerated compared to between two prior exams. No new areas of enhancement or mass effect demonstrated. Similar area of white matter T2 hyperintensity around the enhancing regions. 1 < nCBV < 3; nCBV value is between 1 and 3, based on our internal quality control data, this is an intermediate value, not mitigating clearly in favor of either radiation or recurrence.	None	None	1	None	None	None	None	None	None	None	None	1405	MRI	Follow up	No	NA	Irregular enhancement at and around the left temporal resection cavity appears progressively larger compared to a half a year ago exam. No new areas of enhancement or mass effect demonstrated. Similar area of white matter T2 hyperintensity around the enhancing regions. Relative CBV is again indeterminate, although lower compared to prior exam.	None	None	1	None	None	None	None	None	None	None	None	1463	MRI	Follow up	No	NA	No convincing evidence for progression. Decreasing enhancement anterior and inferior to the left temporal parietal resection cavity, compatible with response to therapy. Stable mild linear enhancement along the ventricles medial to the resection cavity. 	None	None	1	None	None	None	None	None	None	None	None	1519	MRI	Follow up	No	NA	Status post resection of left temporal glioblastoma, as before. There is minimal scattered enhancement adjacent to the resection cavity, unchanged from prior exam but significantly reduced compared to the prior prior exam, likely reflecting Avastin therapy. Adjacent FLAIR signal abnormality is also reduced. Overall, no evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	1574	MRI	Pre-surgery	No	NA	Status post resection of left temporal glioblastoma, as before. Faint enhancement anterior to the resection cavity and surrounding FLAIR hyperintensity are stable compared to the 2 months ago exam but slightly decreased in extent compared to the 5 months ago exam, consistent with response to therapy.	None	None	1	None	None	None	None	None	None	None	None	1634	MRI	Follow up	Possible	NA	Increased, new enhancement along the anterolateral margin of the left temporal resection cavity, since a year ago. 1 < nCBV < 3; nCBV value is between 1 and 3, based on our internal quality control data, this is an intermediate value, not clearly in favor of either radiation or recurrence. Differential consideration would include progressive disease versus radiation necrosis.	None	None	1	None	None	None	None	None	None	None	None	18	100	None	0	None	None	chemo planning	n/a	91	100	None	0	None	None	None	n/a	196	100	None	0	None	n/a	None	n/a	368	90	None	1	None	None	mri followup	n/a	424	90	None	0	None	None	post maint. chemo. followup	n/a	507	90	None	0	None	None	post chemo mri followup	n/a	570	90	None	0	None	None	post chemo mri followup	n/a	647	80	None	0	None	None	post chemo mri followup	some occasions where memory does not seem perfect	749	80	None	0	None	None	mri followup	deterioration in spontaneous language, word finding problems; mri shows signs of progressive disease. planned: repeat craniotomy, Avastin, CCNU	810	70	None	0	None	None	mri followup	difficulty in occasional word finding problems. vision deterioation. start TMZ 21 day cycle. 	993	80	None	0	None	None	None	 is doing well from both clinical and radiographic standpoints	1064	80	None	0	None	None	None	is now able to report the vision problem she has with reading. She describes a line of blurred vision across both eyes when she tries to focus on words. She denies diplopia. Her last vision exam was about 6 months ago. She feels her vision has no changed since her initial surgery.	1096	80	None	0	None	None	None	Doing well, no new problems, no seizures	1118	70	None	0	None	None	None	Replace with a new follow-up visit .......	1166	80	None	0	None	None	None	She has done very well and other than continued problems with speech which is unchanged, she has had no new or progressive symptoms	1235	80	None	0	None	None	None	she denies changes in weight or appetite. she denies fever, chills or signs of infection.HEENT:she denies changes in vision or hearing. NEURO: she denies headaches, seizures or confusion. Strength and balance are unchanged. RESP/CV: she denies cough, shortness of breath, chest pain or swelling of the arms/ legs. GI: she denies nausea, vomiting, diarrhea or constipation.  HEM: she denies unusual bleed of bruising. INTEG: she denies rash or lesions.	1264	80	None	0	None	None	None	She reports significant fatigue and bone pain with the VP 16 which has improved since she stopped taking the medication. We had also started her on Ritalin which has helped her day time fatigue. She feels good now and has no concerns or complaints. She denies headaches and has had no seizures. She denies any new or progressive symptoms. 	1315	80	None	0	None	None	None	On examination, alert and oriented with clear and fluent speech. 	1357	80	None	0	None	None	None	She is doing well and has no new concerns or complaints. She is taking Ritalin once daily with improvement in speech and energy. She has occasional headaches. She reports intermittent bilateral wrist pain with certain activities. She has had no seizures and denies any new neurologic symptoms.	1402	80	None	0	None	None	None	is here for a routine visit. She is currently receiving Avastin monotherapy for a progressing left temporal GBM. She is doing very well and tolerating Aatin without any problems. She denies headaches, seizures, CP, SOB, calf or leg pain and she has had no new neurologic symptoms.	1406	80	None	0	None	None	None	She is doing well and has no new concerns or complaints. She is taking Ritalin once daily with improvement in speech and energy. She denies headaches. She has had no seizures and denies any new neurologic symptoms.	1461	80	None	0	None	None	None	Doing well, no new problems, no sz. Meds: reviewed, no changes. Exam: Alert, fluent in Espaniol (accd to daughter), no drift, gait ok. No new imaging today.	1519	80	None	0	None	None	None	Doing well on single agent Avastin. Continue q 2 wk infusions. RTC 4 weeks and MRI/visit in 8 weeks.	1574	80	None	0	None	None	new doctor	Status post resection of left temporal glioblastoma, as before. Faint enhancement anterior to the resection cavity and surrounding FLAIR hyperintensity are stable compared to the 2 months ago exam but slightly decreased in extent compared to the 5 months ago exam, consistent with response to therapy. 	1634	70	None	0	None	None	None	She is with a left temporal glioblastoma, currently on Avastin monotherapy since a half a year ago, who presents for interval follow-up MRI. She continues to have stable difficulty with word-finding. Denies new or progressive symptoms.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
80	W26-1-1, SN228	W26-1-1	 SN228	http://glioblastoma.alleninstitute.org/ish/specimen/show/278113158	58	Female	100	48.6 kg	148 cm	30	Yes	No	Seizure	Right Parietal, Right Temporal	Complete resection	Yes	No	Glioblastoma	NA	NA	NA	NA	NA	0.45	0.40	0.30	wildtype	NA	Primary	No	Yes	Yes	Yes	9	7	58	1005	NA	1293	Deceased due to tumor progression	3	0	0	0	4	0	0	1	1	0	1	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	0	200 mg PO q12 hr	Phenytoin	7	Steroids	1	4 mg PO q 6hr	Dexamethasone	7	Steroids	7	10 mg IV	Dexamethasone	7	Steroids	7	4 mg IV	Dexamethasone	7	Anti-epileptic	991	500 mg twice daily oral	KEPPRA	1061	antihypertensive	1028	20 mg daily oral	lisinopril	1033	Anti-epileptic	1061	250 mg 3 times a day oral	KEPPRA	1195	Steroids	1195	4 mg daily oral	dexamethasone	1223	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	1007	65 mg	daily oral	1150	Avastin	1160	411-390 mg in NS (0.9% NaCl) IV solution 100 mg	once every 2 weeks	1213	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	9	MRI	Post-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	836	MRI	Follow up		NA	None	None	None	1	None	None	None	None	None	None	None	None	914	MRI	Follow up		NA	None	None	None	1	None	None	None	None	None	None	None	None	944	CT	Follow up		NA	None	None	None	1	None	None	None	None	None	None	None	None	977	MRI	Follow up		NA	None	None	None	1	None	None	None	None	None	None	None	None	1005	MRI	Follow up	Possible	NA	Modest decrease in size of enhancing tumor and significant decrease in extent of surrounding T2 signal abnormality.	None	None	1	None	None	None	None	None	None	None	None	1033	MRI	Follow up	Possible	NA	Mild increased enhancement in the right posterior perisylvian cortical and subcortical region. Otherwise stable examination.	None	None	1	None	None	None	None	None	None	None	None	1091	MRI	Follow up	Yes	NA	Continued decrease in abnormal enhancement in the right parietal lobe compared sequentially to the 2 last prior exams. However, several regions continue to demonstrate significantly elevated cerebral blood volume, concerning for viable tumor.	None	None	1	None	None	None	None	None	None	None	None	1146	MRI	Follow up	Yes	NA	Marked interval progression of enhancing tumor in the right parietal and temporal lobes compared to the prior exam.	None	None	1	None	None	None	None	None	None	None	None	1181	MRI	Follow up	Yes	NA	Significant interval enlargement of enhancing tumor in the right parietal lobe compared to the prior exam, consistent with progression of disease. Enhancing tumor now extends across the splenium of the corpus callosum and there are separate enhancing foci in the contralateral cerebral hemisphere.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	991	60	None	0	None	None	              	I discussed with her the possible options at this point. I told her that surgical resection is probably not going to give her any clear likelihood of improved survival. If we do surgery I would want functional MRI and I would like to do the surgery with brain mapping. She is going to be seen by Dr. Bankers today and these options will be further discussed and we can make recommendations as to whether or not she should proceed with the surgery.	1005	60	None	1	None	None	None	Denies any new or progressive symptoms.	1033	60	None	1	None	None	None	Denies any new or progressive symptoms.	1061	60	None	0	None	None	None	Denies any new or progressive simptoms.	1091	60	None	1	Left	has mild left-sided weakness	None	Denies any new or progressive symptoms.	1146	60	None	0	None	None	None	She has continued cooking and working around the house, however over the past month, has noted increasing fatigue, and some cognitive decline as well as new falls with some increased difficultly in mobility. 	1181	50	None	0	None	None	None	Over the past month, she has continued to decline markedly at home and is no longer able to tend to daily activities. She is now more reliant on the wheelchair.	1195	50	None	0	None	None	None	Over the past few weeks, she has become more fatigued with progressive left-sided weakness and neglect. She is now more dependent on the wheelchair. She denies any further seizures. She has decided to move forward with radiation with continuation of Avastin and consideration of Hospice should her symptoms progress.	1227	None	None	0	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
81	W27-2-1, SN233	W27-2-1	 SN233	http://glioblastoma.alleninstitute.org/ish/specimen/show/287112517	63	Male	90	88.5 kg	186 cm	30	Yes	No	Seizures.	Right Occipital, Right Temporal	Complete resection	Yes	Yes	Glioblastoma WHO grade IV 	NA	NA	NA	NA	NA	0.24	0.06	0.07	wildtype	not detected	Recurrent	No	Yes	No	Yes	3	664	65	689	NA	735	Deceased due to tumor progression	1	0	0	0	5	0	0	2	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	0	500 mg BID	Keppra		Steroids	648	10 mg IV	Dexamethasone	648	Steroids	649	6 mg IV BID	Dexamethasone	651	Steroids	652	2 mg IV QD	Dexamethasone	653	Steroids	652	6 mg IV	Dexamethasone	652	Steroids	654	2 mg PO BID	Dexamethasone		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	38	75 mg/m2	concurrent	82	Temozolomide	89	100 mg/m2	maintenance	104	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	39	IMRT	4600 cGy	6	69	70	IMRT	1400 cGy	7	81	None	None	None	None	None	None	None	None	None	None	663	MRI	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	665	MRI	Post-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	689	MRI	Follow up	Possible	NA	Some areas of nodular enhancement around the resection cavity suspicious for small volume of residual tumor. 	None	None	1	None	None	None	None	None	None	None	None	708	MRI	Follow up	Yes	NA	Extensive amount of signal/enhancement extending into right temporal lobe and posterior corpus callosum raise suspicion for recurrent neoplasm.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	694	90	None	1	Left	left neglect	None	Moderate to severe headaches despite increasing pain medication.	697	70	None	0	Left	left neglect	None	Hospitalization for severe headaches, draining wound, and oconcern about infection at operative site. 	720	60	None	0	Left	left neglect	None	Increase in episodic escalations of headaches.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
83	W28-1-1, SN234	W28-1-1	 SN234	http://glioblastoma.alleninstitute.org/ish/specimen/show/268000655	69	Male	100	71.5 kg	172 cm	30	No	Left	Headache.	Right Occipital, Right Parietal	Subtotal resection 90%	No	No	Glioblastoma WHO grade IV 	NA	NA	NA	NA	NA	0.53	0.09	0.08	wildtype	not detected	Primary	No	Yes	No	Yes	1	0	69	NA	NA	300	Deceased due to tumor progression	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	-1	MRI	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	1	MRI	Post-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	5	80	None	0	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
84	W29-1-1, SN235	W29-1-1	 SN235	http://glioblastoma.alleninstitute.org/ish/specimen/show/287534919	74	Male	100	89.54 kg 	179 cm 	31	No	Left	Decreased balance, occasional tingling in the tips of digits on left hand, dragging of left foot.	Right Parietal	Complete resection	Yes	Yes	Glioblastoma	Negative	amplification	deletion	unmethylated	10%-15%	0.41	0.06	0.05	wildtype	detected	Primary	No	Yes	No	Yes	5	2	74	246	NA	260	Deceased due to tumor progression	3	0	0	0	1	0	0	3	0	0	0	0	0	0	0	0	0	0	1	No	No	No	No	No	Steroids	0	4mg QID decrease to 1mg QD	Dexamethasone	246	Anti-epileptic	2	1000 mg in NS(0.9% NaCl) IV solution 100 mL	KEPPRA	3	Anti-epileptic	3	500 mg x 2caps twice a day oral	KEPPRA	76	Anti-epileptic	77	500 mg oral daily	KEPPRA	95	multi-vitamin	134	1 cap daily oral		164	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	27	140 mg	concurrent	77	Temozolomide	118	400 mg	maintenance 5x/mo.	134	Temozolomide	176	150 mg	maintenance 21x/mo.	246	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	27	IMRT	4500 cGy	25	62	63	IMRT	1800 cGy	10	76	183	Stereotactic	20 Gy	1	183	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large right sided mass, findings are most consistent with a high grade glioma.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	There is no evidence for abnormal contrast enhancement to suggest residual contrast enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	110	MRI	Follow up	No	NA	No evidence for recurrent disease.	None	None	1	None	None	None	None	None	None	None	None	176	MRI	Follow up	No	NA	Interval enlargement of a tiny nodule of enhancement adjacent to rather the trigone of the right lateral ventricle.	None	None	1	None	None	None	None	None	None	None	None	183	MRI	Follow up	No	NA	Stable findings when compared to previous one a week ago.	None	None	1	None	None	None	None	None	None	None	None	246	MRI	Follow up	Yes	NA	There has been slight interval progression of size of abnormal enhancement along the lateral margin compared to previous one.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	8	90	None	0	Left	left leg weakness	Suture removal	Left leg weakness, balance problems.	76	80	None	0	Left	left leg weakness	Surgery	Placement of a subdural to peritoneal shunt due to hydrocephalus.	110	None	28	0	Left	left leg weakness	Maintenance TMZ planning	None	134	70	None	1	None	None	MRI followup	Rapid deterioration in gait and memory. Hold TMZ temporarily. 	176	70	None	0	Left	left sided weakness	MRI followup	Substantial improvement in cognitive function and gait, worsening of left arm/shoulder pain.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
86	W30-1-1, SN238	W30-1-1	 SN238	http://glioblastoma.alleninstitute.org/ish/specimen/show/267499908	60	Male	70	112.1 kg		None	No	Left,Right	Increased right extremities weakness over last 6 weeks, progressive inability to ambulate, some difficulty finding words and memory problems.	Left Parietal	Subtotal resection 90%	Yes	Yes	Glioblastoma, WHO grade IV	Negative	amplification	deletion	methylated 	15%	0.32	0.28	0.31	wildtype	not detected	Primary	No	Yes	No	Yes	2	4	60	NA	NA	759	Deceased due to tumor progression	2	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-1	4mg QID decrease to 3mg TID	Dexamethasone	10	Anti-epileptic	-1	1000mg BID decrease to 500mg BID	KEPPRA	10	Anti-epileptic	49	500 mg twice a day oral	KEPPRA	70	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	64	140mg	concurrent	107	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	64	IMRT	4600 cGy	23	99	100	IMRT	1400 cGy	7	107	570	IMRT	3360 cGy	5	576	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	There is a large intra-axial mass involving the left hemisphere.	None	None	1	None	None	None	None	None	None	None	None	4	MRI	Post-surgery	No	NA	A small amount of residual tumor may be present related to the anteroinferior resection margin.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	45	80	None	0	None	aphasia	Radiation planning 	Memory problems, aphasia. Had DVT complication shortly after surgery. 	82	80	None	0	None	aphasia	None	Aphasia improving.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
90	W31-1-1, SN242	W31-1-1	 SN242	http://glioblastoma.alleninstitute.org/ish/specimen/show/298321876	18	Male	90	76.7 kg	179 cm	27	Yes	No	History of multiple seizures and migraine headaches which had been going on for about 2 weeks.	Left Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Positive	gain	deletion	unmethylated	75%	0.22	0.05	0.03	R132H	not detected	Primary	No	Yes	No	Yes	20	1	18	312	NA	871	Deceased due to tumor progression	8	0	0	0	5	0	0	3	1	0	0	0	0	0	0	1	0	0	1	No	No	No	No	No	Anti-epileptic	-1	1000 mg in NS(0.9% NaCl) IV solution 50 mg once a day	phenytoin	0	Steroids	0	4mg QID taper to 1mg QD	dexamethasone	11	Anti-epileptic	0	1000mg BID decrease to 750mg BID	KEPPRA	30	Anti-epileptic	30	300mg QD	Phenytoin	110	multi-vitamin	46	1 cap daily oral		256	Anti-epileptic	505	100 mg PE injection 3 times a day	fosphenytoin (CEREBYX)	507	Steroids	505	4mg/1mL injection 4mg 4 times a day, 3 times a day	dexamethasone	507	Anti-epileptic	507	300 mg at bedtime oral	phenytoin	515	Steroids	507	4 mg 4 times a day, 4mg 3times a day, 3mg 3 times a day, 2mg twice a day oral, 3mg 3 times a day, 2mg 3 times a day, 2mg twice a day	dexamethasone	515	Anti-epileptic	656	500 mg twice a day oral	KEPPRA	659	Anti-epileptic	659	1000 mg twice a day oral	KEPPRA	690	Anti-epileptic	723	1000 mg twice a day oral	KEPPRA XR	852	Steroids	815	4mg/1mL injection 4mg 4 once	dexamethasone		Steroids	852	4mg/1mL injection 10mg	dexamethasone		None	None	None	None	None	None	None	None	None	None	Temozolomide	11	140 mg 	daily oral	110	Temozolomide	141	400 mg	every 4 weeks for 5 days oral	354	Temozolomide	354	150 mg 	daily oral	498	Lomustine	498	220 mg	maintenance 1x/6wks	656	Avastin	533	820 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	maintenance 1x/2wks	852	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	23	IMRT	4500 cGy	25	52	54	IMRT	1440 cGy	8	67	330	Stereotactic	1800 cGy	1		None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large cystic/solid left frontal lobe mass lesion.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	All enhancing tumor has been resected.	None	None	1	None	None	None	None	None	None	None	None	78	MRI	Follow up	No	NA	The new MRI scan of the brain shows resolution of majority of the immediate postoperative changes seen on the prior study.  There is minimal contrast enhancement along the walls of the surgical cavity, which is likely postoperative in nature.  	None	None	1	None	None	None	None	None	None	None	None	141	MRI	Follow up	No	NA	Further resolution of postoperative changes in the left frontal lobe.	None	None	1	None	None	None	None	None	None	None	None	200	MRI	Follow up	No	NA	Appears stable without new enhancement or change.	None	None	1	None	None	None	None	None	None	None	None	256	MRI	Follow up	No	NA	No changes are seen.	None	None	1	None	None	None	None	None	None	None	None	312	MRI	Follow up	Yes	NA	Mild interval progression of T2 signal change in the region of surgery. Worsening enhancement in this region.	None	None	1	None	None	None	None	None	None	None	None	354	MRI	Follow up	Yes	NA	Progressively increasing T2 hyperintensity, and enhancement in the deep, inferior margin of the left frontal resection cavity. Findings are compatible with progression of disease.	None	None	1	None	None	None	None	None	None	None	None	389	MRI	Follow up	No	NA	Stability of the ring enhancing lesion in the left frontal lobe.	None	None	1	None	None	None	None	None	None	None	None	442	MRI	Follow up	Yes	NA	Some interval increase in thickness of the contrast enhancement in the left frontal lobe lesion.	None	None	1	None	None	None	None	None	None	None	None	498	MRI	Follow up	Yes	NA	Marked interval enlargement of the left frontal tumor, highly suggestive of progressive disease.	None	None	1	None	None	None	None	None	None	None	None	504	MRI	Pre-surgery	No	NA	Large left frontal tumor.	None	None	1	None	None	None	None	None	None	None	None	507	MRI	Post-surgery	No	NA	Near gross total resection of the large left frontal lobe mass lesion.	None	None	1	None	None	None	None	None	None	None	None	564	MRI	Follow up	No	NA	Significantly decreased conspicuity of enhancement of enhancing residual tumor in the periventricular left frontal lobe and corpus callosal genu, witinterval decrease in surrounding T2 hyperintensity likely related to interval Avastin therapy.	None	None	1	None	None	None	None	None	None	None	None	629	MRI	Follow up	Yes	NA	Interval disease progression, in comparison with the last MRI scan. 	None	None	1	None	None	None	None	None	None	None	None	743	MRI	Follow up	Possible	NA	Findings compatible with mixed response to therapy. The new MRI scan of the brain shows marked improvement with complete resolution of abnormal contrast enhancement in bilateral frontal and colossal regions. However, new areas of enhancement with elevated CBV exhibited are highly suspicious for disease progression. 	None	None	1	None	None	None	None	None	None	None	None	802	MRI	Follow up	Possible	NA	These findings are suspicious for disease progression.	None	None	1	None	None	None	None	None	None	None	None	852	MRI	Follow up	Yes	NA	Significant progression of tumor along the corpus callosum, anterior fornix, and along the periventricular region with findings suggestive of subependymal spread and spread along the left cortical spinal tract. Significant edema and inferior transtentorial displacement of the diencephalon into the perimesencephalic cistern with worsening hydrocephalus.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	5	None	27	0	None	None	Post-operative MRI	Mild difficulty with short-term memory.	11	90	None	0	None	None	Suture removal	n/a	46	90	None	0	None	None	Mid radiation followup	n/a	78	90	None	0	None	None	Post radiation followup	n/a	110	90	None	0	None	None	Maintenance TMZ followup	Patient unintentionally started TMZ today instead of 4 wks ago, due to miscommunication/confusion. 	141	90	None	0	None	None	MRI scan followup	n/a	170	90	None	1	None	None	Neuro oncology followup	Took 300mg of TMZ instead of 400 mg TMZ.	200	90	None	0	None	None	Neuro oncology followup	n/a	228	90	None	0	None	None	Neuro oncology followup	n/a	256	90	None	0	None	None	MRI followup	n/a	312	80	None	0	None	None	MRI scan followup	New MRI scan concerning for progressive disease, switching TMZ to 21 day regimen.	354	80	None	0	None	None	MRI followup	n/a	389	80	None	0	None	None	MRI followup	n/a	442	80	None	0	None	None	MRI followup	Increasing enhancement worrisome for tumor progression.	498	70	None	0	None	None	MRI followup	Progressive disease evident.	515	80	None	1	None	None	post surg. mri followup	n/a. begin CCNU the following week, then Avastin the week after. 	564	80	None	0	None	None	MRI followup	n/a	619	70	None	1	None	None	ER visit	Hypotension; found diaphoretic and unresponsive.	743	80	None	0	None	None	None	New MRI scan of the brain shows marked improvement with complete resolution of abnormal contrast enhancement in bilateral frontal and colossal regions.	852	60	None	0	None	None	None	GBM with subsequent development of hydrocephalus s/p VP shunt placement. He has seen a progressive decline over the past two weeks which is concerning for tumor progression and/or shunt malfunction.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
91	W32-1-1, SN243	W32-1-1	 SN243	http://glioblastoma.alleninstitute.org/ish/specimen/show/301313068	57	Male	90	91.3 kg	183 cm	30	Yes	No	Headaches for 1 month and worsening confusion. 	Right Frontal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	gain	gain	methylated	negative	0.85	0.00	1.02	wildtype	not detected	Primary	No	Yes	No	Yes	28	1	57	NA	1484	NA	NA	8	0	0	0	2	0	0	4	0	0	0	0	0	0	0	0	0	0	0	Yes	No	No	No	No	Anti-epileptic	0	750 mg twice a day oral	KEPPRA	1	Anti-epileptic	0	1000 mg in NS(0.9% NaCl) IV solution 100 mg once	fosphenytoin (CEREBYX)		Steroids	1	4mg/1mL injection 4mg 4 times a day, 3mg 4 times a day, 2mg 4 times a day, 2mg 3 times a day, 2mg twice a day	dexamethasone	8	Anti-epileptic	1	1000 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	7	Anti-epileptic	7	1000 mg twice a day oral	KEPPRA	17	Steroids	8	1 mg twice a day, 1mg daily oral	dexamethasone	16	Anti-epileptic	17	1500 mg twice a day oral	KEPPRA	342	Anti-epileptic	342	1500 mg every morning and 1000 mg every evening oral	KEPPRA XR	448	Anti-epileptic	448	1000 mg twice a day oral	KEPPRA XR	841	Anti-epileptic	1202	1000 mg twice daily oral	KEPPRA XR	1293	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	23	160 mg	concurrent	69	Temozolomide	90	400 mg	maintenance 5x/mo.	356	Temozolomide	356	160 mg	maintenance 21x/mo.	415	Temozolomide	415	400 mg	maintenance 5x/mo.	478	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	23	IMRT	4140 cGy	23	47	48	IMRT	1800 cGy	10	69	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Large right frontal region mass.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Postoperative changes as expected after right frontal tumor resectionwithout evidence for residual enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	86	MRI	Follow up	No	NA	There is no evidence for progressive disease.	None	None	1	None	None	None	None	None	None	None	None	107	MRI	Follow up	No	NA	Current MRI was compared to the prior one. This appears stable.	None	None	1	None	None	None	None	None	None	None	None	177	MRI	Follow up	No	NA	The extent of abnormal T2 signal along the posterior aspect of the resection cavity is slightly increased compared to the prior study.  This could represent infiltrating tumor or treatment effect and would bear observation.	None	None	1	None	None	None	None	None	None	None	None	233	MRI	Follow up	No	NA	No evidence for abnormal enhancement or mass effect.	None	None	1	None	None	None	None	None	None	None	None	293	MRI	Follow up	No	NA	Progressive T2 signal abnormality, without focal new areas of enhancement.	None	None	1	None	None	None	None	None	None	None	None	356	MRI	Follow up	No	NA	In comparison with the previous one, no convincing interval progression.	None	None	1	None	None	None	None	None	None	None	None	415	MRI	Follow up	No	NA	No abnormal enhancement, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	478	MRI	Follow up	No	NA	No change in the extent of abnormal T2-weighted signal surrounding the resection cavity, no abnormal enhancement is detected.	None	None	1	None	None	None	None	None	None	None	None	541	MRI	Follow up	No	NA	No abnormal enhancement is seen.	None	None	1	None	None	None	None	None	None	None	None	601	MRI	Follow up	No	NA	Findings felt to represent stable disease without evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	660	MRI	Follow up	No	NA	No convincing interval progression.	None	None	1	None	None	None	None	None	None	None	None	730	MRI	Follow up	No	NA	Nothing definite for progression.	None	None	1	None	None	None	None	None	None	None	None	800	MRI	Follow up	No	NA	Stable minimal enhancement along the posterior medial aspect of the resection cavity with elevated CBV values but no size increase.	None	None	1	None	None	None	None	None	None	None	None	863	MRI	Follow up	No	NA	No evidence of disease progression. T2 hyperintensity in the bilateral frontal lobes is unchanged since 10 month ago. No new nodular areas of enhancement are seen to suggest recurrence. Mild linear enhancement along the posterior medial aspect of the resection cavity demonstrate relative CBV values measuring up to 2.6 times normal white matter, slightly decreased from 3 times normal white matter on the prior exam.	None	None	1	None	None	None	None	None	None	None	None	916	MRI	Follow up	No	NA	Status post resection of tumor in right frontal lobe, as before. There is no abnormal enhancement. Surrounding FLAIR signal abnormality is stable since the year ago exam. Overall, no convincing evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	986	MRI	Follow up	No	NA	Stable appearance of the brain when compared to most recent examination. There are no findings concerning for disease progression at this time.	None	None	1	None	None	None	None	None	None	None	None	1042	MRI	Follow up	No	NA	Stable postoperative, post treatment changes status post resection right frontal lobe, no suspicious findings to suggest tumor recurrence, compared to the prior one.	None	None	1	None	None	None	None	None	None	None	None	1112	MRI	Follow up	No	NA	 No convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	1168	MRI	Follow up	No	NA	Status post resection of right frontal glioblastoma, as before. No abnormal enhancement. FLAIR signal abnormality adjacent to the resection cavity is stable since the prior exam. No evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	1231	MRI	Follow up	No	NA	Stable appearance of the brain when compared to recent MRI examinations. There are no findings concerning for disease progression at this time.	None	None	1	None	None	None	None	None	None	None	None	1294	MRI	Follow up	No	NA	Stable postoperative changes. No evidence for interval development of disease recurrence or progression at this time.	None	None	1	None	None	None	None	None	None	None	None	1350	MRI	Follow up	No	NA	Expected postoperative findings without definitive findings of tumor residua or recurrence. Normal cerebral perfusion.	None	None	1	None	None	None	None	None	None	None	None	1418	MRI	Follow up	No	NA	Stable postoperative changes without evidence of recurrent disease	None	None	1	None	None	None	None	None	None	None	None	1484	MRI	Follow up	No	NA	No acute abnormality or significant change. No evidence for recurrent or residual enhancing intracranial tumor. 	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	10	None	30	0	None	None	ER visit	Taking hot shower when two generalized seizures occured, taken to ER.	14	100	None	0	None	None	ER visit	Extreme right leg pain.	16	100	None	0	None	None	suture removal	n/a	53	90	None	0	None	None	ER visit	Patient feels twisting/ripping in his abdomen.	86	90	None	0	None	None	Maintenance TMZ planning	Fairly significant fatigue.	160	90	None	0	None	None	ER visit	ER visit for syncopal episodes, most consistent with bradyarrhythmia.	177	90	None	0	None	None	MRI followup	n/a	233	100	None	0	None	None	MRI followup	Mild fatigue, constipation, brief episode of near-syncope.	293	90	None	0	None	None	MRI followup	n/a	356	90	None	0	None	None	MRI followup	Gradual increase in T2 signal is of unclear cause, changing treatment regimen from 5 to 21 day cycle.	415	90	None	0	None	None	MRI followup	More difficulty in terms of prolonged fatigue, switching back to 5 day regimen.	478	None	30	0	None	None	MRI followup	n/a	541	90	None	0	None	None	Post radiation followup	n/a	601	80	None	1	None	None	MRI followup	Fatigue, some mild cognitive slowing. Drinks substantial amounts of alcohol daily.	660	90	None	0	None	None	None	Continues to do reasonably well from clinical standpoint and the MRI scan is stable.	730	80	None	0	None	None	None	New MRI scan of the brain shows no change compared to prior studies.  This is consistent with stable disease.	800	90	None	0	None	None	None	New MRI scan of the brain shows no changes compared to prior studies.  There is no evidence for recurrent disease.	863	90	None	0	None	None	None	No new issues. No seizures. He is getting minimal exercise.	916	80	None	0	None	None	None	Doing well except for daytime fatigue and sleepiness. Continues to do well from clinical and radiographic standpoints.	986	80	None	0	None	None	None	He is doing well and has no new concerns or complaints. He continues to struggle with daytime fatigue despite Nuvigil. He denies any new or progressive symptoms.	1042	80	None	0	None	None	None	No new problems. Still with fatigue. Doing well clinically and radiographically. 	1112	80	None	0	None	None	None	Fatigue but no other new issues. Sleeping several hours during the day. No seizures or headaches.  No evidence for progressive tumor. 	1168	80	None	0	None	None	None	Follow up visit in 2 months with a new MRI scan prior.	1231	80	None	0	None	None	None	Excellent stable course from radiographic and clinical standpoints. 	1294	80	None	0	None	None	None	No new problems. Previously noted fatigue. No seizures.	1350	80	None	0	None	None	None	Follow up visit in 2 months with a new MRI scan prior.	1421	80	None	0	None	None	None	presents for interval follow-up with surveillance MRI on observation, as a new patient to me.	1484	90	None	0	None	None	None	presents for interval follow-up with surveillance MRI on observation, now 4 years out from diagnosis, on observation since almost 3 years. Denies new or progressive symptoms.  He remotely had one event consistent with possible seizure for which he as remained on Keppra for prophylaxis.
93	W33-1-1, SN245	W33-1-1	 SN245	http://glioblastoma.alleninstitute.org/ish/specimen/show/272984854	61	Male	80	83.5 kg	183 cm	25	No	No	Fell from bicycle recently. After the fall he had mild headache, confusion, and difficulty concentrating.	Right Parietal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	amplification	loss	methylated	25%	0.51	0.13	0.32	wildtype	not detected	Primary	No	Yes	No	Yes	22	3	61	NA	1434	NA	NA	9	1	0	0	1	0	0	2	0	0	2	2	0	0	0	0	0	0	1	No	No	No	No	No	antihypertensive	-1	25 mg daily oral	Hydrochlorothiazide	138	Steroids	0	4mg QID taper to 1mg QD	Dexamethasone	66	Anti-epileptic	0	1000mg BID decrease to 500mg BID	KEPPRA	97	Cholesterol lowering	3	40mg QD	Simvastatin	9	multi-vitamin	97	1 cap daily oral		127	Cholesterol lowering	139	40 mg daily oral	Simvastatin	141	antihypertensive	297	25 mg daily oral	hydrochlorothiazide	307	Anti-epileptic	353	300 mg 3 times a day, 300 mg twice a day oral	gabapentin	531	Anti-epileptic	531	300 mg in the morning and 400 mg in the evening oral	gabapentin	594	Anti-epileptic	594	100 mg in the morning and 400 mg in the evening oral	gabapentin	837	Anti-depressant	650	20 mg at bedtime oral	citalopram (CELEXA)	1345	Anti-epileptic	837	500 mg twice a day oral	KEPPRA	868	Anti-epileptic	901	1000 mg twice a day oral	KEPPRA	931	Anti-epileptic	990	1000 mg twice daily oral	KEPPRA	1042	Anti-epileptic	1042	1000 mg AM and 1500 mg PM oral	KEPPRA	1224	Anti-epileptic	1224	1500 mg twice a day oral	KEPPRA	1345	Temozolomide	14	140mg QD	concurrent	66	Temozolomide	66	300mg QD increase to 360mg QD	maintenance once a month 5 day cycles	468	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	26	IMRT	4600 cGy	23	47	49	IMRT	1400 cGy	7	66	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Tumor localization.	None	None	1	None	None	None	None	None	None	None	None	4	MRI	Post-surgery	No	NA	No clearly definable residual enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	66	MRI	Follow up	No	NA	Resolving postoperative change, status post tumor resection. Small linear areas of enhancement related to the resection margin. This could represent postoperative findings rather than residual/recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	132	MRI	Follow up	No	NA	Decrease in an area of abnormal enhancement in the right medial, temporal, and occipital regions.	None	None	1	None	None	None	None	None	None	None	None	185	MRI	Follow up	No	NA	 I see no change in enhancement in the region of the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	244	MRI	Follow up	No	NA	Slight increase in the extent of abnormal T2-weighted signal in the white matter of the cerebral hemispheres that most likely represents treatment effect.  No change in enhancement is seen.	None	None	1	None	None	None	None	None	None	None	None	297	MRI	Follow up	No	NA	There has been no change in the study, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	353	MRI	Follow up	No	NA	Overall relatively stable appearance of T2 signal abnormality and similar or slightly decreased enhancement.	None	None	1	None	None	None	None	None	None	None	None	410	MRI	Follow up	No	NA	No change in the extent of abnormal T2-weighted signal. There is a tiny focus of enhancement along the lateral margin of the ventricular trigone, appears stable.	None	None	1	None	None	None	None	None	None	None	None	468	MRI	Follow up	No	NA	No change in enhancement.	None	None	1	None	None	None	None	None	None	None	None	531	MRI	Follow up	No	NA	No changes, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	594	MRI	Follow up	No	NA	No convincing interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	650	MRI	Follow up	No	NA	No convincing evidence for interval disease progression.	None	None	1	None	None	None	None	None	None	None	None	720	MRI	Follow up	No	NA	No definite interval progression.	None	None	1	None	None	None	None	None	None	None	None	773	MRI	Follow up	No	NA	No convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	832	MRI	Follow up	No	NA	Status post resection of right parietal tumor, as before. Resection cavity and adjacent FLAIR signal abnormality are stable in appearance since at least a year ago. No evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	909	MRI	Follow up	No	NA	No convincing evidence for interval progression since 1 year ago. Minimally changed size of the ventricles compared to 1 year and 3 months ago. Diffuse dural enhancement compatible with chronic ventricular shunting. No apparent abnormal subdural fluid collections. Stable chronic changes of right parietal craniotomy with minimal stable extra-axial collection at the craniotomy site.	None	None	1	None	None	None	None	None	None	None	None	979	MRI	Follow up	No	NA	Status post resection of right parietal glioblastoma, as before. Small foci of adjacent enhancement and surrounding FLAIR signal abnormality are stable since at least an year ago exam. No convincing evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	1042	MRI	Follow up	No	NA	No convincing evidence for interval progression since a year and a half ago. Minimally changed size of the ventricles compared to 7 month ago exam. Diffuse dural enhancement compatible with chronic ventricular shunting. No apparent abnormal subdural fluid collections.  Stable chronic changes of right parietal craniotomy with minimal stable extra-axial collection at the craniotomy site.	None	None	1	None	None	None	None	None	None	None	None	1133	MRI	Follow up	No	NA	No convincing evidence for interval progression since 2 years ago. Stable size of the ventricles compared to the prior exam. persistent diffuse dural enhancement along the right cerebral convexity may be reactive/postsurgical. Stable chronic changes of right parietal craniotomy with minimal stable extra-axial collection at the craniotomy site.	None	None	1	None	None	None	None	None	None	None	None	1224	MRI	Follow up	No	NA	Stable examination.	None	None	1	None	None	None	None	None	None	None	None	1315	MRI	Follow up	No	NA	Status post resection of right parietal glioblastoma, as before. No evidence of disease progression since at least a half a year ago exam.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	14	None	25	0	Left	difficulty with left-sided vision	Post surgery followup	None	66	90	None	1	Left	difficulty with left-sided vision	Post radiation followup	Other than fatigue, anorexia, and constipation, patient tolerated the treatments well.	132	80	None	0	Left	left vision difficulty	MRI scan	Gradually progressive neurologic symptoms. Continues to be plagued by fatigue, anorexia, occasional nausea with vomiting, some urinary urgency, and unsteadiness on his feet. Has hydrocephalus.	137	80	None	0	Left	left vision difficulty	None	Complains of fatigue, gait disturbance, urinary incontinence, and occasional nausea. Proceeded with left ventriculoperitoneal shunt placement for hydrocephalus.	185	90	None	0	Left	left vision difficulty	MRI followup	Marked decrease in size of the ventricular system after placement of the posterior left-sided shunt.	220	80	None	0	Left	left eye difficulty	None	Slight itching, nausea, and chills.	244	90	None	0	Left	left eye difficulty 	MRI followup	Once per day, patient has 1-2 min episode of moving visual phenomenon in both visual fields.	297	90	None	0	Left	left eye difficulty	MRI followup	Dark-colored rash over his right shoulder and right back, 1 brief hive.	353	80	None	0	Left	left eye difficulty	MRI followup	Restless leg syndrome (left leg) more noticeable recently.	410	90	None	0	Left	left eye difficulty	MRI followup	n/a	468	90	None	0	Left	left eye difficulty	MRI followup	n/a	531	80	None	0	Left	left eye difficulty	MRI followup	Lower abdominal pain, perhaps chronic prostatitus.	594	80	None	0	Left	left eye dfficulty	Neuro-oncology followup	Graying over of his vision especially under fluorescent lighting, perhaps ocular seizures.	773	90	None	0	None	None	None	Right parietal glioblastoma (MGMT methylated), status post gross total resection, placement of a VP shunt, and completion of chemoradiation and 12 cycles of adjuvant temozolomide, dose reduced for myelosuppression.  Clinically he is doing well on observation since a year ago and radiographically there is no evidence for recurrent disease.	832	90	None	0	None	None	None	Clinically he is doing well on observation since a year ago, and radiographically there is no evidence for recurrent disease.	909	90	None	1	Left	history of intermittent visual field impairment 	None	He states that he is doing well without significant deficit nor new or progressive symptoms. Clinically he has a stable left visual field deficit. He remains active walking 4 miles a day.  He continues on a regimen of herbal supplementation including mushrooms.  Denies headache, numbness, weakness, gait impairment.	979	90	None	0	None	None	None	He is doing well without significant deficit nor new or progressive symptoms. He has not had any recurrent seizures since restarting Keppra 1000 mg BID. His previous history of intermittent visual field impairment have decreased significantly, his last visual aura according approximately 2 weeks ago.   Clinically he has a stable left visual field deficit.	1042	90	None	0	None	None	None	He is accompanied by his wife and states that he is doing well without significant deficit nor new symptoms. His wife has noted some slowly progressive confusion and memory difficulty. Also reports persistent, moderately bothersome fatigue for which he naps frequently throughout the day.  Denies headache, numbness, weakness, gait impairment.	1133	90	None	0	None	None	None	States that he is doing well without significant deficit nor new symptoms. Also reports persistent, moderately bothersome fatigue for which he naps frequently. Clinically, he has a stable left visual field deficit. He remains active walking daily. Reports some increasing left lower extremity weakness. 	1224	90	None	0	None	None	None	He is doing well without significant deficit nor new symptoms.	1315	90	None	0	None	None	None	Clinically, he is doing well without new or progressive symptoms. He continues on Keppra 1500 mg BID with few ocular visual auras. 	1434	None	None	0	None	None	Follow-up visit	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
96	W34-1-1, SN248	W34-1-1	 SN248	http://glioblastoma.alleninstitute.org/ish/specimen/show/267057539	74	Male	90	95.7 kg	185 cm	None	No	Left,Right	One week history of expressive speech problems following aortic root angiogram.	Left Temporal	Complete resection	Yes	Yes	Glioblastoma, WHO grade IV	Negative	gain	deletion	unmethylated	50%	0.29	0.05	0.03	wildtype	not detected	Primary	No	Yes	Yes	Yes	14	1	74	170	NA	351	Deceased due to tumor progression	1	0	0	0	5	0	0	5	1	0	3	0	0	0	0	0	0	0	1	No	No	No	No	No	antihypertensive	-5	50 mg daily oral	losartan (COZAAR)	6	multi-vitamin	-5	1 cap daily		91	Steroids	-5	4mg/mL intravenuos 4 times a day	dexamethasone	5	Anti-epileptic	-5	500 mg x 2caps twice a day oral	KEPPRA	249	Steroids	5	4mg 3 times a day, 3mg 3 times a day, 3mg twice a day, 2mg twice a day, 1mg twice a day, 1 mg daily oral	dexamethasone	19	antihypertensive	6	25 mg twice a day for 7 days then 50 mg twice a day oral	metoprolol (LOPRESSOR)	80	Steroids	90	2 mg oral twice a day	dexamethasone	92	Steroids	149	10 mg twice a day oral	prednisone	193	Steroids	193	4 mg twice a day till 0.5 daily oral	dexamethasone	241	antihypertensive	257	2.5 mg daily oral	amlodipine (NORVASC)	302	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	29	150 mg	concurrent	74	Temozolomide	99	300 mg	maintenance 5x/mo.	113	Temozolomide	113	360 mg	maintenance 5x/mo.	208	Temozolomide	208	140 mg	concurrent w/ cyberknife, QD	222	Avastin	212	1000 mg	maintenance 1x/14 days		Temozolomide	232	280 mg	maintenance 5x/28 days		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	29	IMRT	6000 cGy		74	208	Stereotactic	2400 cGy	3	212	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Irregularly enhancing, necrotic mass centered in anterior left temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	A tiny linear focus of abnormal contrast enhancement along the posterior margin of the resection cavity could represent a small amount of residual enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	170	MRI	Follow up	Yes	NA	Progressively increasing abnormal enhancement at the posterior superior left temporal resection margin with enlarging nodular enhancement in the anterior left temporal lobe. Perfusion metrics suggestive of recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	194	MRI	Follow up	Yes	NA	Significant increase in size of enhancing tumor in the left temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	246	MRI	Follow up	No	NA	Interval decrease in extent of enhancement at the left mesial temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	303	MRI	Follow up	Possible	NA	Findings concerning for interval disease progression. Abnormal T2 signal with relatively positive mass effect.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	9	90	None	0	None	expressive aphasia	Post surgery followup	Expressive aphasia improvng.	11	90	None	0	None	expressive aphasia	Chemoradiation planning	n/a	57	90	None	0	None	expressive aphasia	Chemoradiation followup	Speech has being gradually improving.	72	80	None	0	None	expressive aphasia	ER visit	ER hospitalization for about a week due to imbalance, hypotension, development of pneumonia, and overall failure to thrive; intitiated dexamethasone taper.	85	90	None	0	None	expressive aphasia	Radiation followup	Speech gradually improving.	90	80	None	0	None	expressive apasia	Hospital visit 	Admitted to hospital with progressive weakness and dizziness, intermittent loss of hearing in left ear.	99	80	None	0	None	expressive aphasia	Radiation followup	n/a	113	90	None	0	None	expressive aphasia	None	Patient doing well, increasing TMZ dosage to 360 mg.	149	90	None	0	None	expressive aphasia	Maintenance TMZ followup	n/a	185	80	None	0	None	expressive aphasia	None	Worsening of tumor, worsening weakness. 	218	70	None	0	None	expressive aphasia	Post Cyberknife followup	Feels weak.	246	70	None	0	None	expressive aphasia	MRI scan followup	Trouble with memory and communication.	303	60	None	0	None	expressive aphasia	MRI followup	n/a	323	50	None	1	Left	expressive apashia, left sided weakness	None	Rapidly worsening neurological symptoms with worsening weakness on the left side.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
97	W35-1-1, SN249	W35-1-1	 SN249	http://glioblastoma.alleninstitute.org/ish/specimen/show/292828452	37	Female	100	59.3 kg	169 cm	None	Yes	No	Seizure	Right Parietal	Complete resection	Yes	Yes	Anaplastic astrocytoma WHO grade III/IV 	Negative	gain	gain	methylated	0%	0.85	0.23	0.78	R132H	not detected	Primary	No	Yes	Yes	Yes	24	7	37	NA	1420	NA	NA	5	2	0	0	2	0	0	3	0	0	0	0	1	0	0	0	0	0	1	No	No	No	No	No	Anti-epileptic	0	300 mg 3 times a day, then 300 mg once a day oral	phenytoin	9	Steroids	7	4mg/1mL injection 4mg 4 times a day	dexamethasone	9	Steroids	9	from 3 mg 3 times a day to 1mg daily oral	dexamethasone	16	Anti-epileptic	9	1000 mg twice a day oral	KEPPRA	173	multi-vitamin	37	1 cap daily		386	cardiotonic	104	250 mg daily oral	disulfiram (ANTABUSE)	831	Anti-epileptic	247	500 mg twice a day oral	KEPPRA XR	897	Anti-epileptic	897	Week 1 and 2: 25 mg BID; Week 3 and 4:50 mg BID Week 5 and On: 100 mg BID	lamOTRIGINE (LAMICTAL)	956	Anti-epileptic	956	100 mg twice a day oral	Lamotrigine	1196	Anti-depressant	1042	0.25 mg daily oral as needed	alprazolam	1160	Anti-depressant	1196	0.25 mg daily oral as needed	alprazolam	1308	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	33	120 mg	concurrent	79	Temozolomide	89	330 mg	maintenance 5x/mo.	302	Temozolomide	302	250 mg	maintenance 5x/mo.	440	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	33	IMRT	4500 cGy	25	69	71	IMRT	1440 cGy	8	79	None	None	None	None	None	None	None	None	None	None	2	MRI	Pre-surgery	No	NA	Large heterogeneous enhancing mass involving the right parietal lobe. The appearance is suspicious for a high-grade glioma.	None	None	1	None	None	None	None	None	None	None	None	7	MRI	Post-surgery	No	NA	Most if not all of the previously demonstrated lesion has been resected.	None	None	1	None	None	None	None	None	None	None	None	89	MRI	Follow up	No	NA	The enhancement along the deep margin of the cavity also looks like it is postoperative in nature.	None	None	1	None	None	None	None	None	None	None	None	145	MRI	Follow up	No	NA	There is no evidence for progressive disease.	None	None	1	None	None	None	None	None	None	None	None	208	MRI	Follow up	No	NA	Evolving postoperative findings, no convincing evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	260	MRI	Follow up	No	NA	No change compared to prior studies.  This is consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	327	MRI	Follow up	No	NA	No convincing evidence for interval disease progression. No new enhancement demonstrated.	None	None	1	None	None	None	None	None	None	None	None	386	MRI	Follow up	No	NA	No change compared to prior studies, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	440	MRI	Follow up	No	NA	No changes, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	484	MRI	Follow up	No	NA	No changes, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	544	MRI	Follow up	No	NA	No interval progression, no new enhancement.	None	None	1	None	None	None	None	None	None	None	None	600	MRI	Follow up	No	NA	No convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	671	MRI	Follow up	No	NA	No convincing interval progression since last MRI. 	None	None	1	None	None	None	None	None	None	None	None	740	MRI	Follow up	No	NA	Stable findings since the prior exam. No evidence of tumor progression.	None	None	1	None	None	None	None	None	None	None	None	796	MRI	Follow up	No	NA	Stable postoperative findings without evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	853	MRI	Follow up	No	NA	Stable examination.	None	None	1	None	None	None	None	None	None	None	None	930	MRI	Follow up	No	NA	Status post resection of right parietal anaplastic astrocytoma, as before. There is no abnormal enhancement adjacent to the resection cavity and modest, surrounding FLAIR signal abnormality is stable in extent since at least the half a year ago exam. No evidence of disease progression. Hippocampi are symmetric and demonstrate normal volume, contour, and signal. No evidence of mesial temporal sclerosis.	None	None	1	None	None	None	None	None	None	None	None	1000	MRI	Follow up	No	NA	Status post resection of right parietal anaplastic astrocytoma, as before. No abnormal enhancement. Surrounding FLAIR signal abnormality is stable since 9 months ago exam. No evidence of disease progression, but there is elevated cerebral blood volume within this tissue, concerning for residual, infiltrative disease.	None	None	1	None	None	None	None	None	None	None	None	1063	MRI	Follow up	No	NA	Status post resection of right parietal occipital glioblastoma, as before. There is no abnormal enhancement along the resection cavity and adjacent FLAIR signal abnormality is stable since at least at the last 2 prior exams. No evidence of disease progression.	None	None	1	None	None	None	None	None	None	None	None	1126	MRI	Follow up	No	NA	Stable examination.	None	None	1	None	None	None	None	None	None	None	None	1196	MRI	Follow up	No	NA	Stable examination.	None	None	1	None	None	None	None	None	None	None	None	1266	MRI	Follow up	No	NA	Stable examination.	None	None	1	None	None	None	None	None	None	None	None	1329	MRI	Follow up	No	NA	Stable right parietal abnormality.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	16	90	None	0	Left	None	Radiation planning	Transient decrease in vision to the left side.	47	90	None	0	Left	poor left eye vision	Neuropathology review	n/a	89	90	None	0	None	poor left eye vision	post radiation followup	mild fatigue	145	90	None	0	None	poor left eye vision	MRI followup	Mild fatigue.	208	100	None	0	Left	poor left eye vision	MRI followup	n/a	236	100	None	0	None	poor left eye vision	TMZ followup	n/a	260	90	None	0	Left	poor left eye vision	MRI followup	n/a	302	90	None	0	None	None	TMZ followup	Lowering of TMZ dose.	327	100	None	0	Left	poor left eye vision	MRI followup	Patient doing better on the slightly reduced TMZ dose of 150 mg/m2.	386	100	None	0	Left	poor left eye vision	MRI followup	n/a	440	80	None	1	Left	poor left eye vision	MRI followup	Missed 2 days of keppra, subsequently had 2 seizures, involving staring off into space, irregular respiratory sounds, and oral movements. Returned to baseline after 2g keppra was given at local ER.	484	90	None	1	Left	poor left eye vision	MRI followup	Seizure.	600	90	None	0	None	None	None	None	740	100	None	0	None	None	None	Patient has done well without neurologic deficit nor recurrent seizures.	796	90	None	0	None	None	None	The MRI scan performed today shows no significant change in terms of the T2 signal and flair abnormality in the right periventricular region. I did not appreciate any new enhancement. This was corroborated by the radiology report. She has no new signs or symptoms of clinical progression.	853	90	None	0	None	None	None	I do not see any new areas of enhancement although the images may show some slight increase in flair.	930	100	None	0	None	None	None	Neurologically she has had no worsening, and she has no increased seizure activity.	1000	100	None	0	None	None	None	She is doing very well. I see no evidence of tumor recurrence on the new scan performed today. She has changed her anticonvulsant medication and this seems to be helping her much more. We will continue to follow her carefully and have her come back in another 2 months.	1063	90	None	0	None	None	None	She returns to the office again today. She was last here 2 months ago. She has another MRI scan of the brain. I compared her current scan from today to the previous one. I do not see any significant change, specifically any evidence of new T2 signal change or enhancement. She continues to take Valcyte and disulfiram. She denies any new signs or symptoms of tumor progression. Overall, she is doing quite well at this point and I will recommend that she continue her current treatment plan.	1126	90	None	0	None	None	None	Returns to the office today for another postoperative visit. I reviewed her MRI and I see no evidence of tumor recurrence at this 2 month interval. We discussed the fact that she continues to take Valcyte and disulfiram and she would like to take mebendazole as well. Otherwise she is doing great neurologically other than her persistent field cut. 	1196	90	None	0	None	None	None	Follow up visit in 2 months with a new MRI scan prior. 	1266	90	None	0	None	None	None	Returns to the office for a MRI visit. Her last scan was in September and this repeat scan shows no significant change according to my evaluation. She has no new complaints. Otherwise she seems to be doing well.	1329	90	None	0	None	None	None	Clinically she is doing well without seizures or neurologic deficit, aside from mild cognitive difficulty. She has no longer been working due to inability to keep up with her work. She continues on Lamictal for seizures, her last 3 years ago without recurrent event. She has continued on Valcyte and disulfiram.	1420	None	None	0	None	None	Follow-up visit	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
98	W36-1-1, SN250	W36-1-1	 SN250	http://glioblastoma.alleninstitute.org/ish/specimen/show/267058141	62	Male	80	88.5 kg	178 cm	26	No	Right	Blurry vision in in his right eye	Left Parietal	Subtotal resection 90%	Yes	Yes	Glioblastoma, WHO grade IV	Negative	gain	gain	unmethylated	70%	0.33	0.04	0.03	wildtype	not detected	Primary	No	Yes	Yes	Yes	13	3	62	241	NA	544	Deceased due to tumor progression	2	1	0	0	1	0	0	2	2	0	2	1	1	1	0	1	0	0	1	No	No	No	No	No	Cholesterol lowering	0	10mg QD	Atorvastatin		Steroids	0	4mg QID taper to 1mg QD	Dexamethasone	30	antihypertensive	0	50mg QD	metoprolol XL (TOPROL XL)	31	Anti-depressant	0	50mg QD	Sertraline	32	Anti-epileptic	0	10 mg daily oral	rosuvastatin (CRESTOR)	3	Anti-epileptic	3	1000mg twice a day oral	KEPPRA	460	multi-vitamin	31	1 cap daily oral	ONE-A-DAY	32	antihypertensive	31	2.5 mg injection	verapamil (ISOPTIN)		cardiotonic	32	75mg QD	Clopidogrel		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	24	140mg QD	concurrent	71	Temozolomide	92	140-280 mg	maintenance x4/28 days	485	Avastin	253	10mg/kg    (735mg)	x1 / 14 days	395	Avastin	396	10 mg/kg	x1 / 21 days	542	Lomustine	396	210 mg	x1 / 42 days	435	Etoposide	435	1600 mg	21x/  28 days	462	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	24	IMRT	46 Gy	23	57	58	IMRT	14 Gy	7	71	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	There is a 4 cm ring-enhancing lesion in the posterior aspect of the left temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	3	MRI	Post-surgery	No	NA	There appears to be a small amount of residual, enhancing capsule along the posterior and anteromesial margins of the resection. However, the majority of the lesion has been resected.	None	None	1	None	None	None	None	None	None	None	None	241	MRI	Follow up	Yes	NA	There has been clear interval increase in size of the abnormal contrast enhancing tissue around the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	276	MRI	Follow up	No	NA	Substantial interval decrease in extent of enhancement and edema at the site of surgery. Findings consistent with residual tumor.	None	None	1	None	None	None	None	None	None	None	None	339	MRI	Follow up	No	NA	No change in the enhancing nature of the lesion.	None	None	1	None	None	None	None	None	None	None	None	395	MRI	Follow up	Yes	NA	Moderate worsening in size of the minimally enhancing left temporal lobe lesion, consistent with tumor growth.	None	None	1	None	None	None	None	None	None	None	None	435	MRI	Follow up	Yes	NA	Clear progression of tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	14	90	None	0	None	None	Radiation planning	Chronic back pain, difficulty in cognitive retention and reading words.	87	90	None	0	None	None	Chemotherapy planning	Poor cognitive function.	112	80	None	0	Left	None	None	Difficulties with word finding skills, left eye fatigue.	155	90	None	0	None	expressive dysphasia 	None	None	178	90	None	0	None	expressive dysphasia,	None	Lower back pain.	220	None	26	0	None	None	MRI review	Constipation after TMZ cycle causes near debilitating low back pain.	241	80	None	0	None	None	MRI scan	Progressive disease.	248	80	None	1	None	None	None	Surgeon decided not to subject the patient to repeat craniotomy, started on Avastin instead.	276	80	None	0	None	None	None	Scan shows marked interval reduction in abnormal enhancement around his tumor.	339	80	None	0	None	None	None	No change in the enhancing nature of the lesion.	366	80	None	0	None	None	None	Cognitive function has slowed slightly; progressive disease.	435	80	None	0	None	None	None	Further clear increase in tumor size.	462	70	None	0	None	None	None	Clinical deterioration, GI toxicity from the VP-16.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
100	W38-1-1, SN254	W38-1-1	 SN254	http://glioblastoma.alleninstitute.org/ish/specimen/show/712644	65	Female	70	63.5 kg 	170.2 cm 	26	Yes	Left	Left visual field hallucinations, difficulty with mental processing and with completing tasks, headaches, trouble with gait.	Right Temporal	Subtotal resection 90%	Yes	Yes	Glioblastoma, WHO grade IV/IV	Negative	gain	Normal	methylated	negative	0.82	0.79	0.79	wildtype	not detected	Primary	No	Yes	No	Yes	10	5	65	236	NA	311	Deceased due to tumor progression	5	2	0	0	6	0	0	4	1	0	0	1	0	0	0	0	0	0	0	No	No	Yes	No	No	Anti-epileptic	-1		phenytoin		Anti-epileptic	-1	750 mg oral twice a day	KEPPRA	1	Cholesterol lowering	-1	10 mg oral daily	Simvastatin	35	Anti-depressant	0	10 mg oral daily	citalopram (CELEXA)	28	Steroids	1	4mg/1mL injection 4mg 4 times a day	dexamethasone	5	Anti-epileptic	1	 750 mg in NS (0.9% NaCl) IV solution 100 mL  	KEPPRA	12	Steroids	5	4mg/1mL injection 10mg 4 times 	dexamethasone	7	Steroids	7	4mg/1mL injection 6mg 4 times	dexamethasone	9	Steroids	9	4mg/1mL injection 4mg 4 times a day	dexamethasone	11	Steroids	12	4mg/1mL injection 2mg 4 times a day	dexamethasone	20	Anti-epileptic	12	750 mg oral twice a day	KEPPRA	28	Anti-epileptic	28	0.5 mg daily oral	clonazepam (KLONOPIN)	63	Anti-depressant	29	30 mg oral daily	citalopram (CELEXA)	35	Steroids	208	4mg by mouth twice on the day of treatment. Then taper to 2mg two times a day for one day, then 1mg two times a day for one day then 1 mg 	dexamethasone	251	None	None	None	None	None	None	None	None	None	None	Temozolomide	48	120 mg	concurrent	80	Temozolomide	144	 270 mg	maintenance 5 day cycle	175	Temozolomide	175	350 mg	maintenance 5 day cycle	267	Avastin	260	None	maintenance	267	Temozolomide	267	75 mg	maintenance 7 day cycle	273	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	48	IMRT	4600 cGy	23 	72	73	IMRT	1400 cGy	7	80	208	Stereotactic	7500 cGy	5	212	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Aggressive appearing right temporal lobe mass with irregular peripheral enhancement most marked along the deep margin, measuring 6 x 5.6 cm axial x 5.6 cm vertical.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Postoperative resection of the large right temporal mass with reduced mass effect on the right lateral ventricle.	None	None	1	None	None	None	None	None	None	None	None	5	MRI	Follow up	No	NA	Interval worsening of mass effect with increased shift of midline structures to the left.	None	None	1	None	None	None	None	None	None	None	None	8	MRI	Follow up	No	NA	Decreased mass effect and midline shift.	None	None	1	None	None	None	None	None	None	None	None	72	MRI	Follow up	No	NA	There has been significant resolution of the abundant postoperative changes seen the prior scan.	None	None	1	None	None	None	None	None	None	None	None	103	MRI	Follow up	No	NA	There has been significant resolution of the abundant postoperative changes seen more than 3 months ago.	None	None	1	None	None	None	None	None	None	None	None	174	MRI	Follow up	No	NA	The new MRI scan of the brain shows a new 7 mm focus of abnormal enhancement in the region of posterior limb of the right internal capsule. Other imaging findings are stable.	None	None	1	None	None	None	None	None	None	None	None	236	MRI	Follow up	Yes	NA	Overall findings concerning for progressive disease, with increasing enhancement.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	14	80	None	0	Left,Right	left hemiparesis 	Comprehensive rehabilitation followup	Left hemiparesis and left neglect, ptosis on the right, facial movement decreased on the right.	103	70	26	0	Left	left hemiparesis	MRI followup	left hemiparesis	111	None	28	0	Left	left sided weakness	None	DC Vax protocol, 1st injection.	142	80	None	0	Left	left sided weakness	None	3rd DC Vax injection.	174	70	None	0	Left,Right	left weakness, right ptosis	MRI followup	New imaging findings are concerning for progressive disease.	175	70	None	0	None	left sided weakness	None	4th DC Vax injection.	236	60	None	0	Left	decline of left motor function	None	Early progression of disease while on the DCVax protocol, decline of left motor function.	252	70	None	0	Left	left weakness	None	5th DC Vax injection. 	253	60	None	0	Left	left sided weakness	None	Suffering further deterioration of function on her left side.	267	50	None	0	Left	left sided weakness	None	Tumors continues to worsen despite Avastin treatment.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
102	W40-1-1, SN263	W40-1-1	 SN263	http://glioblastoma.alleninstitute.org/ish/specimen/show/268000554	65	Male	100	110.7 kg	172.7 cm 	31	No	No	History of increasing confusion, difficulty with numbers/letters, telling time, and difficulty reading.	Left Parietal	Complete resection	Yes	Yes	Glioblastoma	Negative	gain	loss	unmethylated	40%	0.53	0.10	0.00	wildtype	not detected	Primary	No	Yes	No	Yes	1	3	65	NA	NA	184	Deceased due to tumor progression	2	0	0	0	2	0	0	1	0	0	3	0	1	0	0	0	0	0	0	No	No	No	No	No	Steroids	0	4 mg 4 times a day oral	dexamethasone	3	Anti-epileptic	0	1000 mg twice a day oral	KEPPRA	3	cardiotonic	0	5 mg daily oral	warfarin	10	antihypertensive	0	120 mg daily oral	diltiazem	4	Steroids	3	4mg/1mL injection 4mg 4 times a day, 3 times a day	dexamethasone	9	Anti-epileptic	3	1000 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	9	antihypertensive	4	30 mg 4 times a day oral	diltiazem	5	antihypertensive	5	120 mg QPM oral	diltiazem	9	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	38	None	daily oral during radiation	81	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	38	IMRT	4600 cGy		70	73	IMRT	1400 cGy		81	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Dimensions have increased from 30 x 31 mm to 33 x 34 mm and maximal cephalocaudal dimension has increased from 44 mm to 50 mm. 	None	None	1	None	None	None	None	None	None	None	None	3	MRI	Post-surgery	No	NA	No evidence of residual tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	82	30	None	0	None	None	hospice care	They have decided to hold all the medical treatments and go with hospice care.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
118	SN257, W39-1-1	 W39-1-1	SN257	http://glioblastoma.alleninstitute.org/ish/specimen/show/308929980	68	Female	60	68.4 kg	152.4 cm	31	No	Left	Left-sided weakness.	Right Frontal	Subtotal resection 90% (95+% resection, )	Yes	Yes	Glioblastoma	Negative	amplification	loss	methylated	25%	0.24	0.00	0.57	wildtype	NA	Primary	No	Yes	No	Yes	16	8	68	97	NA	880	Deceased due to tumor progression	6	0	0	0	2	0	0	4	1	0	1	3	0	0	0	0	0	0	1	No	No	No	No	No	Anti-epileptic	0	750 mg twice a day oral	KEPPRA	207	Cholesterol lowering	0	80 mg at bedtime oral	Simvastatin	13	Steroids	1	4mg/1mL injection 4mg 4 times a day	dexamethasone	3	antihypertensive	3	20 mg daily oral	lisinopril	129	Steroids	3	4 mg 4 times a day, 2 mg 4 times a day till 1 mg daily oral	dexamethasone	59	Cholesterol lowering	13	40 mg at bedtime oral	Simvastatin	181	multi-vitamin	125	5 ml daily oral	THERA MULTI-VITAMIN	145	Anti-epileptic	207	100mg/mL 750 mg oral solution	KEPPRA	712	Cholesterol lowering	300	40 mg at bedtime oral	Simvastatin	403	Anti-epileptic	712	750 mg twice a day oral	KEPPRA	739	Anti-epileptic	739	1000-750 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	745	Anti-epileptic	745	1500 mg twice a day oral	KEPPRA	839	Anti-epileptic	839	1500 mg in AM and 2000 mg in PM oral	KEPPRA	869	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	27	120 mg	concurrent	68	Temozolomide	115	240 mg	maintenance 5 day cycle	129	Temozolomide	181	220 mg	maintenance 5 day cycle	300	Temozolomide	300	210 mg	maintenance 5 day cycle	363	Avastin	721	525 mg in NS(0.9% NaCl) IV solution 100 mg	intravenuos every 2 weeks	833	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	27	IMRT	4600 cGy	23	53	55	IMRT	1400 cGy	7	68	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Approximately 7.1 x 4.9 x 5.6 cm ring-enhancing mass.	None	None	1	None	None	None	None	None	None	None	None	8	MRI	Post-surgery	No	NA	95 to 99% resection, with areas of residual at the mesial, anterior and posterior margins.	None	None	1	None	None	None	None	None	None	None	None	97	MRI	Follow up	Yes	NA	New area of abnormal contrast enhancement along the anterior aspect of the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	129	MRI	Follow up	No	NA	Stable focus of abnormal contrast enhancement along the anterior aspect of the resection cavity in the right frontal lobe.  This is consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	244	MRI	Follow up	No	NA	Slight interval increase in area of enhancement, concerning for recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	300	MRI	Follow up	No	NA	Findings consistent with response to therapy. Extent of enhancement has been gradually decreasing over time.	None	None	1	None	None	None	None	None	None	None	None	363	MRI	Follow up	No	NA	No changes, consistent with stable disease.	None	None	1	None	None	None	None	None	None	None	None	437	MRI	Follow up	No	NA	Stable enhancement, no definite interval progression of enhancing tumor.	None	None	1	None	None	None	None	None	None	None	None	507	MRI	Follow up	No	NA	MRI of brain appears stable.	None	None	1	None	None	None	None	None	None	None	None	570	MRI	Follow up	No	NA	No apparent interval progression since last MRI. No new areas of enhancement.	None	None	1	None	None	None	None	None	None	None	None	640	MRI	Follow up	Yes	NA	Findings are worrisome for early tumor progression.	None	None	1	None	None	None	None	None	None	None	None	710	MRI	Follow up	Yes	NA	Interval increase in extent of enhancement, consistent with disease progression.	None	None	1	None	None	None	None	None	None	None	None	783	MRI	Follow up	No	NA	No convincing evidence of disease progression. There is stable T2 hyperintensity within the bilateral frontal white lobes stable since 3 months ago. Since 4 months ago, there is decreased enhancement along the posterior and anterior margins of the resection cavity. Visually, these areas appear larger but measurements do not support this finding.	None	None	1	None	None	None	None	None	None	None	None	839	MRI	Follow up	Yes	NA	Status post resection of glioblastoma in the right frontal lobe, as before. There is increased extent of enhancement and FLAIR signal abnormality since 2 months ago exam, concerning for progression of disease. FLAIR signal abnormality with restricted diffusion is again demonstrated in the splenium and left forceps major with a new focus of restricted diffusion in the anterior genu of the corpus callosum, also consistent with progression of disease.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	17	90	None	0	Left	left sided weakness	Radiation planning	Left sided weakness continues, but somewhat improved.	97	90	None	0	Left	left sided weakness	Radiation completion	Area of abnormal contrast enhancement in MRI scan.	129	80	None	0	Left	left sided weakness	MRI followup	Pneumonia, fairly significant mucositis. Delay Temodar for one month. Stable focus of abnormal contrast consistent with pseudo-progression. 	167	80	None	0	Left	left sided weakness	None	Cough worsened, developed bronchitis.  Temodar cycle 2 delayed.	181	80	None	0	Left	left sided weakness	None	Significant improvement in coughing. Restart Temodar.	244	70	None	1	Left	left sided weakness	MRI followup	Seizure 2 months ago, another episode of shingles, upper left extremity affected.	300	70	None	1	Left	left sided weakness	MRI followup	Some left handed swelling, mild abulia. 	363	70	None	0	Left	left sided weakness	None	Marked restriction on left shoulder movement, pruritic rash develops after each dosage of temodar. 	403	80	None	1	Left	left sided weakness	Routine followup	Slight improvement of rash, although temodar will be discontinued. 	437	80	None	0	None	None	None	Patient is doing reasonably well from a clinical standpoint and the MRI scan shows stable disease.	507	70	None	0	Left	left sided weakness	None	Marked decline in motory status, more confusion.	570	60	None	0	None	None	None	Has returned to baseline since treating her UTI. Repeat UA pending today, but preliminarily appears okay.	640	60	None	0	None	None	None	Stable neurological status; and if anything she is getting better. While there is a suggestion of progression on the most recent scan, this is subtle.	710	50	None	0	None	None	None	Her functional status is impaired and her mobility over the past year seems to have been in a decline.	783	50	None	0	None	None	None	Clinically, she has remained stable, with baseline limited mobility. She has not had any further seizures since her Keppra was increased to 1500 mg BID. Denies any new or progressive neurologic symptoms.	839	50	None	1	None	None	None	Clinically, she has been declining with respect to her mobility, cognition and ability to care for herself.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
133	W42-1-1, SN285	W42-1-1	 SN285	http://glioblastoma.alleninstitute.org/ish/specimen/show/272887632	60	Female	70	89.994 kg	172.45 cm	None	No	No	One-month history of fainting spells, visual distortions, and tremor in right upper extremity.	Right Frontal, Right Temporal	Complete resection (concerning for a small amount of residual tumor)	Yes	Yes	Glioblastoma	NA	NA	NA	NA	NA	0.36	0.24	0.47	wildtype	detected	Primary	No	Yes	No	No	5	1	60	NA	NA	197	Deceased due to tumor progression	2	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	No	No	No	No	No	Steroids	-4	4mg/mL intravenuos 4 mg 4 tiimes a day	dexamethasone	-3	Anti-epileptic	-4	1000 mg in NS(0.9% NaCl) IV solution 100 mL twice a day	KEPPRA	-3	Steroids	-3	4 mg twice a day oral	dexamethasone	6	Anti-epileptic	-3	1000 mg twice a day oral	KEPPRA	7	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	34	150 mg	concurrent	83	Temozolomide	111	100 mg	maintenance 5 day cycles		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	34				83	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Heterogeneous mass located within the right anterior temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	 There is evidence of near-total, right temporal lobectomy. There is a fair quantity of T1 hyperintense material in the resection cavity, likely representing hemorrhage and/or surgical packing material.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	8	90	None	0	None	None	Suture removal	None	30	80	None	1	Right	right arm tremor	Radiation planning	Seizures, trembling of the hand and arms (right), headaches, dizziness, fainting, numbness, tingling, trouble with balance.	44	80	None	1	Right	right arm tremor	Radiation evaluation	None	107	70	None	0	Right	right arm tremor	Post radiation	Fatigue, right leg edema, right arm tremor.	121	60	None	1	Right	right arm tremor	TMZ evaluation	Fatigue, edema in right leg, headache, backache, nausea, vomiting. Symptons concerning for progressive disease.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
134	W43-1-1, SN286	W43-1-1	 SN286	http://glioblastoma.alleninstitute.org/ish/specimen/show/267499992	62	Female	90	76.749 kg	163.56 cm	28	No	Left,Right	Two-week history of headaches, cognitive and speech difficulty, nausea, vomiting, falls associated with dizziness.	Right Temporal	Complete resection (no abnormal enhancement demonstrated to suggest residual tumor)	Yes	Yes	Glioblastoma	NA	NA	NA	NA	NA	0.51	0.06	0.01	wildtype	NA	Primary	No	Yes	No	Yes	8	1	62	133	NA	300	Deceased due to tumor progression	3	0	0	0	3	0	0	3	1	0	0	0	0	0	0	0	0	0	1	No	No	No	No	No	multi-vitamin	0	1 cap daily oral	ONE-A-DAY	4	Steroids	0	6 mg 4 times a day, 4 mg 4 times a day, 3 mg 4 times a day till 1 mg daily oral	dexamethasone	39	Anti-epileptic	0	1000 mg twice a day oral	KEPPRA	1	Anti-epileptic	1	1000 mg in NS(0.9% NaCl) IV solution 100 mg twice a day	KEPPRA	3	Anti-epileptic	3	1000 mg twice a day oral	KEPPRA	221	Steroids	183	4 mg once oral	dexamethasone		Steroids	244	1 mg twice a day oral	dexamethasone	263	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	18	140 mg	concurrent	71	Temozolomide	84	280mg	maintenance 5 day cycle	183	Temozolomide	183	140 mg	maintenance 21 day cycle	239	Avastin	221	None	intravenuos every 2 weeks	256	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	18		6300 cGy		71	236	Stereotactic	2400 cGy	3	239	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Two masses are identified in the lateral aspect of the right temporal lobe.	None	None	1	None	None	None	None	None	None	None	None	1	MRI	Post-surgery	No	NA	Enhancing lesions appear to have been completely resected. No abnormal enhancement demonstrated to suggest residual tumor.	None	None	1	None	None	None	None	None	None	None	None	84	MRI	Follow up	No	NA	There is some linear enhancement along the margin of the resection cavity, but no evidence of nodular recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	133	MRI	Follow up	Possible	NA	Slight increase in abnormal contrast enhancement along the surgical margin.	None	None	1	None	None	None	None	None	None	None	None	183	MRI	Follow up	Yes	NA	Further increase in abnormal contrast enhancement around the resection margin.	None	None	1	None	None	None	None	None	None	None	None	221	MRI	Follow up	No	NA	Decreased enhancement edema and mass effect compared to previous scan, suggestive of partial response.	None	None	1	None	None	None	None	None	None	None	None	263	MRI	Follow up	Possible	NA	Overall enhancing lesion size is slightly increased, differential consideration includes progressive disease.	None	None	1	None	None	None	None	None	None	None	None	272	MRI	Follow up	Possible	NA	Enhancement along the margins of the resection bed of uncertain significance, either representing postoperative changes or residual/recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	11	None	None	0	None	None	Suture removal	None	11	None	28	0	None	None	Radiation planning	None	39	90	None	0	None	None	Mid radiation visit	None	84	90	None	0	None	None	Post radiation visit	None	133	80	None	0	None	None	MRI followup	Signs of tumor progression.	183	80	None	0	None	None	None	Increasing symptoms that reflect the worsening contrast enhancement. Switching from 5 day to 21 day Temodar regimen. Starting Avastin. 	221	90	None	1	None	None	2 month followup	Drastic improvement of enhancement.	263	70	None	0	None	None	2 month followup	Headaches, poor balance, numb feet, and drowsiness. Stopped Temodar after Cyberknife.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
153	SN309, W48-1-1	 W48-1-1	SN309	http://glioblastoma.alleninstitute.org/ish/specimen/show/267552611	52	Male	80	87.8 kg	177.8 cm	26	No	No	History of headaches, nausea.	Right Parietal	Complete resection (Apparent gross total resection, no residual tumor)	Yes	Yes	Glioblastoma	NA	NA	NA	NA	NA	0.26	0.09	0.05	R132G	not detected	Primary	No	Yes	No	Yes	11	1	52	92	NA	456	Deceased due to tumor progression	5	0	0	0	8	0	0	4	1	0	1	0	0	2	0	0	0	0	0	No	No	Yes	No	No	Steroids	-4	4mg/1mL injection 4mg 4 times a day	dexamethasone	-2	Anti-epileptic	-4	750 mg in NS(0.9% NaCl) IV solution 100 mL twice a day	KEPPRA	-3	Anti-epileptic	-3	1000 mg twice a day oral	KEPPRA	22	Steroids	-2	4 mg oral  4-3  times a day oral	dexamethasone	4	Steroids	5	1 mg 4 times a day oral	dexamethasone	9	Steroids	9	2-1 mg 3-2-1  times a day oral	dexamethasone	17	Anti-epileptic	22	1000 mg twice a day oral	KEPPRA XR	107	Steroids	233	2 mg 3 times a day oral	dexamethasone	234	Anti-epileptic	233	1000 mg twice a day oral	KEPPRA	246	Steroids	234	4mg/1mL injection 2-4mg 3-4 times a day	dexamethasone	237	Steroids	237	from 4 mg 3 times a day till 1 mg daily oral	dexamethasone	246	Steroids	427	8mg twice a day oral	dexamethasone	471	antihypertensive	440	20 mg daily oral	lisinopril	470	Anti-epileptic	441	500 mg twice a day oral	KEPPRA	471	None	None	None	None	None	None	None	None	None	None	Temozolomide	35	145 mg	concurrent	77	Temozolomide	128	290 mg	daily oral	133	Temozolomide	162	400 mg	daily oral	236	Temozolomide	266	195 mg	daily oral	281	Avastin	282	753 mg in NS(0.9% NaCl) IV solution 100 mL 	every 2 weeks	442	Etoposide	372	50 mg	daily oral	394	Etoposide	411	100 mg	daily oral	432	None	None	None	None	None	None	None	None	None	None	35	IMRT	6000 cGy	30	77	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Apparent  gross  total  resection  status  post  right  parietal  tumor resection.  No  residual  enhancing  tumor.  Expected  postoperative changes,  without  evidence  for  significant  intracranial  hemorrhage. Mild  cytotoxic  edema  in  the  medial  and  posterior  margin  of  the right  parietal  resection  cavity.	None	None	1	None	None	None	None	None	None	None	None	92	MRI	Follow up	Possible	NA	None	None	None	1	None	None	None	None	None	None	None	None	162	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	225	MRI	Pre-surgery	Yes	NA	New  nodular  enhancement  along  the  anterior  inferior  and  anterior superior  margin  of  the  right  temporal  resection  cavity,  worrisome  for disease  progression.  Differential  consideration  include pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	234	MRI	Post-surgery	No	NA	There  are  surgical  changes  of  a  right  temporal  craniotomy  and  right parietal  craniotomy.  There  is  a  collection  within  the  right  temporal and  right  parietal  extra-axial  space  measuring  up  to  10  mm  in greatest  thickness,  consistent  with  a  postoperative  hematoma.  There is  a  small  amount  of  gas  density  along  the  right  frontal  extra-axial convexity.  There  is  a  small  focus  of  susceptibility  in  the interhemispheric  fissure,  consistent  with  blood  products. The  diffusion-weighted  images  demonstrate  diffusion  restriction  along the  margins  of the  resection  bed,  consistent  with  small  areas  of cerebral  infarction,  which  is  expected  in  the  recent  postoperative state.  No  additional  areas  of  diffusion  restriction  are  demonstrated.	None	None	1	None	None	None	None	None	None	None	None	281	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	316	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	372	MRI	Follow up	Possible	NA	Increased areas of T2 hyperintensity with enhancement anterior and superior to the resection cavity with elevated relative CBV values concerning for disease progression.	None	None	1	None	None	None	None	None	None	None	None	432	MRI	Follow up	Yes	NA	Findings consistent with tumor progression, marked expansion of the right middle temporal lobe, suspected extension into the right internal capsule, new right to left midline shift of 6.2 mm, compared with 2 months ago. Likely recurrent, progressive tumor in the right middle temporal lobe, right precuneus.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	12	None	None	0	Left	left hemianopsia	Suture removal	Left hemianopsia, occasionally hears a "sqeaky" noise inside his head near the incision site.	12	None	26	0	Left	left hemianopsia	Radiation planning	None	26	90	None	0	Left	left hemianopsia	Radiation planning	Left hemianopsia, very slight left lower extremity weakness.	57	90	None	0	Left	left hemianopsia	Mid radiation followup	Occasional brief headaches.  His left-sided visual problems have improved.	92	90	None	0	Left	left hemianopsia	Post radiation followup	Patient discontinued keppra without being instructed to do so.	99	90	None	0	Left	hemianopsia 	None	DC Vax protocol, 1st injection today.	115	90	None	0	None	None	Radiation Oncology followup	No residual visual field cuts.	281	90	None	0	None	None	None	Denies seizures, headache, cognitive changes, gait impairment.	316	90	None	0	None	None	None	Reports some memory loss, fatigue, depression, trouble sleeping, and anxiety.	372	90	None	0	None	None	None	Returns today for surveillance scan and reports doing well without new or progressive symptoms. 	440	70	None	0	Left	None	None	Clinically, he continues to have a left hemiparesis which is modestly more apparent compared to a few weeks ago. He denies headaches and is able to ambulate independently with some unsteadiness. He denies any history of seizures.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
153	SN332, W48-2-1	 W48-2-1	SN332	None	52	Male	80	87.8 kg	177.8 cm	26	No	No	History of headaches, nausea.	Right Temporal	Complete resection	Yes	Yes	Glioblastoma	NA	NA	NA	NA	NA	0.37	0.05	0.03	wildtype	not detected	Recurrent	No	Yes	No	Yes	11	233	53	92	NA	456	Deceased due to tumor progression	5	0	0	0	8	0	0	4	1	0	1	0	0	2	0	0	0	0	0	No	No	Yes	No	No	Steroids	-4	4mg/1mL injection 4mg 4 times a day	dexamethasone	-2	Anti-epileptic	-4	750 mg in NS(0.9% NaCl) IV solution 100 mL twice a day	KEPPRA	-3	Anti-epileptic	-3	1000 mg twice a day oral	KEPPRA	22	Steroids	-2	4 mg oral  4-3  times a day oral	dexamethasone	4	Steroids	5	1 mg 4 times a day oral	dexamethasone	9	Steroids	9	2-1 mg 3-2-1  times a day oral	dexamethasone	17	Anti-epileptic	22	1000 mg twice a day oral	KEPPRA XR	107	Steroids	233	2 mg 3 times a day oral	dexamethasone	234	Anti-epileptic	233	1000 mg twice a day oral	KEPPRA	246	Steroids	234	4mg/1mL injection 2-4mg 3-4 times a day	dexamethasone	237	Steroids	237	from 4 mg 3 times a day till 1 mg daily oral	dexamethasone	246	Steroids	427	8mg twice a day oral	dexamethasone	471	antihypertensive	440	20 mg daily oral	lisinopril	470	Anti-epileptic	441	500 mg twice a day oral	KEPPRA	471	None	None	None	None	None	None	None	None	None	None	Temozolomide	35	145 mg	concurrent	77	Temozolomide	128	290 mg	daily oral	133	Temozolomide	162	400 mg	daily oral	236	Temozolomide	266	195 mg	daily oral	281	Avastin	282	753 mg in NS(0.9% NaCl) IV solution 100 mL 	every 2 weeks	442	Etoposide	372	50 mg	daily oral	394	Etoposide	411	100 mg	daily oral	432	None	None	None	None	None	None	None	None	None	None	35	IMRT	6000 cGy	30	77	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Apparent  gross  total  resection  status  post  right  parietal  tumor resection.  No  residual  enhancing  tumor.  Expected  postoperative changes,  without  evidence  for  significant  intracranial  hemorrhage. Mild  cytotoxic  edema  in  the  medial  and  posterior  margin  of  the right  parietal  resection  cavity.	None	None	1	None	None	None	None	None	None	None	None	92	MRI	Follow up	Possible	NA	None	None	None	1	None	None	None	None	None	None	None	None	162	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	225	MRI	Pre-surgery	Yes	NA	New  nodular  enhancement  along  the  anterior  inferior  and  anterior superior  margin  of  the  right  temporal  resection  cavity,  worrisome  for disease  progression.  Differential  consideration  include pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	234	MRI	Post-surgery	No	NA	There  are  surgical  changes  of  a  right  temporal  craniotomy  and  right parietal  craniotomy.  There  is  a  collection  within  the  right  temporal and  right  parietal  extra-axial  space  measuring  up  to  10  mm  in greatest  thickness,  consistent  with  a  postoperative  hematoma.  There is  a  small  amount  of  gas  density  along  the  right  frontal  extra-axial convexity.  There  is  a  small  focus  of  susceptibility  in  the interhemispheric  fissure,  consistent  with  blood  products. The  diffusion-weighted  images  demonstrate  diffusion  restriction  along the  margins  of the  resection  bed,  consistent  with  small  areas  of cerebral  infarction,  which  is  expected  in  the  recent  postoperative state.  No  additional  areas  of  diffusion  restriction  are  demonstrated.	None	None	1	None	None	None	None	None	None	None	None	281	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	316	MRI	Follow up	No	NA	None	None	None	1	None	None	None	None	None	None	None	None	372	MRI	Follow up	Possible	NA	Increased areas of T2 hyperintensity with enhancement anterior and superior to the resection cavity with elevated relative CBV values concerning for disease progression.	None	None	1	None	None	None	None	None	None	None	None	432	MRI	Follow up	Yes	NA	Findings consistent with tumor progression, marked expansion of the right middle temporal lobe, suspected extension into the right internal capsule, new right to left midline shift of 6.2 mm, compared with 2 months ago. Likely recurrent, progressive tumor in the right middle temporal lobe, right precuneus.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	12	None	None	0	Left	left hemianopsia	Suture removal	Left hemianopsia, occasionally hears a "sqeaky" noise inside his head near the incision site.	12	None	26	0	Left	left hemianopsia	Radiation planning	None	26	90	None	0	Left	left hemianopsia	Radiation planning	Left hemianopsia, very slight left lower extremity weakness.	57	90	None	0	Left	left hemianopsia	Mid radiation followup	Occasional brief headaches.  His left-sided visual problems have improved.	92	90	None	0	Left	left hemianopsia	Post radiation followup	Patient discontinued keppra without being instructed to do so.	99	90	None	0	Left	hemianopsia 	None	DC Vax protocol, 1st injection today.	115	90	None	0	None	None	Radiation Oncology followup	No residual visual field cuts.	281	90	None	0	None	None	None	Denies seizures, headache, cognitive changes, gait impairment.	316	90	None	0	None	None	None	Reports some memory loss, fatigue, depression, trouble sleeping, and anxiety.	372	90	None	0	None	None	None	Returns today for surveillance scan and reports doing well without new or progressive symptoms. 	440	70	None	0	Left	None	None	Clinically, he continues to have a left hemiparesis which is modestly more apparent compared to a few weeks ago. He denies headaches and is able to ambulate independently with some unsteadiness. He denies any history of seizures.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
158	SN315, W50-1-1	 W50-1-1	SN315	http://glioblastoma.alleninstitute.org/ish/specimen/show/267060258	27	Male	90	92.08 kg	185.4 cm	30	Yes	Right	Right sided numbness, right eye visual phenomenon.	Left Parietal	Complete resection	Yes	Yes	Glioblastoma WHO grade IV	NA	NA	NA	NA	NA	0.47	0.11	0.34	wildtype	not detected	Primary	No	Yes	No	Yes	27	6	27	93	951	NA	NA	8	1	0	0	6	0	0	2	1	0	0	0	0	0	0	2	0	0	1	No	No	No	No	No	Steroids	-40	4mg/1mL injection	dexamethasone		Anti-epileptic	-39	750 mg x 1 cap twice a day	KEPPRA	8	Steroids	6	4mg/1mL injection	dexamethasone	7	Steroids	8	1 mg x 2 caps twice a day	dexamethasone	58	Anti-epileptic	8	1000 mg x 1 cap twice a day	KEPPRA	58	Steroids	124	1 mg by mouth twice a day	dexamethasone	155	Anti-depressant	155	15 mg at bedtime	mirtazapine	187	Anti-epileptic	156	1000mg (morning and evening) and 500mg in the afternoon	KEPPRA	187	Anti-epileptic	189	0.5 mg daily oral as needed	clonazepam (KLONOPIN)	253	multi-vitamin	215	1 cap daily oral	with FLUORIDE	255	Steroids	253	4mg/1mL injection	dexamethasone	256	Anti-epileptic	253	500 mg x 3 caps oral 	KEPPRA	455	Anti-epileptic	456	1500 mg twice a day oral	KEPPRA XR	516	Anti-epileptic	516	100 mg twice a day	Lamotrigine	695	Anti-epileptic	698	1500 mg twice a day oral	KEPPRA XR	961	Steroids	890	2 mg AM for a week then 1 mg AM oral	dexamethasone	923	Temozolomide	16	160 mg daily oral	None	46	Temozolomide	58	160-440 mg	every month for 5 days oral	579	Lomustine	502	160 mg	daily oral	698	Lomustine	762	160 mg	daily oral	793	Avastin	839	960 mg	intravenous every 2 weeks	951	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	36	IMRT	6000 cGy	30	78	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Areas  of  cortical  activation  for  right  hand  and  right  foot  movement are  delineated  with  cortical  spinal  tractography.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	Status  post  craniotomy  and  resection  of  previously  demonstrated, nonenhancing,  left  parietal  lobe  neoplasm. There  is  a  residual,  geographic  area  of  FLAIR  hyperintensity  that extends  from  the  anterior  margin  of  the  resection  cavity  caudad  into the  left  peritrigonal  region.  Differential  diagnostic  considerations include  vasogenic  edema,  nonenhancing  tumor  and  a  combination  of  the two.	None	None	1	None	None	None	None	None	None	None	None	93	MRI	Follow up	Possible	NA	Focal nodular 10 x 7 x 5 mm enhancement developing at the anterior margin of the left parietal resection site. Differential consideration include recurrent disease versus pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	155	MRI	Follow up	Possible	NA	Overall findings are worrisome for progression of disease although differential consideration includes pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	187	MRI	Follow up	Yes	NA	Anatomic imaging and perfusion imaging suggests tumor progression.	None	None	1	None	None	None	None	None	None	None	None	243	MRI	Follow up	Possible	NA	Slight  sequential  increase  in  nodular  regions  of  enhancement  anterior superior  to  the  left  parietal  resection  cavity.  Findings  may represent  disease  progression.	None	None	1	None	None	None	None	None	None	None	None	252	MRI	Pre-surgery	Yes	NA	Multifocal  nodular  enhancement  at  the  anterior  margin  of  the  left parietal  resection  cavity  and  in  the  left  parietal  lobe  superior  to the  left  parietal  resection  cavity  without  significant  change  in  size compared  to  the previous one.  Extent  of  left  parietal  T2  signal abnormalities  appear  stable.	None	None	1	None	None	None	None	None	None	None	None	254	MRI	Post-surgery	No	NA	Interval  redo  craniotomy  for  resection  of  the  multiple  nodular enhancing  foci  within  the  left  parietal  lobe  with  expected postsurgical changes.  These  nodular  foci  of  enhancement  are  no  longer seen  compatible  with  complete  resection. No  restricted  diffusion  is  identified  to  suggest  perioperative infarct.	None	None	1	None	None	None	None	None	None	None	None	302	MRI	Follow up	No	NA	Status post left parietal resection of tumor, as before. There has been expected evolution of postoperative changes since the prior exam. No suspicious enhancement at the resection cavity. Surrounding FLAIR signal abnormality has increased in extent compared to the prior exam which may reflect tumor infiltration versus post treatment effect.	None	None	1	None	None	None	None	None	None	None	None	356	MRI	Follow up	Possible	NA	Evolving postoperative changes, compared to 2 previous MRIs without convincing evidence for interval rogression of enhancing disease. There is slight increased T2 FLAIR hyperintensity in the periventricular left parietal temporal region which may reflect tumor infiltration versus post treatment effects.	None	None	1	None	None	None	None	None	None	None	None	415	MRI	Follow up	Possible	NA	Since prior examination  there has been development of few nodular subcentimeter foci of enhancement in the left parietal lobe, mostly distributed in the periventricular region. The largest is in the lateral periventricular region, measuring 5 mm. This is concerning for early progression although relative CBV are relatively low. Continued maturing ostoperative changes of left parietal tumor resection.	None	None	1	None	None	None	None	None	None	None	None	462	MRI	Follow up	Possible	NA	Status post resection of left parietal anaplastic astrocytoma, as before. There are at least 3 foci of enlarging enhancement along the resection bed compared to the prior exam, but cerebral blood volume is only mildly elevated. Findings favor pseudo-progression, but progressive tumor cannot be excluded. 	None	None	1	None	None	None	None	None	None	None	None	488	MRI	Follow up	Possible	NA	Two additional subcentimeter foci of enhancement on lateral periventricular margin of the parietal lobe compared to the prior exam. There is no apparent enlargement of previously identified foci of enhancement. Again differential consideration would include pseudo-progression and progression.	None	None	1	None	None	None	None	None	None	None	None	537	MRI	Follow up	No	NA	No significant interval progression compared to the prior exam, although linear enhancement along the lateral periventricular margin of the left parietal lobe appears to have increased without significant increase in periventricular vasogenic edema or new mass effect.	None	None	1	None	None	None	None	None	None	None	None	579	MRI	Follow up	No	NA	Status post resection of left parietal anaplastic astrocytoma, as before. Small scattered foci of enhancement along the resection cavity are minimally changed compared to the 3 months ago exam although increased compared to the half a year ago exam. Relative cerebral blood volume is low, favoring treatment response over progressive disease. Adjacent FLAIR signal abnormality is not significantly changed since a half a year ago exam.	None	None	1	None	None	None	None	None	None	None	None	635	MRI	Follow up	No	NA	Decreased size and conspicuity of periventricular periependymal enhancement along the posterior horn of left lateral ventricle at the left parietal resection site. Findings are compatible with post treatment effects.	None	None	1	None	None	None	None	None	None	None	None	698	MRI	Follow up	No	NA	Stable examination, without convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	762	MRI	Follow up	No	NA	Status post resection of left parietal high-grade glioma, as before. There is new nodular enhancement adjacent to the resection cavity since the 2 months ago exam. However, corresponding relative cerebral blood volume is only minimally elevated, favoring treatment effect over disease progression. Short interval followup is recommended.	None	None	1	None	None	None	None	None	None	None	None	793	MRI	Follow up	No	NA	Increasing enhancement in the anterior medial aspect of the left parietal resection cavity since a month ago, however   this is more consistent with radiation effect. 	None	None	1	None	None	None	None	None	None	None	None	834	MRI		No	NA	Progressive increasing size of the periventricular irregular enhancement along the anteromedial margin of the left parietal resection cavity when compared to a month ago exam.	None	None	1	None	None	None	None	None	None	None	None	890	MRI	Follow up	No	NA	Status post resection of left parietal anaplastic astrocytoma, as before. Enhancement along the anterior aspect of the resection cavity and surrounding FLAIR hyperintensity are markedly decreased compared to 2 months old exam, likely reflecting Avastin therapy. 	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	-54	None	30	1	Right	numbness starting in the right lower extremity	None	None	-33	100	None	0	None	None	None	Patient comes in after undergoing a stereotactic needle biopsy of his left parietal mass lesion 1 week ago.	14	100	None	0	None	None	Suture removal	None	17	90	None	1	Right	None	Radiation planning	Sensory abnormality in his right leg, migrates to right chest wall as spasms.	58	80	None	1	None	None	Mid radiation followup	Fairly prolonged right-sided seizure.	93	80	None	1	None	None	None	Patient is doing reasonably well after completing involved field radiation and Temodar for a left parietal anaplastic astrocytoma.	187	90	None	0	None	None	None	 Since last seen he has not had any additional seizures. His headaches are much better.	215	90	None	0	None	None	None	There are no new areas of enhancement, nor progressive T2/FLAIR signal changes.	243	100	27	0	None	None	None	???????MRI of the brain from today was personally reviewed showing continued increase in the size of the most superior enhancing nodule by approximately 1mm. The most inferior enhancing nodules remain stable to subtly less prominent. 	272	90	None	0	None	None	None	???????MRI of the brain from 2 weeks ago was personally reviewed showing interval resection of multiple enhancing nodules as well as previously noted T2/FLAIR hyperintensity. There is no residual enhancement.	302	90	None	0	None	None	None	Denies any focal weakness or falls. Denies further seizures.	328	80	None	0	Right	reports decreased sensation on the distal dorsal and plantar surface of the right foot which is unchanged. 	None	At times he says he has a little difficulty walking because of the sensory deficit. He otherwise has no complaints. He feels he is stronger than prior to surgery. His appetite is good. He denies headaches and has had no seizures.	356	90	None	0	None	None	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This markedly improved, however has persisted in the distal foot which is worse some days.  Denies any focal weakness or falls. Denies further seizures.	387	90	None	0	Left	None	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This has continued to improve and now only involves the most medial aspect of his left foot distally with some spatial perceptional difficulties of his left foot.   Denies any focal weakness or falls. Denies further seizures.	415	90	None	0	Left	numbness in his distal left lower extremity (foot)	None	Denies any focal weakness or falls. Denies further seizures.	462	90	None	0	Left	some spatial perceptional difficulties of his left foot.	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This has continued to improve and now only involves the most medial aspect of his left foot distally with some spatial perceptional difficulties of his left foot.   Denies any focal weakness or falls. Denies further seizures.	488	90	None	0	None	None	None	Doing well.	537	90	None	0	None	None	None	Clinically, he has stable numbness in his distal left lower extremity which he noted post-operatively.  Denies any focal weakness or falls or further seizures. No new or progressive symptoms. His last sensory seizure was approximately 1-3 months ago. Reports occasional numbness in the hands.  He continues to follow with his psychologist for depression.	579	90	None	0	None	None	None	Clinically he has tolerated CCNU well with stable numbness in the distal left lower extremity which he noted post-operatively. He has also noted intermittent numbness in the left 4th and 5th digits which is more prominent while lifting weights. Denies focal weakness.	635	90	None	0	None	None	None	Clinically he has tolerated CCNU well with stable numbness in the distal left lower extremity which he noted post-operatively. He has no longer experienced focal sensory seizures, currently on Keppra 1500 mg BID, Lamictal 100 mg BID and Trileptal 600 mg BID. Denies focal weakness. Reports persistent fatigue for which Ritalin was increased to 10 mg BID. 	698	90	None	0	None	None	None	Clinically, he overall feels better since completion of chemotherapy. He continues to have fatigue, however is not sleeping well due to frequent nightmares associated with PTSD. Continues on Ritalin 10 mg BID. He continues to have stable numbness in the distal left lower extremity which he noted post-operatively.	762	90	None	0	None	None	None	Clinically, he is doing well with some persistent distal numbness in the right foot and minimal incoordination on the right. He continues to follow with a therapist for PTSD. He continues on Keppra 1500 mg BID, Lamictal 125 mg BID and Trileptal 600 mg BID for his focal sensory seizures.  Since his last visit, reports 1-2 focal sensory seizures in the RUE as well as an episode of RUE cramping.  	793	90	None	0	None	None	None	Clinically, he is doing well with stable distant numbness in the right foot and minimal incoordination on the right. 	834	90	None	0	None	None	None	Clinically, he is doing well with stable distant numbness in the right foot and minimal incoordination on the right. He has had fewer focal sensory seizures since increase in Lamictal to 150 mg BID, also on Trileptal 600 mg BID and Keppra 1500 mg BID. Has had a few muscle twitches in the right forearm since.	890	90	None	0	None	None	None	Clinically, he denies new or progressive symptoms. Lamictal was increased to 200 mg BID and Keppra decreased in parallel due to mood lability to 1500 mg BID.  He has tolerated Avastin well, however reports frontal headaches over the past month occurring 1-4 times a week that are bothersome for which he is taking Tylenol.	909	90	None	0	None	None	None	presents for interval follow-up prior to his next dose of Avastin.  His most recent surveillance MRI showed improved findings.  Clinically, he denies new or progressive symptoms. He continues to have mild numbness in the distal right lower extremity that is stable.  His generalized/frontal headaches persist and are mild to moderate for which he takes tylenol when bothersome.  We treated with a short course of decadron 2 mg once daily x 1 week, then 1 mg x 1 week without improvement.  He continues on Lamictal 200 mg BID, Keppra 1500 mg BID and Trileptal and is followed by neurology due for follow-up in the next week. 	951	90	None	0	None	None	None	presents for interval follow-up prior to his next dose of Avastin.  Clinically, he denies new or progressive symptoms. He continues to have mild numbness in the distal right lower extremity that is stable.  He continues on Lamictal 200 mg BID, Keppra 1500 mg BID and Trileptal and is followed by neurology.	None	None	None	None	None	None	None	None
158	SN340, W50-2-1	 W50-2-1	SN340	None	27	Male	90	92.08 kg	185.4 cm	30	Yes	Right	Right sided numbness, right eye visual phenomenon.	Left Parietal	Complete resection	Yes	Yes	Anaplastic astrocytoma WHO grade III 	NA	NA	NA	NA	NA	0.39	0.12	0.41	R132G	not detected	Recurrent	No	Yes	No	Yes	27	253	28	93	951	NA	NA	8	1	0	0	6	0	0	2	1	0	0	0	0	0	0	2	0	0	1	No	No	No	No	No	Steroids	-40	4mg/1mL injection	dexamethasone		Anti-epileptic	-39	750 mg x 1 cap twice a day	KEPPRA	8	Steroids	6	4mg/1mL injection	dexamethasone	7	Steroids	8	1 mg x 2 caps twice a day	dexamethasone	58	Anti-epileptic	8	1000 mg x 1 cap twice a day	KEPPRA	58	Steroids	124	1 mg by mouth twice a day	dexamethasone	155	Anti-depressant	155	15 mg at bedtime	mirtazapine	187	Anti-epileptic	156	1000mg (morning and evening) and 500mg in the afternoon	KEPPRA	187	Anti-epileptic	189	0.5 mg daily oral as needed	clonazepam (KLONOPIN)	253	multi-vitamin	215	1 cap daily oral	with FLUORIDE	255	Steroids	253	4mg/1mL injection	dexamethasone	256	Anti-epileptic	253	500 mg x 3 caps oral 	KEPPRA	455	Anti-epileptic	456	1500 mg twice a day oral	KEPPRA XR	516	Anti-epileptic	516	100 mg twice a day	Lamotrigine	695	Anti-epileptic	698	1500 mg twice a day oral	KEPPRA XR	961	Steroids	890	2 mg AM for a week then 1 mg AM oral	dexamethasone	923	Temozolomide	16	160 mg daily oral	None	46	Temozolomide	58	160-440 mg	every month for 5 days oral	579	Lomustine	502	160 mg	daily oral	698	Lomustine	762	160 mg	daily oral	793	Avastin	839	960 mg	intravenous every 2 weeks	951	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	36	IMRT	6000 cGy	30	78	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery	No	NA	Areas  of  cortical  activation  for  right  hand  and  right  foot  movement are  delineated  with  cortical  spinal  tractography.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	Status  post  craniotomy  and  resection  of  previously  demonstrated, nonenhancing,  left  parietal  lobe  neoplasm. There  is  a  residual,  geographic  area  of  FLAIR  hyperintensity  that extends  from  the  anterior  margin  of  the  resection  cavity  caudad  into the  left  peritrigonal  region.  Differential  diagnostic  considerations include  vasogenic  edema,  nonenhancing  tumor  and  a  combination  of  the two.	None	None	1	None	None	None	None	None	None	None	None	93	MRI	Follow up	Possible	NA	Focal nodular 10 x 7 x 5 mm enhancement developing at the anterior margin of the left parietal resection site. Differential consideration include recurrent disease versus pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	155	MRI	Follow up	Possible	NA	Overall findings are worrisome for progression of disease although differential consideration includes pseudo-progression.	None	None	1	None	None	None	None	None	None	None	None	187	MRI	Follow up	Yes	NA	Anatomic imaging and perfusion imaging suggests tumor progression.	None	None	1	None	None	None	None	None	None	None	None	243	MRI	Follow up	Possible	NA	Slight  sequential  increase  in  nodular  regions  of  enhancement  anterior superior  to  the  left  parietal  resection  cavity.  Findings  may represent  disease  progression.	None	None	1	None	None	None	None	None	None	None	None	252	MRI	Pre-surgery	Yes	NA	Multifocal  nodular  enhancement  at  the  anterior  margin  of  the  left parietal  resection  cavity  and  in  the  left  parietal  lobe  superior  to the  left  parietal  resection  cavity  without  significant  change  in  size compared  to  the previous one.  Extent  of  left  parietal  T2  signal abnormalities  appear  stable.	None	None	1	None	None	None	None	None	None	None	None	254	MRI	Post-surgery	No	NA	Interval  redo  craniotomy  for  resection  of  the  multiple  nodular enhancing  foci  within  the  left  parietal  lobe  with  expected postsurgical changes.  These  nodular  foci  of  enhancement  are  no  longer seen  compatible  with  complete  resection. No  restricted  diffusion  is  identified  to  suggest  perioperative infarct.	None	None	1	None	None	None	None	None	None	None	None	302	MRI	Follow up	No	NA	Status post left parietal resection of tumor, as before. There has been expected evolution of postoperative changes since the prior exam. No suspicious enhancement at the resection cavity. Surrounding FLAIR signal abnormality has increased in extent compared to the prior exam which may reflect tumor infiltration versus post treatment effect.	None	None	1	None	None	None	None	None	None	None	None	356	MRI	Follow up	Possible	NA	Evolving postoperative changes, compared to 2 previous MRIs without convincing evidence for interval rogression of enhancing disease. There is slight increased T2 FLAIR hyperintensity in the periventricular left parietal temporal region which may reflect tumor infiltration versus post treatment effects.	None	None	1	None	None	None	None	None	None	None	None	415	MRI	Follow up	Possible	NA	Since prior examination  there has been development of few nodular subcentimeter foci of enhancement in the left parietal lobe, mostly distributed in the periventricular region. The largest is in the lateral periventricular region, measuring 5 mm. This is concerning for early progression although relative CBV are relatively low. Continued maturing ostoperative changes of left parietal tumor resection.	None	None	1	None	None	None	None	None	None	None	None	462	MRI	Follow up	Possible	NA	Status post resection of left parietal anaplastic astrocytoma, as before. There are at least 3 foci of enlarging enhancement along the resection bed compared to the prior exam, but cerebral blood volume is only mildly elevated. Findings favor pseudo-progression, but progressive tumor cannot be excluded. 	None	None	1	None	None	None	None	None	None	None	None	488	MRI	Follow up	Possible	NA	Two additional subcentimeter foci of enhancement on lateral periventricular margin of the parietal lobe compared to the prior exam. There is no apparent enlargement of previously identified foci of enhancement. Again differential consideration would include pseudo-progression and progression.	None	None	1	None	None	None	None	None	None	None	None	537	MRI	Follow up	No	NA	No significant interval progression compared to the prior exam, although linear enhancement along the lateral periventricular margin of the left parietal lobe appears to have increased without significant increase in periventricular vasogenic edema or new mass effect.	None	None	1	None	None	None	None	None	None	None	None	579	MRI	Follow up	No	NA	Status post resection of left parietal anaplastic astrocytoma, as before. Small scattered foci of enhancement along the resection cavity are minimally changed compared to the 3 months ago exam although increased compared to the half a year ago exam. Relative cerebral blood volume is low, favoring treatment response over progressive disease. Adjacent FLAIR signal abnormality is not significantly changed since a half a year ago exam.	None	None	1	None	None	None	None	None	None	None	None	635	MRI	Follow up	No	NA	Decreased size and conspicuity of periventricular periependymal enhancement along the posterior horn of left lateral ventricle at the left parietal resection site. Findings are compatible with post treatment effects.	None	None	1	None	None	None	None	None	None	None	None	698	MRI	Follow up	No	NA	Stable examination, without convincing evidence for interval progression.	None	None	1	None	None	None	None	None	None	None	None	762	MRI	Follow up	No	NA	Status post resection of left parietal high-grade glioma, as before. There is new nodular enhancement adjacent to the resection cavity since the 2 months ago exam. However, corresponding relative cerebral blood volume is only minimally elevated, favoring treatment effect over disease progression. Short interval followup is recommended.	None	None	1	None	None	None	None	None	None	None	None	793	MRI	Follow up	No	NA	Increasing enhancement in the anterior medial aspect of the left parietal resection cavity since a month ago, however   this is more consistent with radiation effect. 	None	None	1	None	None	None	None	None	None	None	None	834	MRI		No	NA	Progressive increasing size of the periventricular irregular enhancement along the anteromedial margin of the left parietal resection cavity when compared to a month ago exam.	None	None	1	None	None	None	None	None	None	None	None	890	MRI	Follow up	No	NA	Status post resection of left parietal anaplastic astrocytoma, as before. Enhancement along the anterior aspect of the resection cavity and surrounding FLAIR hyperintensity are markedly decreased compared to 2 months old exam, likely reflecting Avastin therapy. 	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	-54	None	30	1	Right	numbness starting in the right lower extremity	None	None	-33	100	None	0	None	None	None	Patient comes in after undergoing a stereotactic needle biopsy of his left parietal mass lesion 1 week ago.	14	100	None	0	None	None	Suture removal	None	17	90	None	1	Right	None	Radiation planning	Sensory abnormality in his right leg, migrates to right chest wall as spasms.	58	80	None	1	None	None	Mid radiation followup	Fairly prolonged right-sided seizure.	93	80	None	1	None	None	None	Patient is doing reasonably well after completing involved field radiation and Temodar for a left parietal anaplastic astrocytoma.	187	90	None	0	None	None	None	 Since last seen he has not had any additional seizures. His headaches are much better.	215	90	None	0	None	None	None	There are no new areas of enhancement, nor progressive T2/FLAIR signal changes.	243	100	27	0	None	None	None	???????MRI of the brain from today was personally reviewed showing continued increase in the size of the most superior enhancing nodule by approximately 1mm. The most inferior enhancing nodules remain stable to subtly less prominent. 	272	90	None	0	None	None	None	???????MRI of the brain from 2 weeks ago was personally reviewed showing interval resection of multiple enhancing nodules as well as previously noted T2/FLAIR hyperintensity. There is no residual enhancement.	302	90	None	0	None	None	None	Denies any focal weakness or falls. Denies further seizures.	328	80	None	0	Right	reports decreased sensation on the distal dorsal and plantar surface of the right foot which is unchanged. 	None	At times he says he has a little difficulty walking because of the sensory deficit. He otherwise has no complaints. He feels he is stronger than prior to surgery. His appetite is good. He denies headaches and has had no seizures.	356	90	None	0	None	None	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This markedly improved, however has persisted in the distal foot which is worse some days.  Denies any focal weakness or falls. Denies further seizures.	387	90	None	0	Left	None	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This has continued to improve and now only involves the most medial aspect of his left foot distally with some spatial perceptional difficulties of his left foot.   Denies any focal weakness or falls. Denies further seizures.	415	90	None	0	Left	numbness in his distal left lower extremity (foot)	None	Denies any focal weakness or falls. Denies further seizures.	462	90	None	0	Left	some spatial perceptional difficulties of his left foot.	None	Clinically, he has numbness in his distal left lower extremity which he noted post-operatively. This has continued to improve and now only involves the most medial aspect of his left foot distally with some spatial perceptional difficulties of his left foot.   Denies any focal weakness or falls. Denies further seizures.	488	90	None	0	None	None	None	Doing well.	537	90	None	0	None	None	None	Clinically, he has stable numbness in his distal left lower extremity which he noted post-operatively.  Denies any focal weakness or falls or further seizures. No new or progressive symptoms. His last sensory seizure was approximately 1-3 months ago. Reports occasional numbness in the hands.  He continues to follow with his psychologist for depression.	579	90	None	0	None	None	None	Clinically he has tolerated CCNU well with stable numbness in the distal left lower extremity which he noted post-operatively. He has also noted intermittent numbness in the left 4th and 5th digits which is more prominent while lifting weights. Denies focal weakness.	635	90	None	0	None	None	None	Clinically he has tolerated CCNU well with stable numbness in the distal left lower extremity which he noted post-operatively. He has no longer experienced focal sensory seizures, currently on Keppra 1500 mg BID, Lamictal 100 mg BID and Trileptal 600 mg BID. Denies focal weakness. Reports persistent fatigue for which Ritalin was increased to 10 mg BID. 	698	90	None	0	None	None	None	Clinically, he overall feels better since completion of chemotherapy. He continues to have fatigue, however is not sleeping well due to frequent nightmares associated with PTSD. Continues on Ritalin 10 mg BID. He continues to have stable numbness in the distal left lower extremity which he noted post-operatively.	762	90	None	0	None	None	None	Clinically, he is doing well with some persistent distal numbness in the right foot and minimal incoordination on the right. He continues to follow with a therapist for PTSD. He continues on Keppra 1500 mg BID, Lamictal 125 mg BID and Trileptal 600 mg BID for his focal sensory seizures.  Since his last visit, reports 1-2 focal sensory seizures in the RUE as well as an episode of RUE cramping.  	793	90	None	0	None	None	None	Clinically, he is doing well with stable distant numbness in the right foot and minimal incoordination on the right. 	834	90	None	0	None	None	None	Clinically, he is doing well with stable distant numbness in the right foot and minimal incoordination on the right. He has had fewer focal sensory seizures since increase in Lamictal to 150 mg BID, also on Trileptal 600 mg BID and Keppra 1500 mg BID. Has had a few muscle twitches in the right forearm since.	890	90	None	0	None	None	None	Clinically, he denies new or progressive symptoms. Lamictal was increased to 200 mg BID and Keppra decreased in parallel due to mood lability to 1500 mg BID.  He has tolerated Avastin well, however reports frontal headaches over the past month occurring 1-4 times a week that are bothersome for which he is taking Tylenol.	909	90	None	0	None	None	None	presents for interval follow-up prior to his next dose of Avastin.  His most recent surveillance MRI showed improved findings.  Clinically, he denies new or progressive symptoms. He continues to have mild numbness in the distal right lower extremity that is stable.  His generalized/frontal headaches persist and are mild to moderate for which he takes tylenol when bothersome.  We treated with a short course of decadron 2 mg once daily x 1 week, then 1 mg x 1 week without improvement.  He continues on Lamictal 200 mg BID, Keppra 1500 mg BID and Trileptal and is followed by neurology due for follow-up in the next week. 	951	90	None	0	None	None	None	presents for interval follow-up prior to his next dose of Avastin.  Clinically, he denies new or progressive symptoms. He continues to have mild numbness in the distal right lower extremity that is stable.  He continues on Lamictal 200 mg BID, Keppra 1500 mg BID and Trileptal and is followed by neurology.	None	None	None	None	None	None	None	None
174	W53-1-1, SN331	W53-1-1	 SN331	http://glioblastoma.alleninstitute.org/ish/specimen/show/278101407	55	Male	90	69.673 kg	171.5 cm	None	No	No	Three month history of word finding difficulties.	Left Temporal	Complete resection	Yes	Yes	Glioblastoma WHO grade IV 	NA	NA	NA	NA	NA	0.81	0.29	0.45	wildtype	not detected	Primary	None	None	None	Yes	19	9	55	312	708	NA	NA	3	0	0	0	1	0	0	3	0	0	0	0	0	3	0	0	0	0	0	No	No	No	No	No	Anti-epileptic	29	1000 mg twice a day oral	KEPPRA	55	Steroids	29	2 mg twice a day oral	dexamethasone	55	Anti-epileptic	55	500 mg twice a day oral	KEPPRA	113	Anti-epileptic	434	1000 mg once oral	KEPPRA		None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	33	140 mg	daily oral	80	Temozolomide	139	340 mg	every 2 weeks for 5 days oral	285	Temozolomide	285	140 mg	 everyday for 21 days oral	306	Etoposide	379	100 mg 	daily oral	581	Etoposide	586	100 mg	daily oral	673	Etoposide	680	100 mg	daily oral	699	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	36	IMRT	4600 cGy	23	63	64	IMRT	1400 cGy	7	78	317	IMRT	21 Gy	1 for medial, and 1 for inferior 		None	None	None	None	None	0	MRI	Pre-surgery	No	NA	5.5 cm left temporal enhancing mass. Appearance is concerning for a primary brain neoplasm, most likely glioblastoma multiforme. No additional lesions are identified.	None	None	1	None	None	None	None	None	None	None	None	9	MRI	Post-surgery	No	NA	Post left temporal craniotomy and resection of left temporal lobe mass without residual abnormal enhancement. Slight improvement of mass effect.	None	None	1	None	None	None	None	None	None	None	None	113	MRI	Follow up	No	NA	Expected evolution of postsurgical changes status post left anterior temporal tumor resection. No abnormal enhancement around the resection margin. Minimal T2 hyperintensity around the resection margin. No apparent evidence for recurrent tumor.	None	None	1	None	None	None	None	None	None	None	None	173	MRI	Follow up	No	NA	No convincing evidence for interval progression since 2 months ago.	None	None	1	None	None	None	None	None	None	None	None	228	MRI	Follow up	No	NA	No acute abnormality or significant change. No evidence for residual or recurrent enhancing tumor or increased abnormal left temporal perioperative T2 hyperintensity to suggest tumor recurrence.	None	None	1	None	None	None	None	None	None	None	None	312	MRI	Follow up	Yes	NA	Enlarging enhancing nodule in the medial aspect of the left anterior temporal resection cavity, compatible with progressive disease. A few other smaller foci of enhancement are seen along the anterior medial, and posterior inferior margin as described above.	None	None	1	None	None	None	None	None	None	None	None	432	MRI	Follow up	No	NA	Further enlargement of nodule in the medial left temporal lobe compared to 4 months ago. In consideration for interval gamma knife therapy, possibly represent radiation therapy changes although progressive tumor cannot be completely excluded. Evolving subacute infarct in the left corona radiata.	None	None	1	None	None	None	None	None	None	None	None	467	MRI	Follow up	No	NA	Stable enhancing lesion in the medial left temporal lobe, medial to the left temporal resection cavity. Relative CBV measures up to 2 times normal, indeterminate. No convincing evidence for interval progression compared to the prior exam. Evolving subacute infarct with decreasing enhancement compared to the prior exam. No evidence for new infarct or perfusion deficit.	None	None	1	None	None	None	None	None	None	None	None	526	MRI	Follow up	No	NA	Stable enhancing lesion in the medial left temporal lobe, medial to the left temporal resection cavity. Relative CBV measures up to 2 times normal, indeterminate. No convincing evidence for interval progression compared to 3 months ago exam. Chronic left corona radiata infarct which no longer enhances. No new infarct or perfusion deficit.	None	None	1	None	None	None	None	None	None	None	None	586	MRI	Follow up	No	NA	Relative cerebral blood volume of the enhancing tissue in the medial left temporal lobe is significantly elevated, measuring up to 3.3 times that of normal-appearing contralateral white matter. Relative cerebral blood volume of the nonenhancing, FLAIR hyperintense parenchyma is mildly elevated measuring up to 2.2 times that of normal-appearing contralateral white matter.	None	None	1	None	None	None	None	None	None	None	None	652	MRI	Follow up	No	NA	Stable examination. No convincing evidence for interval progression in irregular areas of enhancement in the left mesial temporal lobe medial to the left resection cavity. Stable chronic appearing infarct in the left corona radiata.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	29	90	None	1	Right	right leg weakness	None	Has undergone near gross total resection of a large left temporal GBM.  	55	90	None	0	None	None	None	Has never had a seizure. Neurologic and general review of systems is otherwise negative in detail.	113	100	None	0	None	None	None	He is doing well. We will move forward with adjuvant TMZ.	139	90	None	0	None	None	None	Is doing well. He had no other problems with chemotherapy. He denies headaches or seizures.	173	90	None	0	None	None	None	Had a migraine headache about two weeks ago which resolved with immitrex. One day prior to the migraine, he noted numbness in each of his finger tips which lasted about 10 minutes. He had no other symptoms.	196	90	None	0	None	None	None	He has had no headaches or seizures and no new neurologic deficits.	229	100	None	0	None	None	None	He continues to feel he is improving in terms of his cognitive function. He has no new neurologic concerns or complaints. He denies headaches and has had no seizures.	285	90	None	0	None	None	None	No changes.	313	80	None	0	None	None	None	Disease progression. Stop TMZ, move to radiosurgery of two lesions.	379	70	None	1	None	None	None	Two months ago he received gamma knife to a progressing nodular focus of enhancement along the medial aspect of the surgical cavity. He was doing well then developed worsening speech difficulties and right sided weakness. He otherwise denies headaches, seizures, or other neurologic deficits.	432	70	None	0	None	None	None	Has been working with PT and has had improvement in right sided strength. He is more fatigued since starting VP16 and weakness is more pronounced with fatigue. He denies nausea. He otherwise has no new concerns. He denies headaches. He has had no new or progressive symptoms.	467	70	None	0	None	None	None	Has now completed three cycles of VP 16 which he is tolerating with minimal side effects other than fatigue. He feels both his speech and right sided strength are improving although right hand and arm remain weak. He continues to take Plavix daily for stroke prevention. 	495	70	None	0	None	None	None	MRI showed increased enhancement along the previously treated gamma knife region. Recommended patient start Etoposide in the event the enhancement reflects tumor progression. He has now completed 4 cycles which he is tolerating well with his only complaint being fatigue. He denies headaches and has had no seizures. Strength and balance are stable. 	526	70	None	0	None	None	None	Doing well clinically and radiographically.	558	70	None	0	None	None	None	Is doing okay, no new concerns or complaints.	586	70	None	0	None	None	None	Alert, fluent, grip improved, gait ok. Neuroimaging from today reviewed in clinic: stable. Doing well clinically and radiographically. Two additional cycles of VP16. 	652	70	None	0	None	None	None	None	680	70	None	0	None	None	None	No new problems, he thinks his arm is still slowly improving.	708	None	None	0	None	None	Follow-up visit	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
187	W54-1-1, SN347	W54-1-1	 SN347	http://glioblastoma.alleninstitute.org/ish/specimen/show/288073164	58	Male	70	154 kg	178 cm	None	Yes	No	Three week history of headaches and expressive aphasia.	Left Temporal	Complete resection	No	No	Glioblastoma WHO grade IV 	NA	NA	NA	unmethylated	NA	0.47	0.15	0.04	wildtype	not detected	Primary	No	No	No	None	2	27	58	NA	NA	62	Deceased due to tumor progression	0	1	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0	No	No	Yes	No	No	Steroids	18	from 4 mg twice a day till 1 mg daily oral	dexamethasone	37	antihypertensive	28	10 mg daily oral	lisinopril	31	Anti-depressant	28	50 mg twice a day oral	quetiapine	32	antihypertensive	31	20 mg daily oral	lisinopril	32	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery		NA	Large left temporal lesion with peripherial irregular enhancement.	None	None	1	None	None	None	None	None	None	None	None	28	CT	Post-surgery	No	NA	There are surgical changes of a left frontal and left temporal craniotomy. There are multiple gas densities demonstrated in the extra-axial space of the left temporal and left frontal lobe. This is expected in the recent postoperative state.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	18	90	None	0	None	None	None	He began having severe headaches about 3 weeks ago. He was also having expressive aphasia.	48	70	None	0	Right	right-sided weakness	None	Continues to have stable expressive aphasia and right-sided weakness.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
197	W55-1-1, SN357	W55-1-1	 SN357	http://glioblastoma.alleninstitute.org/ish/specimen/show/293252106	53	Male	100	95 kg	185 cm	None	No	No	Mild headaches, memory loss.	Right Temporal	Complete resection	No	Yes	Glioblastoma WHO grade IV 	NA	NA	NA	NA	NA	0.30	0.12	0.67	wildtype	detected-ACT+	Primary	No	Yes	No	Yes	2	1	53	NA	23	NA	NA	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	Yes	No	No	Steroids	0	4mg/1mL injection 4mg 4 times a day	dexamethasone	2	Steroids	2	4 mg 4 times a day oral	dexamethasone	3	Steroids	3	from 3 mg 3 times a day till 2 mg daily oral	dexamethasone	10	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	27	IMRT	4500 cGy	25	63	64	IMRT	1620 cGy	9	79	None	None	None	None	None	None	None	None	None	None	0	MRI	Pre-surgery		NA	Large heterogeneously enhancing mass centered in the right temporal lobe. The mass demonstrates elevated relative CBV values up to 5.6 times normal white matter. These findings are most consistent with a high-grade glioma or metastasis.	None	None	1	None	None	None	None	None	None	None	None	2	MRI	Post-surgery	No	NA	Interval right frontotemporal craniotomy for resection of a large heterogeneously enhancing right temporal lobe mass. There are expected postsurgical changes consisting of subgaleal hematoma, blood products within the resection cavity, and pneumocephalus. No significant midline shift is appreciated. Focal areas of nodular and irregular enhancement anterior, posteroinferior, and medial to the resection cavity suggestive of residual tumor.	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	7	100	None	0	None	None	None	Clinically he is without deficit, headaches, nor history of seizures.	23	100	None	0	None	None	None	Clinically, he is doing quite well without neurologic deficit nor history of seizures. Has established care with local providers for both radiation and chemotherapy and will plan to transfer coordination for the DCVax study out of state.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
229	W45-1-1, SN297	W45-1-1	 SN297	http://glioblastoma.alleninstitute.org/ish/specimen/show/267547685	64	Female	80	69 kg	167 cm	27	Yes	No		Right Frontal	Complete resection	Yes	Yes	glioblastoma	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Primary	None	None	None	None	10	5	64	64	NA	542	Deceased due to tumor progression	6	0	0	0	4	0	0	4	2	0	0	0	0	0	0	0	0	0	0	Yes	No	Yes	No	No	Steroids	71	2 mg oral daily	dexamethasone 	147	Anti-epileptic	71	500 mg by mouth twice a day	KEPPRA	161	Steroids	148	2 mg twice a day oral	dexamethasone 	291	Anti-epileptic	161	1000 mg by mouth twice a day	KEPPRA	193	Anti-epileptic	193	1500 mg by mouth twice a day	KEPPRA	200	Anti-epileptic	200	1000 mg by mouth twice a day	KEPPRA	235	Anti-epileptic	266	500 mg by mouth twice a day	KEPPRA	291	Steroids	291	2 mg oral daily	dexamethasone 	432	Anti-epileptic	291	1500 mg by mouth twice a day	KEPPRA	462	Steroids	432	2 mg twice a day oral	dexamethasone 	447	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Temozolomide	74	130mg 	starting the first day of radiation until the last day of radiation	148	Temozolomide	148	260mg 	everyday for 5 days 	181	Temozolomide	181	180 mg	everyday for 5 days 	215	Temozolomide	215	130mg	for 21 days	274	Avastin	245	 725 mg in NS (0.9% NaCl) IV solution 100 mL  	once every 2 weeks	263	Avastin	355	400 mg in NS (0.9% NaCl) IV solution 100 mL  	once every 2 weeks	425	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	118	Stereotactic	60 Gy			None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	4	MRI	Pre-surgery		NA	MRI was performed for stereotactic localization.	None	None	1	None	None	None	None	None	None	None	None	6	MRI	Post-surgery	No	NA	Has undergone recent right frontal craniotomy. Interval surgical resection of contrast enhancing component of right frontal mass. No residual contrast enhancing abnormality is identified.	None	None	1	None	None	None	None	None	None	None	None	64	MRI	Pre-surgery	Yes	NA	New nodular enhancement at the margins of the right frontal surgical resection cavity, including a component extending slightly into the right corpus callosum suspicious for recurrent glioblastoma multi forme.	None	None	1	None	None	None	None	None	None	None	None	70	MRI	Post-surgery	No	NA	Status post resection and placement Gliadel wafer. There is a minimum amount of enhancing tissue seen at the deep margin of the surgical cavity just adjacent to  the Gliadel wafer.	None	None	1	None	None	None	None	None	None	None	None	147	MRI	Follow up	Possible	NA	Allowing for noncontrast technique, there is a least mild interval progression of extent of abnormal T2 signal involving the right frontal cortex, and interval increase in size of right frontal resection cavity.	None	None	1	None	None	None	None	None	None	None	None	175	MRI	Follow up	No	NA	In comparison to the prior exam, findings are consistent with at least partial response to therapy. There is diminished T2 signal, diminished mass effect, and diminished enhancement.	None	None	1	None	None	None	None	None	None	None	None	242	MRI	Follow up	Yes	NA	Progressive increase in marginal, peripheral enhancement around the right frontal resection cavity. There is also a satellite nodular enhancement seen along the medial right cingulate/callosal body more posteriorly in the right frontal lobe. Progressive increase in area of T2 hyperintensity around the right frontal resection cavity along with increasing thickness of masslike T2 hyperintensity medial to the resection cavity.	None	None	1	None	None	None	None	None	None	None	None	277	MRI	Follow up	No	NA	Incomplete study. The examination was terminated before postcontrast images could be obtained. In addition, there is significant motion artifact on the axial FLAIR sequence, severely limiting its diagnostic quality. It is impossible to comment one potential tumor progression, given that contrast images have not been obtained. However, grossly known areas of abnormal FLAIR hyperintensity appear stable.	None	None	1	None	None	None	None	None	None	None	None	291	MRI	Follow up	No	NA	Decreased extent, and intensity of enhancement around the right frontal resection cavity. Decreased enhancement within the right callosal body. Stable extent of infiltrative T2 hyperintensity in the right cerebral hemisphere without new mass effect or diffusion restriction. No apparent interval disease progression. Overall finding represent partial response to therapy.	None	None	1	None	None	None	None	None	None	None	None	347	MRI	Follow up	Possible	NA	Overall findings compatible with interval progression. Enlarging focus of enhancement and T2 hyperintensity in the right callosal body compared to 2 and 3 month ago exams. Enlarging focus of enhancing 1.7 x 1.7 x 1.8 cm masslike T2 hyperintensity in the right anterior temporal tip compared to 2 month ago exam.	None	None	1	None	None	None	None	None	None	None	None	385	MRI	Follow up	Yes	NA	Findings compatible with interval progression relative to the prior exam, with enlarging, enhancing expansile T2 hyperintense lesion in the anterior right temporal lobe. Peripheral enhancement around the right frontal resection margin and focus of satellite nodular enhancement in the right supraventricular centrum semiovale appear grossly similar. 	None	None	1	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	71	None	28	1	None	None	None	About a half a year ago she first began to experience some changes in her personality and cognition.  Three months ago she experienced two seizures on the left side of her body without a significant alteration of consciousness.  This led to the identification of a 3-cm enhancing right frontal lobe lesion.	105	90	None	1	None	None	None	She has been experiencing some fatigue and feels like she is being hit with a hammer each day.  She was in a local emergency room with a focal motor seizure 3 weeks ago.	147	80	None	0	None	None	None	Has noted cognitive deterioration over the last 2 to 3 weeks.  She has had no seizures.	175	80	None	0	None	None	None	She is having some mild headaches.  Overall, she is not significantly different than on her last visit a month ago.	340	70	None	0	Left	None	None	She has had some gradual deterioration in her left-sided function and in cognitive function. She is slightly more confused now compared to her last visit.  She has had some episodes of shaking of both hands with full maintenance of consciousness. 	375	60	None	0	None	None	None	There have been no seizures or fevers.	385	50	None	0	None	None	None	 Denies headaches, seizures, chest pain, abdominal pain. She has some mild shortness of breath with ambulation. No dysuria, abdominal pain.	418	50	None	0	None	None	None	Overall she remains clinically stable with significance cognitive and memory impairments as well as mild left-sided weakness requiring a wheelchair for ambulation long distances. She denies any chest pain, shortness of breath, lower extremity edema or seizures.	447	50	None	0	None	None	None	She has decided that she no longer wants to continue therapy with Avastin and would like to transition to hospice. Recently, she fell while in the kitchen without using her walker and sustained bruising to her LUE and a small laceration to her lip which are improving. Her left upper extremity has become weaker and she has some discomfort in the left shoulder. She is increasingly dependent on her wheelchair.	495	40	None	0	None	None	None	Hospice RN requests verbal approval for lorazepam and haldol; states lorazepam is taking a bit longer to take effect and would like an alternative.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
